{"docstore/data": {"84d029b5-1235-4b6b-a948-258149099077": {"__data__": {"id_": "84d029b5-1235-4b6b-a948-258149099077", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter. ", "original_text": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3632ed99-d63e-45f7-a8a8-f7e41a0a253c", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n", "original_text": "(NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. "}, "hash": "4f36b87ce3e7c2f37201af8d5e20009349984fb3e810e951f0472a0786332cd5", "class_name": "RelatedNodeInfo"}}, "text": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "start_char_idx": 0, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3632ed99-d63e-45f7-a8a8-f7e41a0a253c": {"__data__": {"id_": "3632ed99-d63e-45f7-a8a8-f7e41a0a253c", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n", "original_text": "(NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84d029b5-1235-4b6b-a948-258149099077", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter. ", "original_text": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a42e3a4ee0c09b28aa05d0890e3be591d29a15cf4012f1b568c0a64acacfe0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62f2883b-1023-47dc-96bf-d0e6650b9551", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024. ", "original_text": "On the basis of U.S. "}, "hash": "96776d8526c274d1b1f707b41b6cd90404fb508548b119eec262c3834a4f6e11", "class_name": "RelatedNodeInfo"}}, "text": "(NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. ", "start_char_idx": 357, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62f2883b-1023-47dc-96bf-d0e6650b9551": {"__data__": {"id_": "62f2883b-1023-47dc-96bf-d0e6650b9551", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3632ed99-d63e-45f7-a8a8-f7e41a0a253c", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n", "original_text": "(NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4c1cd6321300cce693ef9d9aa8a428b79ebc4e5659d5f59f1e1d88908aead54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aad4d32f-5033-42d8-b394-5879080777d2", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter. "}, "hash": "aa13b8ab539276f7b9975b21846b4c82c2cac6becba27fcf35227925409f6a7e", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 517, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aad4d32f-5033-42d8-b394-5879080777d2": {"__data__": {"id_": "aad4d32f-5033-42d8-b394-5879080777d2", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62f2883b-1023-47dc-96bf-d0e6650b9551", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab93cc298c95dc201e5ffa089475e25fe22a732c5228a9067da9fc57afec8db7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "501befc5-2790-4c7a-b5d7-aa4ac3433459", "node_type": "1", "metadata": {"window": "(NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n"}, "hash": "28664d51019a1e22938186acf08ad0b8a3eb8a27821aa9ca7310c12f07ef4b58", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter. ", "start_char_idx": 538, "end_char_idx": 718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "501befc5-2790-4c7a-b5d7-aa4ac3433459": {"__data__": {"id_": "501befc5-2790-4c7a-b5d7-aa4ac3433459", "embedding": null, "metadata": {"window": "(NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aad4d32f-5033-42d8-b394-5879080777d2", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "256e4576d54688a6fb252f19a855fc9f2d10bc20489fbaa6383e5d85de8ce7f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2602981-c2e0-48b1-a358-9cde8aae5c5e", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n", "original_text": "Cencora is updating its outlook for fiscal year 2024. "}, "hash": "05c7fa24d20ea441cfd77326cc6b1a0021f79768bdb3905290f48ad07298bd47", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n", "start_char_idx": 718, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2602981-c2e0-48b1-a358-9cde8aae5c5e": {"__data__": {"id_": "c2602981-c2e0-48b1-a358-9cde8aae5c5e", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n", "original_text": "Cencora is updating its outlook for fiscal year 2024. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "501befc5-2790-4c7a-b5d7-aa4ac3433459", "node_type": "1", "metadata": {"window": "(NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c376215cbb9eb1f9d5601b47c70d2d716d6c3ec5076e5b18ca1fa9b17f38a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b7e580d-2a90-4d2d-986a-3f39122d1204", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. "}, "hash": "cde7be4c81b2edbf003d62b414354779959050303ed698adcd33ad4e528a9600", "class_name": "RelatedNodeInfo"}}, "text": "Cencora is updating its outlook for fiscal year 2024. ", "start_char_idx": 919, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b7e580d-2a90-4d2d-986a-3f39122d1204": {"__data__": {"id_": "7b7e580d-2a90-4d2d-986a-3f39122d1204", "embedding": null, "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2602981-c2e0-48b1-a358-9cde8aae5c5e", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n", "original_text": "Cencora is updating its outlook for fiscal year 2024. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "538062e948ddedceaa38fcaaacff346fbf73fcaeb0e693f66b9820feaaf968c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c5ec67-ee86-4b05-9bd1-4378b903197d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n"}, "hash": "fcb289b96a125ce7c0e7221147d71623aaa56b0fb1dd1966b67018b703dee7ea", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "start_char_idx": 973, "end_char_idx": 1098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c5ec67-ee86-4b05-9bd1-4378b903197d": {"__data__": {"id_": "42c5ec67-ee86-4b05-9bd1-4378b903197d", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b7e580d-2a90-4d2d-986a-3f39122d1204", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9630563b03f6c3b1e0e85a2077379ef1672a7db0db046fd96cad02892b051315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7223bde6-9eed-410c-862b-02b532dcf3df", "node_type": "1", "metadata": {"window": "Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n"}, "hash": "64f7d9988c27a18754c6e5dc8d731da1dfe6bafdf9e7998cd1ec37c765dda05e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n", "start_char_idx": 1098, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7223bde6-9eed-410c-862b-02b532dcf3df": {"__data__": {"id_": "7223bde6-9eed-410c-862b-02b532dcf3df", "embedding": null, "metadata": {"window": "Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c5ec67-ee86-4b05-9bd1-4378b903197d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased\n21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.\n Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fc977eebe496cdda19019ccc6063ad8d0892ee751764cf8b1271815a3243d5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9cac26d-1faf-4848-afd3-32d600d084e1", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n"}, "hash": "0b35e41ac044fd52e184ba6bfaf7aa9a667b8810077478c8e0521263c895ffae", "class_name": "RelatedNodeInfo"}}, "text": "\u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n", "start_char_idx": 1220, "end_char_idx": 1613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9cac26d-1faf-4848-afd3-32d600d084e1": {"__data__": {"id_": "a9cac26d-1faf-4848-afd3-32d600d084e1", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7223bde6-9eed-410c-862b-02b532dcf3df", "node_type": "1", "metadata": {"window": "Cencora is updating its outlook for fiscal year 2024.  The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78bcac36056f301b2e9f2ae42856bd16f9a52d33ccb2c5ef402addca616523db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7506e5f0-3795-4934-a29e-659717edc616", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "Collis. "}, "hash": "4deab293844c970833282dd73b69264fe689fa2704ec719ee16cd84517eca518", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n", "start_char_idx": 1613, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7506e5f0-3795-4934-a29e-659717edc616": {"__data__": {"id_": "7506e5f0-3795-4934-a29e-659717edc616", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "Collis. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9cac26d-1faf-4848-afd3-32d600d084e1", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as\ndiscussed below in Fiscal Y ear 2024 Expectations.  Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e183932065a7003640a00cf50e9606b1724e840bef00da218dee861f021fa9d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f205d30-9323-43e7-bbce-fa53559188b2", "node_type": "1", "metadata": {"window": "\u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1"}, "hash": "2b72b5073e31babcd95c5135f8c01e8317c82b659902e84625d3925f660d4b15", "class_name": "RelatedNodeInfo"}}, "text": "Collis. ", "start_char_idx": 1872, "end_char_idx": 1880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f205d30-9323-43e7-bbce-fa53559188b2": {"__data__": {"id_": "8f205d30-9323-43e7-bbce-fa53559188b2", "embedding": null, "metadata": {"window": "\u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ec80978b-137f-4482-889d-7177d5e2d6bd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80becc73025c5697db50106f0a874b0471d90380a4c210567d11bc7f69e72c0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7506e5f0-3795-4934-a29e-659717edc616", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous range of $12.70\nto $13.00 to a range of $13.25 to $13.50.\n \u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "Collis. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0cf7901b37423a7d2fd8ba0ea01306ec9b08a3445dca61562120f2c3de14f18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "910713d5-67b7-4518-ac75-e7e5e9345c4f", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc. "}, "hash": "38525b4818c384f974e2a54d597b00994da858fb97c3dea20dd93b75801f42f0", "class_name": "RelatedNodeInfo"}}, "text": "\u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "start_char_idx": 1880, "end_char_idx": 2327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "910713d5-67b7-4518-ac75-e7e5e9345c4f": {"__data__": {"id_": "910713d5-67b7-4518-ac75-e7e5e9345c4f", "embedding": null, "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f205d30-9323-43e7-bbce-fa53559188b2", "node_type": "1", "metadata": {"window": "\u201cCencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in\nour business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we\nbring to our customers and stakeholders,\u201d said S teven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.\n \u201cAs we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing\nopportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,\u201d continued Mr.\n Collis.  \u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "original_text": "\u201cI remain inspired by our team members\u2019 drive to deliver on our purpose by demonstrating passion and adaptability as we\nwork through a complex, global healthcare system to improve lives every day.\u201d\nFirst Quar ter Fiscal Y ear 2024 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $72.3B $72.3B\nGross Pr ofit $2.5B $2.4B\nOperating Expenses $1.6B $1.5B\nOperating Income $823M $886M\nInterest Expense, Net $41M $41M\nEffectiv e Tax Rat e230% 210%\n1", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d51aafaa677d4948e8415010e1305943199fa7f3a769db67cc9fec396a348771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3364d98-7020-46dd-ba48-d049b3a8d6fb", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "original_text": "$602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "a06176dbe80e5de3863ca314f7f048f858c108967148aaef400990a019f2ed8e", "class_name": "RelatedNodeInfo"}}, "text": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc. ", "start_char_idx": 0, "end_char_idx": 55, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3364d98-7020-46dd-ba48-d049b3a8d6fb": {"__data__": {"id_": "e3364d98-7020-46dd-ba48-d049b3a8d6fb", "embedding": null, "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "original_text": "$602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "910713d5-67b7-4518-ac75-e7e5e9345c4f", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "316b2e51a6ee5750076cc0cff35631c21377a860ad857340c9b7accae6339553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9be65c5-87df-46a7-bca1-46c93bc1cd4d", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "df550f34bc7b6e0169a5d7520564f33c4d1a618739b0c9a45edeb0a6125ef6f2", "class_name": "RelatedNodeInfo"}}, "text": "$602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 55, "end_char_idx": 262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9be65c5-87df-46a7-bca1-46c93bc1cd4d": {"__data__": {"id_": "f9be65c5-87df-46a7-bca1-46c93bc1cd4d", "embedding": null, "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3364d98-7020-46dd-ba48-d049b3a8d6fb", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "original_text": "$602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aff5ebb43c94d76fdb1f6fff677c49b9b0d15f94cec42b2996c0b9af5675eb19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6982918-f1dc-4f47-99f8-aff3491867c4", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "original_text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n"}, "hash": "dca67fb9ad17f2a3c5568532ddcd0b4bceb3ad9e0153c6ee92450284adebfb03", "class_name": "RelatedNodeInfo"}}, "text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 262, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6982918-f1dc-4f47-99f8-aff3491867c4": {"__data__": {"id_": "c6982918-f1dc-4f47-99f8-aff3491867c4", "embedding": null, "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "original_text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9be65c5-87df-46a7-bca1-46c93bc1cd4d", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82856b7823f956f91adb0cc0c3849efd634522edbcd455bddd37ad7bf1efa4c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed69b32-cd74-47b8-bd7b-1df889def60d", "node_type": "1", "metadata": {"window": "$602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. "}, "hash": "559eac13366ed1483118947a46a29a5781bfccd5f163a370c1d766f1b37c35cb", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "start_char_idx": 354, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed69b32-cd74-47b8-bd7b-1df889def60d": {"__data__": {"id_": "fed69b32-cd74-47b8-bd7b-1df889def60d", "embedding": null, "metadata": {"window": "$602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6982918-f1dc-4f47-99f8-aff3491867c4", "node_type": "1", "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "original_text": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edae1385127752d5f471cecff89fa76329d465a9ddf5154d0454818db9ad0cfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ca3cbc0-1c37-4937-827f-73898f30c908", "node_type": "1", "metadata": {"window": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense. ", "original_text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n"}, "hash": "4f0836acda20e2798f001a171f09a87d6ce7848a96e214448f205b443d65df8f", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "start_char_idx": 577, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ca3cbc0-1c37-4937-827f-73898f30c908": {"__data__": {"id_": "9ca3cbc0-1c37-4937-827f-73898f30c908", "embedding": null, "metadata": {"window": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense. ", "original_text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed69b32-cd74-47b8-bd7b-1df889def60d", "node_type": "1", "metadata": {"window": "$602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a48a62ec620973de3fe511c25f1b50c3ba1acbb27c4cb7a39e8e14ea048d08f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed9989f3-68ce-40b1-9ed5-20ff7f9de0af", "node_type": "1", "metadata": {"window": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements. ", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. "}, "hash": "5fd47f28738bdee008d9d641cd471d708b6cec43968789ad86458b3cfe9abb96", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n", "start_char_idx": 812, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed9989f3-68ce-40b1-9ed5-20ff7f9de0af": {"__data__": {"id_": "ed9989f3-68ce-40b1-9ed5-20ff7f9de0af", "embedding": null, "metadata": {"window": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements. ", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ca3cbc0-1c37-4937-827f-73898f30c908", "node_type": "1", "metadata": {"window": "In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense. ", "original_text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fa806d2edd39972d5d42d09e7edb0fb62401dde18a1417654c6ab7889848262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f3ea537-898d-4d65-a75b-0e3dbe9afadb", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n", "original_text": "Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n"}, "hash": "d140eb73afbd4d5841c2e86ba9215139094ddb9633e0a02b1fca3882fd288d9e", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "start_char_idx": 914, "end_char_idx": 1251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f3ea537-898d-4d65-a75b-0e3dbe9afadb": {"__data__": {"id_": "2f3ea537-898d-4d65-a75b-0e3dbe9afadb", "embedding": null, "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n", "original_text": "Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed9989f3-68ce-40b1-9ed5-20ff7f9de0af", "node_type": "1", "metadata": {"window": "For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements. ", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61d1794787966f1dd413911c290b9d747368dc91fafcc970d2255b8eb7f82a2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba015488-b4e1-47e3-b8f8-90524046c0ab", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense. "}, "hash": "6fa2a6f46ec3c37f45c3987ab60f2d2646af599a75f02db8839dba73a0c6854a", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n", "start_char_idx": 1251, "end_char_idx": 1367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba015488-b4e1-47e3-b8f8-90524046c0ab": {"__data__": {"id_": "ba015488-b4e1-47e3-b8f8-90524046c0ab", "embedding": null, "metadata": {"window": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f3ea537-898d-4d65-a75b-0e3dbe9afadb", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n", "original_text": "Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fdca543f9f735c63db2c96d05f1189be2f7655d431045b649cd860289f25bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce1db80d-6020-40e8-bf87-e0f3cb4b52f1", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n", "original_text": "This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements. "}, "hash": "cc6d1d2e11382fb88ee00ff8efeaad1f8d7cc049bc0fb1dfdb0b508ee36be778", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense. ", "start_char_idx": 1367, "end_char_idx": 1644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce1db80d-6020-40e8-bf87-e0f3cb4b52f1": {"__data__": {"id_": "ce1db80d-6020-40e8-bf87-e0f3cb4b52f1", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n", "original_text": "This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba015488-b4e1-47e3-b8f8-90524046c0ab", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e13af0e31a5aca9205d174c31726847a8f53d2db35278f57806984b93bfb702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b87b31f-979c-49f9-ac74-fe41541fcf35", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n", "original_text": "The prepayment was made in January 2024.\n"}, "hash": "7eccef61f88beeec482a544350c20d227ea38903ec0c9cda78261de8e4e49453", "class_name": "RelatedNodeInfo"}}, "text": "This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements. ", "start_char_idx": 1644, "end_char_idx": 1925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b87b31f-979c-49f9-ac74-fe41541fcf35": {"__data__": {"id_": "0b87b31f-979c-49f9-ac74-fe41541fcf35", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n", "original_text": "The prepayment was made in January 2024.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce1db80d-6020-40e8-bf87-e0f3cb4b52f1", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2024 was $2.5 billion, a 15.0 percent increase compared to the same\nperiod in the previous fiscal year, primarily due to increases in gross profit in both reportable segments and a LIFO credit in\nthe current year quarter in comparison to LIFO expense in the prior year quarter.  Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n", "original_text": "This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "716e0d0413ef76ca0a2ee99e6884ca757568d67d320175a31e91ba96ffd10ee9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6714649b-793b-4bcc-a112-29df51a099fe", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense. ", "original_text": "Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. "}, "hash": "8c3766a3c0ba748d854404d4df258455999454353a2f665b21da9d11f46df7bd", "class_name": "RelatedNodeInfo"}}, "text": "The prepayment was made in January 2024.\n", "start_char_idx": 1925, "end_char_idx": 1966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6714649b-793b-4bcc-a112-29df51a099fe": {"__data__": {"id_": "6714649b-793b-4bcc-a112-29df51a099fe", "embedding": null, "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense. ", "original_text": "Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b87b31f-979c-49f9-ac74-fe41541fcf35", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was\n3.42 percent, an increase of 1 basis point from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n", "original_text": "The prepayment was made in January 2024.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "988e91abe627b2de8967436d07d29a2a7f45e7b7c314a1b8e647deb3a64ec275", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73a49c6e-66b9-4fe6-8fbc-a904261669c7", "node_type": "1", "metadata": {"window": "This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n"}, "hash": "078e742e852c9ea9efb3d653e5d2789c5821f0289fbcff15a66a65b85c157411", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "start_char_idx": 1966, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73a49c6e-66b9-4fe6-8fbc-a904261669c7": {"__data__": {"id_": "73a49c6e-66b9-4fe6-8fbc-a904261669c7", "embedding": null, "metadata": {"window": "This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6714649b-793b-4bcc-a112-29df51a099fe", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2024, operating expenses were $1.6 billion, an 8.8 percent increase compared\nto the same period in the previous fiscal year, driven by increases in distribution, selling, and administrative expenses and\namortization expense.  This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense. ", "original_text": "Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b01111898684663aa22e7f46bec49874957dcba13ce14666cf7eb01579006e45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7c2168b-1f56-4331-8f49-a2b79e89810c", "node_type": "1", "metadata": {"window": "The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n", "original_text": "Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n"}, "hash": "6ef6e24e71e58fe864aecf20a80f202977d6d3ff00f144ea9b946a9db92eac0a", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n", "start_char_idx": 2230, "end_char_idx": 2400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7c2168b-1f56-4331-8f49-a2b79e89810c": {"__data__": {"id_": "e7c2168b-1f56-4331-8f49-a2b79e89810c", "embedding": null, "metadata": {"window": "The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n", "original_text": "Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73a49c6e-66b9-4fe6-8fbc-a904261669c7", "node_type": "1", "metadata": {"window": "This increase was partially offset by a $0.1 billion opioid litigation settlement accrual reduction\nprimarily as a result of our commitment, which we made in December 2023, to prepay the net present value of a future\nobligation as permitted under our opioid settlement agreements.  The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83449f455fb7255b35965e72cf934a520bcd7f91fa5c50a85885103a865148a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8095d78-a4d0-4fff-9c8a-517abf14cc81", "node_type": "1", "metadata": {"window": "Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense. "}, "hash": "b3a17bc29eab88e6de0a77300594e13dd304a41a59ea202be3e46dd9db6a0fd9", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n", "start_char_idx": 2400, "end_char_idx": 2854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8095d78-a4d0-4fff-9c8a-517abf14cc81": {"__data__": {"id_": "d8095d78-a4d0-4fff-9c8a-517abf14cc81", "embedding": null, "metadata": {"window": "Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7c2168b-1f56-4331-8f49-a2b79e89810c", "node_type": "1", "metadata": {"window": "The prepayment was made in January 2024.\n Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n", "original_text": "Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a1acef2dfdecf368818036c0b555466a86e7badc5a3d542968dd490494df3d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55c01c78-0329-4fc9-b292-471c47d53a08", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "original_text": "The effective tax rate was 19.8 percent in the prior year quarter.\n"}, "hash": "977ff0d9ea54887afaffcfbe43a20b83ced3f12b67841b4ce1c88145a34fd80b", "class_name": "RelatedNodeInfo"}}, "text": "Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense. ", "start_char_idx": 2854, "end_char_idx": 2990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55c01c78-0329-4fc9-b292-471c47d53a08": {"__data__": {"id_": "55c01c78-0329-4fc9-b292-471c47d53a08", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "original_text": "The effective tax rate was 19.8 percent in the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8095d78-a4d0-4fff-9c8a-517abf14cc81", "node_type": "1", "metadata": {"window": "Operating Income:  In the first quarter of fiscal 2024, operating income was $822.9 million, a 30.0 percent increase compared\nto the same period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating\nexpenses.  Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba8d0c36006a82a26cc73c177c37b951b665e1e5224e2522636e03ef05e8cf2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "033f471e-945d-414b-b4a1-f302c6473f13", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n"}, "hash": "969fd686d9cc4f9d4e85224025963ae74864b19b501e6da79ad0826a02038ccb", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate was 19.8 percent in the prior year quarter.\n", "start_char_idx": 2990, "end_char_idx": 3057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "033f471e-945d-414b-b4a1-f302c6473f13": {"__data__": {"id_": "033f471e-945d-414b-b4a1-f302c6473f13", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55c01c78-0329-4fc9-b292-471c47d53a08", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "original_text": "The effective tax rate was 19.8 percent in the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5915a746d3b093d47a77d8e4bfc4a90d77c5ed3a13c7e53b341035d1bea3f7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a09f03bd-c07d-4389-b092-b38d1c2f130e", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n"}, "hash": "32ea4cbcb26771c978d14a4f9283aaaaadcc5425d8ebbb56838b7b72cd602f0c", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n", "start_char_idx": 3057, "end_char_idx": 3248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a09f03bd-c07d-4389-b092-b38d1c2f130e": {"__data__": {"id_": "a09f03bd-c07d-4389-b092-b38d1c2f130e", "embedding": null, "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "033f471e-945d-414b-b4a1-f302c6473f13", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the first quarter of fiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus\nthe prior year quarter primarily due to an increase in interest income as a result of higher investment interest rates in the\ncurrent year quarter in comparison to the prior year quarter and a decrease in interest expense primarily due to the\nSeptember 30, 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt.\n Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a8f8e2867a67e6b87199d47bd5334618f1b807163843fba9dc5f262703e04fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed336d73-2854-43ea-b6e8-9f42da7dd6dc", "node_type": "1", "metadata": {"window": "The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. "}, "hash": "0dffe4b7ea3961616952befca3e21b39c34e96130ccf0272a37970daa2ca7bd5", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "start_char_idx": 3248, "end_char_idx": 3491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed336d73-2854-43ea-b6e8-9f42da7dd6dc": {"__data__": {"id_": "ed336d73-2854-43ea-b6e8-9f42da7dd6dc", "embedding": null, "metadata": {"window": "The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a09f03bd-c07d-4389-b092-b38d1c2f130e", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 23.0 percent for the first quarter of fiscal 2024 and included a discrete tax\nexpense.  The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34e4249984c2a26365b27d19ff347514007410317ef3821467d3b1631c1d581f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c711e221-a83f-4394-87ad-a033c60a883f", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions. "}, "hash": "f6ffdd36a3cc2b5861fda52b2a76bbbef5ecf618afd5afca9a1e71926f706c0a", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "start_char_idx": 3491, "end_char_idx": 3742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c711e221-a83f-4394-87ad-a033c60a883f": {"__data__": {"id_": "c711e221-a83f-4394-87ad-a033c60a883f", "embedding": null, "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed336d73-2854-43ea-b6e8-9f42da7dd6dc", "node_type": "1", "metadata": {"window": "The effective tax rate was 19.8 percent in the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5da686cb451c0f78828aeb527568b4c12f0349b4d340d615d892713d96d2488", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4832a68-6a34-4cfc-ae8a-f1a3b06759fe", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n"}, "hash": "3e0ca38348b77aa21c9a28fec72403a22e6a335cf9ec8da47fefe71a0c974566", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions. ", "start_char_idx": 3742, "end_char_idx": 3844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4832a68-6a34-4cfc-ae8a-f1a3b06759fe": {"__data__": {"id_": "e4832a68-6a34-4cfc-ae8a-f1a3b06759fe", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c711e221-a83f-4394-87ad-a033c60a883f", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase\ncompared to $2.33 in the previous fiscal year\u2019s first quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5f9ba83d18c6d85eab1faabab533b9670a84b3c68298669f9501604b501aa23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c375f1ef-0d30-47a8-b6bb-f411e7771b8d", "node_type": "1", "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2"}, "hash": "928f4bfd241a8a994a04ea1c5cabe78f746bb6d2187087cc1511116ad7416dc6", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n", "start_char_idx": 3844, "end_char_idx": 3998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c375f1ef-0d30-47a8-b6bb-f411e7771b8d": {"__data__": {"id_": "c375f1ef-0d30-47a8-b6bb-f411e7771b8d", "embedding": null, "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07bd8210-72e7-4ac1-968d-a30965a836af", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957b08ad8dde507ead1a011fe55a439798fce9dfa66754730d9eeda2433d0c2e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4832a68-6a34-4cfc-ae8a-f1a3b06759fe", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8\nmillion, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6ffac75bb0645622ebf69c3dfc48ae4784c78656d661f30865ed386df310b9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "576d7163-2b42-4866-9188-4cf36131c16e", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n"}, "hash": "eeed594e02221e990e90166627d40c744d02563d989b3cba1c105e8a1b37c780", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "start_char_idx": 3998, "end_char_idx": 4123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "576d7163-2b42-4866-9188-4cf36131c16e": {"__data__": {"id_": "576d7163-2b42-4866-9188-4cf36131c16e", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c375f1ef-0d30-47a8-b6bb-f411e7771b8d", "node_type": "1", "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  In the first quarter of fiscal 2024, revenue was $72.3 billion, up 15.0 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 15.9 percent increase in revenue within U.S.  Healthcare Solutions and a 6.9 percent increase in\nrevenue within International Healthcare Solutions.  On a constant currency basis, revenue was up 15.2 percent, reflecting 8.7\npercent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2024 was $2.4 billion, a 12.5 percent increase\n2", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f67357e5c90fb4a0990199ca01467b6d23b88d7fe6cd773558c3b1bb632c345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc729b38-6e98-4c02-ace7-7f968d212a51", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S. "}, "hash": "d1244de8ed7750409e1472861aefdbc920f585fe5c093b9935a3eec1b515e381", "class_name": "RelatedNodeInfo"}}, "text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "start_char_idx": 0, "end_char_idx": 118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc729b38-6e98-4c02-ace7-7f968d212a51": {"__data__": {"id_": "cc729b38-6e98-4c02-ace7-7f968d212a51", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "576d7163-2b42-4866-9188-4cf36131c16e", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07e48daac2e0244045a386981d6b61e2068ea463d7fe4063beb0ee1b7422cebd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f06d75eb-cc52-46e2-b0ee-5229a91c72d0", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions. ", "original_text": "Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n"}, "hash": "ca78603f977419d7817b3bc6b21d9ff4f7a78b3f1ff261e9d0842de51a586e4e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S. ", "start_char_idx": 118, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f06d75eb-cc52-46e2-b0ee-5229a91c72d0": {"__data__": {"id_": "f06d75eb-cc52-46e2-b0ee-5229a91c72d0", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions. ", "original_text": "Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc729b38-6e98-4c02-ace7-7f968d212a51", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54fcb6a856dcf64732b5cc20001266e791e19ea8ab239ecd3a14e2a7aa11b840", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1779473a-735f-4ce4-88a7-f61305fe1ba4", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n"}, "hash": "a1ffde492c73ac36d22d83c0133c7ae75aec50b74b07f30dec60c80b6cb08ff7", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n", "start_char_idx": 307, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1779473a-735f-4ce4-88a7-f61305fe1ba4": {"__data__": {"id_": "1779473a-735f-4ce4-88a7-f61305fe1ba4", "embedding": null, "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f06d75eb-cc52-46e2-b0ee-5229a91c72d0", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions. ", "original_text": "Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69a7a22d227c00bb5ce1f7851be7ba6d5cc529dad3b1be95203c94af2b0cb1a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94c7a456-834a-4c1c-90b0-808b91f2bf1b", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent. ", "original_text": "Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S. "}, "hash": "dddbf967ad306f99c3ff057f911f60c42a254c5357ed6881a7e0fb8747c64433", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n", "start_char_idx": 585, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94c7a456-834a-4c1c-90b0-808b91f2bf1b": {"__data__": {"id_": "94c7a456-834a-4c1c-90b0-808b91f2bf1b", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent. ", "original_text": "Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1779473a-735f-4ce4-88a7-f61305fe1ba4", "node_type": "1", "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8997118e145d023977c456acd27b7a4932cd66c9cb1e4291d6d955ef1ad26af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "739d0066-4c95-435f-a826-d9fd2995b306", "node_type": "1", "metadata": {"window": "Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions. "}, "hash": "8336073e71173dbaa8711be072f7a3d10f0a761d843184a1333e24b324fc8551", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S. ", "start_char_idx": 907, "end_char_idx": 1138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "739d0066-4c95-435f-a826-d9fd2995b306": {"__data__": {"id_": "739d0066-4c95-435f-a826-d9fd2995b306", "embedding": null, "metadata": {"window": "Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94c7a456-834a-4c1c-90b0-808b91f2bf1b", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent. ", "original_text": "Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "897f3e892ba063ff45e260afb5101d693116787dcb1593642ef0280d6c74893a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8132ccf2-f094-472a-935f-01d87cbee875", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter. "}, "hash": "705cdbed0bff4a84060629f3ca0f6f2d8869236af0e8e02eaef6132203388e31", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions. ", "start_char_idx": 1138, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8132ccf2-f094-472a-935f-01d87cbee875": {"__data__": {"id_": "8132ccf2-f094-472a-935f-01d87cbee875", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "739d0066-4c95-435f-a826-d9fd2995b306", "node_type": "1", "metadata": {"window": "Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93af097ceaf57840c5e67dedf376b72f218190d078efb63917adfec3a97a8d1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cbcfdfe-d758-41a9-8a86-f849d73f6e88", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n", "original_text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent. "}, "hash": "73bb7f75f63c313db542bf2f6234581cfb611a38680f09a05a98626f7209eda1", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter. ", "start_char_idx": 1226, "end_char_idx": 1355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cbcfdfe-d758-41a9-8a86-f849d73f6e88": {"__data__": {"id_": "1cbcfdfe-d758-41a9-8a86-f849d73f6e88", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n", "original_text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8132ccf2-f094-472a-935f-01d87cbee875", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c64e304af0d0c156ecba1d3aee91128210c68e51e94180d70f5d5e923c08d7e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fc906d2-95b0-4d6a-95a4-df4ec293465f", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n"}, "hash": "0b7d220dcfe4b5136cf215f9ae7984b3f6bf3a7badefef69ce65c253523e5995", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent. ", "start_char_idx": 1355, "end_char_idx": 1469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fc906d2-95b0-4d6a-95a4-df4ec293465f": {"__data__": {"id_": "1fc906d2-95b0-4d6a-95a4-df4ec293465f", "embedding": null, "metadata": {"window": "Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cbcfdfe-d758-41a9-8a86-f849d73f6e88", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the first quarter of fiscal 2024, adjusted operating income was $885.7 million, a 20.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 22.0 percent increase in U.S.  Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n", "original_text": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6309e1edd3f2bf71c707815273527ca4665e6959d485ddfd542ea9620c15fa3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "079cd54f-3349-4df5-b386-fd8006f09d91", "node_type": "1", "metadata": {"window": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "baac042b7cd8394588dd884a5672563da8aef6a2c6c42d814559af8d884e50b0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n", "start_char_idx": 1469, "end_char_idx": 1637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "079cd54f-3349-4df5-b386-fd8006f09d91": {"__data__": {"id_": "079cd54f-3349-4df5-b386-fd8006f09d91", "embedding": null, "metadata": {"window": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fc906d2-95b0-4d6a-95a4-df4ec293465f", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nand a 16.3 percent increase in International Healthcare Solutions.  On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68d3bc590014d5bc82566ef8bee97d930ed6211c08963628a1a47f01367112d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e02e99f0-7a91-43c3-9938-0f530f37b0ea", "node_type": "1", "metadata": {"window": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n", "original_text": "In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n"}, "hash": "105f79069beb2a34ae22002be6b683dbca285e0fea89449012f0aa4d7a907b98", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1637, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e02e99f0-7a91-43c3-9938-0f530f37b0ea": {"__data__": {"id_": "e02e99f0-7a91-43c3-9938-0f530f37b0ea", "embedding": null, "metadata": {"window": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n", "original_text": "In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "079cd54f-3349-4df5-b386-fd8006f09d91", "node_type": "1", "metadata": {"window": "On a constant currency basis, the Company\u2019s adjusted\noperating income increased 21.6 percent compared to the prior year quarter.  On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d975165f1d632a43afca5f4ee37103ebf1954a78325a20396b09d7ee0cfd9bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e59336fd-00de-4d36-88fa-831de139376f", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n"}, "hash": "cefdb43fbd5511769551f33ca5b759dcf359325f1f5cda47bd1236e18ae451e3", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n", "start_char_idx": 1736, "end_char_idx": 2167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e59336fd-00de-4d36-88fa-831de139376f": {"__data__": {"id_": "e59336fd-00de-4d36-88fa-831de139376f", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e02e99f0-7a91-43c3-9938-0f530f37b0ea", "node_type": "1", "metadata": {"window": "On a constant currency basis, International\nHealthcare Solutions segment operating income increased 20.2 percent.  Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n", "original_text": "In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08bc39d5689699ddcac87a6352c78e84f25aa9e1ae225346f7a21e537427ba03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "217489dc-3299-48e6-b3f2-963a9d15bde4", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter. "}, "hash": "4739adaae6ad89927e7dfa30729271d755e81dde8c5068d696f5581944e6298c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n", "start_char_idx": 2167, "end_char_idx": 2336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "217489dc-3299-48e6-b3f2-963a9d15bde4": {"__data__": {"id_": "217489dc-3299-48e6-b3f2-963a9d15bde4", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e59336fd-00de-4d36-88fa-831de139376f", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.23% in the fiscal 2024 first quarter, an increase of 6 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dabf5beaee3d188a65f41ecea9f6c09b67323321fe527e2e4e1b899381664ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c34ee94-592d-4f5b-98c9-b254af119bfc", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n"}, "hash": "76ba7f25d2652651e1e0acc40ecdc215ab1e726f496ddae09950b9ea95bab061", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter. ", "start_char_idx": 2336, "end_char_idx": 2538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c34ee94-592d-4f5b-98c9-b254af119bfc": {"__data__": {"id_": "0c34ee94-592d-4f5b-98c9-b254af119bfc", "embedding": null, "metadata": {"window": "In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "217489dc-3299-48e6-b3f2-963a9d15bde4", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "172ee7f6569f17618bb5ff3b55db32f931a1b1f39259d403b97a51c67fb1ab17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5677678b-0421-4409-8583-7935c47fc472", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "24980c5ad6140dc0e76773636c67dbe5c1da0a9ca40b28671acf16b0eacf9bf4", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n", "start_char_idx": 2538, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5677678b-0421-4409-8583-7935c47fc472": {"__data__": {"id_": "5677678b-0421-4409-8583-7935c47fc472", "embedding": null, "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c34ee94-592d-4f5b-98c9-b254af119bfc", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2024, net interest expense of $40.6 million decreased 11.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates in the current year quarter in comparison to the\nprior year quarter and a decrease in interest expense primarily due to the September 30, 2023 divestiture of our less-than-\nwholly-owned subsidiary in Egypt.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c09efd5ef90436b99e7d80cd0f47af639e82c32dfb7949eff778eba3e043102", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec89659-dcf0-4024-bce1-406efa52f63d", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n"}, "hash": "0cb8a845a710fc3a7d1e0ddbf509d1684dbde4d3b7bdbcb4231fa49cf4e72618", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2663, "end_char_idx": 2773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec89659-dcf0-4024-bce1-406efa52f63d": {"__data__": {"id_": "bec89659-dcf0-4024-bce1-406efa52f63d", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5677678b-0421-4409-8583-7935c47fc472", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2024 compared to\n19.1 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d645277d7e816e8860aac0f04ba537b2b1e7e207aeca30ac7d9b0210009280bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be544d03-f78b-4e4d-83d0-b5151b0f5426", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. "}, "hash": "967eefc86a21cbf7ce9adf3659d9db239e84aceece9bd3f1ba61f4c8545584ca", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n", "start_char_idx": 2773, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be544d03-f78b-4e4d-83d0-b5151b0f5426": {"__data__": {"id_": "be544d03-f78b-4e4d-83d0-b5151b0f5426", "embedding": null, "metadata": {"window": "On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bec89659-dcf0-4024-bce1-406efa52f63d", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0%\nincrease compared to $2.71 in the previous fiscal year\u2019s first quarter.  On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75eb2f7c25cfcfce2ebdd2f3a428a1e7c7be642bd73c5cd7f8b832db9383d8bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8e1f8c4-e966-48a9-87e6-24ada0e97ba9", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n"}, "hash": "b7d6ccefa93ef9cf6c7ba7823f914bceb113214cac27f81e2a9b89f7a97e3e0b", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "start_char_idx": 2987, "end_char_idx": 3148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8e1f8c4-e966-48a9-87e6-24ada0e97ba9": {"__data__": {"id_": "c8e1f8c4-e966-48a9-87e6-24ada0e97ba9", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be544d03-f78b-4e4d-83d0-b5151b0f5426", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted diluted earnings\nper share increased 21.8 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9145c8bebe2096898a6bbe2be48978e5d0619f0092862b50066be0671d3a53f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f7f75e6-fe9b-4e4e-88db-1d11efedc648", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n", "original_text": "U.S. "}, "hash": "b103432ff4251505b3943f77794993f21dca21a67622f722662ec56f96b2aac9", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and International Healthcare Solutions.\n", "start_char_idx": 3148, "end_char_idx": 3209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f7f75e6-fe9b-4e4e-88db-1d11efedc648": {"__data__": {"id_": "0f7f75e6-fe9b-4e4e-88db-1d11efedc648", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8e1f8c4-e966-48a9-87e6-24ada0e97ba9", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1475e58eb0644c93d283ae5d74debaf77027b80ee936a842cae53c764030de85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21cf16c9-caec-433d-a92f-036ef5ee7f23", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business. ", "original_text": "Healthcare Solutions\nU.S. "}, "hash": "60c11dcf711e6ee42b3f78bc630d1b42f100b9237e12fbe9d8c7570c1f00745c", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 302, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21cf16c9-caec-433d-a92f-036ef5ee7f23": {"__data__": {"id_": "21cf16c9-caec-433d-a92f-036ef5ee7f23", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f7f75e6-fe9b-4e4e-88db-1d11efedc648", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus\nthe prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99dc463275b24e1d12225efed7b425b53ed6d1890ecaeaa0c4794313274657dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d815cc8-ed81-4b7a-8550-73feab3fd37c", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines. "}, "hash": "ad404557c3519aa3c7c3b9e197c9d60cf6f743ea55634540bc6a7c5083cd386f", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nU.S. ", "start_char_idx": 3214, "end_char_idx": 3240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d815cc8-ed81-4b7a-8550-73feab3fd37c": {"__data__": {"id_": "9d815cc8-ed81-4b7a-8550-73feab3fd37c", "embedding": null, "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21cf16c9-caec-433d-a92f-036ef5ee7f23", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9285ebcb29cff5b3f7d22989696d5ef7f7fb26009346b251de24872de92c901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b29917c-b820-47d2-bc8f-27f8261a360f", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n"}, "hash": "dd7257d56c01d8aaeeef68dca5f2c6fff59770f60714ae579dbc3e08c8eb6661", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines. ", "start_char_idx": 3240, "end_char_idx": 3700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b29917c-b820-47d2-bc8f-27f8261a360f": {"__data__": {"id_": "4b29917c-b820-47d2-bc8f-27f8261a360f", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d815cc8-ed81-4b7a-8550-73feab3fd37c", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5748b96265fb843661cb2a82f5d8ea039e7b82b16abf3cb1b115709099a81d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d656d6cc-4edc-400c-b445-9578dda9694b", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business. "}, "hash": "4fa246ca96f4d9204b579dfdeaea39124abd1fa74b18502ba640914a284985c6", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n", "start_char_idx": 3700, "end_char_idx": 3950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d656d6cc-4edc-400c-b445-9578dda9694b": {"__data__": {"id_": "d656d6cc-4edc-400c-b445-9578dda9694b", "embedding": null, "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b29917c-b820-47d2-bc8f-27f8261a360f", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3eb7f8981d520dc19b53ebaf37c94b4ff582caa1bee2f3358de568787de99be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9961832-887a-4091-874d-081e7346b34d", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3"}, "hash": "a1badabf2d17675bbf31addc43b81cac37a48cbc55eb864a8436b52f601c9191", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business. ", "start_char_idx": 3950, "end_char_idx": 4275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9961832-887a-4091-874d-081e7346b34d": {"__data__": {"id_": "f9961832-887a-4091-874d-081e7346b34d", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d174f196ceacc628f6f6f1176309968c56e64168646fe43fcebc4b2372e1e81c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d656d6cc-4edc-400c-b445-9578dda9694b", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business. ", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740adbe1ab3f1243cb96fe41065aad097f79bf7184d9abe49ec3b95972f28720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd38e0f7-5f17-40f8-92f3-6720de87744c", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n", "original_text": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter. "}, "hash": "955fddca2c9bffd44ebe4c02fc9c2447553c266e8f47711948dec0d722f3ff20", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "start_char_idx": 4275, "end_char_idx": 4647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd38e0f7-5f17-40f8-92f3-6720de87744c": {"__data__": {"id_": "fd38e0f7-5f17-40f8-92f3-6720de87744c", "embedding": null, "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n", "original_text": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9961832-887a-4091-874d-081e7346b34d", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the\nsame quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased\nsales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician\npractices and health systems, and increased sales of C OVID-19 vaccines.  Segment operating income of $698.1 million in the first\nquarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross\nprofit, partially offset by an increase in operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the\nprevious fiscal year\u2019s first quarter primarily due to increased sales in our European distribution business and increased sales in our\nCanadian business.  Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "original_text": "Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent,\nprimarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and\ngrowth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our\n3", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33d1741acc1dbffc9d32ccb03d0288cc34b8339b4d75249791ddbfbff2c4b273", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c123bf81-6dd3-4069-a5f9-eb5a43d9a6aa", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress. ", "original_text": "On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n"}, "hash": "df96bca1b8c7a9cc0db3b50e79189c5fe59f4ae2df88b99b96344d8fdc9468e5", "class_name": "RelatedNodeInfo"}}, "text": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter. ", "start_char_idx": 0, "end_char_idx": 176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c123bf81-6dd3-4069-a5f9-eb5a43d9a6aa": {"__data__": {"id_": "c123bf81-6dd3-4069-a5f9-eb5a43d9a6aa", "embedding": null, "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress. ", "original_text": "On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd38e0f7-5f17-40f8-92f3-6720de87744c", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n", "original_text": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "369c8e267d98898645054dfcfc6c68b5c97ec3ff7e23b0db97ae5f033f51fb29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0b6bf1c-9d59-4459-882e-331b104bd8be", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n", "original_text": "Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n"}, "hash": "f71aa0a8546ca7f28c96585ed53971dde65e0d7d550fd6844312857170c3ddf8", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n", "start_char_idx": 176, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0b6bf1c-9d59-4459-882e-331b104bd8be": {"__data__": {"id_": "b0b6bf1c-9d59-4459-882e-331b104bd8be", "embedding": null, "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n", "original_text": "Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c123bf81-6dd3-4069-a5f9-eb5a43d9a6aa", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress. ", "original_text": "On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7418f617d5ed38e5c8a3a189f0f94a774fac22f539538e90d8104f6d8c55c68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "976bd4e5-7573-456c-a697-e80951802fa7", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n"}, "hash": "c477df7e755f4a3b8c68b099c815af2b7bf1bc97543c7e62ff00b2057f1ddf42", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n", "start_char_idx": 327, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "976bd4e5-7573-456c-a697-e80951802fa7": {"__data__": {"id_": "976bd4e5-7573-456c-a697-e80951802fa7", "embedding": null, "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0b6bf1c-9d59-4459-882e-331b104bd8be", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n", "original_text": "Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a4b0e9fbd25ebf78f5a5a0bab27d698003a7912f0f07a80ec41b28ce850f2b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81d7be04-c27c-437b-bbdf-9763ee16ce28", "node_type": "1", "metadata": {"window": "On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress. "}, "hash": "92e55f583f6b1a5ddd54e8c0ae87a05c77536eea41bb363fd3a8f898e9c94181", "class_name": "RelatedNodeInfo"}}, "text": "Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n", "start_char_idx": 547, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81d7be04-c27c-437b-bbdf-9763ee16ce28": {"__data__": {"id_": "81d7be04-c27c-437b-bbdf-9763ee16ce28", "embedding": null, "metadata": {"window": "On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "976bd4e5-7573-456c-a697-e80951802fa7", "node_type": "1", "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dd914edabe2a690d551ddd6622728072737956e5ba5d3de9deb9569cc234707", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b8981c3-674a-476d-9201-04add9428ec4", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter. ", "original_text": "For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n"}, "hash": "1d22014ae19c9530385864bb17df9f9e8a811c0d1819511b2dad751415aab8ac", "class_name": "RelatedNodeInfo"}}, "text": "On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress. ", "start_char_idx": 648, "end_char_idx": 820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b8981c3-674a-476d-9201-04add9428ec4": {"__data__": {"id_": "8b8981c3-674a-476d-9201-04add9428ec4", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter. ", "original_text": "For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81d7be04-c27c-437b-bbdf-9763ee16ce28", "node_type": "1", "metadata": {"window": "On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edd7028f81571ddc1b0824c62b0481a7bc6b10d450e941584566574c27f4ff7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50934e2a-5449-49d4-b823-b4d8d1e65c62", "node_type": "1", "metadata": {"window": "Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged. ", "original_text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "a3e93788ff1a5456935c320ed294375de729e20c4ca99c1c4aff0a5075a47962", "class_name": "RelatedNodeInfo"}}, "text": "For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n", "start_char_idx": 820, "end_char_idx": 954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50934e2a-5449-49d4-b823-b4d8d1e65c62": {"__data__": {"id_": "50934e2a-5449-49d4-b823-b4d8d1e65c62", "embedding": null, "metadata": {"window": "Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged. ", "original_text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b8981c3-674a-476d-9201-04add9428ec4", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter. ", "original_text": "For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae59abad57dc16303c0beb593db81f99aa68d507225a288bf22134d3a01695a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6ff13f6-a333-4fe5-be0c-f5da68de995e", "node_type": "1", "metadata": {"window": "On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "3f7e51f297784c73991f3c37f56d561cd0e9a2e4827c08f77a7451114b644b68", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 954, "end_char_idx": 1198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6ff13f6-a333-4fe5-be0c-f5da68de995e": {"__data__": {"id_": "f6ff13f6-a333-4fe5-be0c-f5da68de995e", "embedding": null, "metadata": {"window": "On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50934e2a-5449-49d4-b823-b4d8d1e65c62", "node_type": "1", "metadata": {"window": "Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged. ", "original_text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b32d5cd7b8bd343e87871f917da5054da8e5db6cc460a03d487bdfa92485841e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58abbb71-1e45-4620-b6f6-a71816f03005", "node_type": "1", "metadata": {"window": "For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter. "}, "hash": "531e0af89a8cfbe336037edc1ebcb7bc870a0321413b52798184525e24961958", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1198, "end_char_idx": 1331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58abbb71-1e45-4620-b6f6-a71816f03005": {"__data__": {"id_": "58abbb71-1e45-4620-b6f6-a71816f03005", "embedding": null, "metadata": {"window": "For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6ff13f6-a333-4fe5-be0c-f5da68de995e", "node_type": "1", "metadata": {"window": "On January 30, 2024, Cencora released its 2023 ESG R eporting Index and microsite, detailing the impact of its environmental,\nsocial, and governance programs and progress.  For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1749fe287b7b20e3289ab615a6072cd995a99fed8b089c56db00d3e61a06a10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02d0af9e-db43-407a-99d4-0ec6f0cf6300", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent. ", "original_text": "The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged. "}, "hash": "db6627af83c6412044856486ba230028d77dbbe54a5ad533d278fe8d2766d1f9", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter. ", "start_char_idx": 1331, "end_char_idx": 1642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02d0af9e-db43-407a-99d4-0ec6f0cf6300": {"__data__": {"id_": "02d0af9e-db43-407a-99d4-0ec6f0cf6300", "embedding": null, "metadata": {"window": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent. ", "original_text": "The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58abbb71-1e45-4620-b6f6-a71816f03005", "node_type": "1", "metadata": {"window": "For the sixth year in a row, selected information within the 2023 report was\nassured by ERM Certification and V erification Services.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c80e0e8031b3dc79ef706843e2de40315d704fe41903501d88d6e4a07ff62533", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb06f4a9-433f-41c4-a17e-f36dd351e065", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S. ", "original_text": "The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S. "}, "hash": "7f2723aee98e74174dcab1c5f2280577f177c8c9c0fe5ef0f46ec2eace432833", "class_name": "RelatedNodeInfo"}}, "text": "The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged. ", "start_char_idx": 1642, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb06f4a9-433f-41c4-a17e-f36dd351e065": {"__data__": {"id_": "fb06f4a9-433f-41c4-a17e-f36dd351e065", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S. ", "original_text": "The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02d0af9e-db43-407a-99d4-0ec6f0cf6300", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent. ", "original_text": "The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2379260b5f0deb54f442629a31831503abf269de752898f1485515d6802fb2ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a1ee768-d38a-4b69-a665-37410a3eb3d1", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent. ", "original_text": "Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n"}, "hash": "58faead415da243bb57fd9bb117a230dbd8595fad2fb5979cef1ca7f577f91aa", "class_name": "RelatedNodeInfo"}}, "text": "The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S. ", "start_char_idx": 1759, "end_char_idx": 1891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a1ee768-d38a-4b69-a665-37410a3eb3d1": {"__data__": {"id_": "0a1ee768-d38a-4b69-a665-37410a3eb3d1", "embedding": null, "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent. ", "original_text": "Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb06f4a9-433f-41c4-a17e-f36dd351e065", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S. ", "original_text": "The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9e3887dc2955f1a5b5f6b607fe4013b45cd417741d08bbe812e46de39e349a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1209509-d1f2-49ef-8083-1771eac74b10", "node_type": "1", "metadata": {"window": "The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent. "}, "hash": "b0e9402c326384d554c630ed3c8ea35ffecf27d8bad8e7dd3c0180d94e319985", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n", "start_char_idx": 1891, "end_char_idx": 2142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1209509-d1f2-49ef-8083-1771eac74b10": {"__data__": {"id_": "a1209509-d1f2-49ef-8083-1771eac74b10", "embedding": null, "metadata": {"window": "The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a1ee768-d38a-4b69-a665-37410a3eb3d1", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year,\nincluding the incremental contributions from commercial C OVID-19 vaccine distribution in the first quarter.  The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent. ", "original_text": "Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac6cf9375bb3254ad99449a3d483cb0aa30c0b758c443cc48873045a8750a7ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3821ce94-2fe1-4736-b551-af63d6142c43", "node_type": "1", "metadata": {"window": "The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n", "original_text": "Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S. "}, "hash": "b8354399cb74ad3f144d9444b7e5bab4353bc1810f3ff625f06c7e4d6c1ce9ca", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent. ", "start_char_idx": 2142, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3821ce94-2fe1-4736-b551-af63d6142c43": {"__data__": {"id_": "3821ce94-2fe1-4736-b551-af63d6142c43", "embedding": null, "metadata": {"window": "The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n", "original_text": "Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1209509-d1f2-49ef-8083-1771eac74b10", "node_type": "1", "metadata": {"window": "The Company\u2019s\npreviously communicated expectations for exclusive C OVID-19 treatment contributions remain unchanged.  The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b29fe6e6170f1f15f4e58b3b624c6709f22d583080985ec6bc2b3e55f137297f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9cee65f-3e98-4f0d-a0bf-599fbd5eb50a", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent. "}, "hash": "d1049e11cd7e12cf14c3dd39c14926346aa6ea65bcb834b07e3de4b974a4c47d", "class_name": "RelatedNodeInfo"}}, "text": "Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S. ", "start_char_idx": 2310, "end_char_idx": 2501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9cee65f-3e98-4f0d-a0bf-599fbd5eb50a": {"__data__": {"id_": "b9cee65f-3e98-4f0d-a0bf-599fbd5eb50a", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3821ce94-2fe1-4736-b551-af63d6142c43", "node_type": "1", "metadata": {"window": "The Company now\nexpects:\nRevenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n", "original_text": "Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e9121098b1a960e5402d935c484aad0d4562c4950c23427e9a883cbc892ce22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6ebbd7b-5b6c-46b2-bc0b-b8c9c65a17fb", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n"}, "hash": "a847e860a53d07188501f92654a0d5edbda99d44560436d11a810f585efea489", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent. ", "start_char_idx": 2501, "end_char_idx": 2639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6ebbd7b-5b6c-46b2-bc0b-b8c9c65a17fb": {"__data__": {"id_": "c6ebbd7b-5b6c-46b2-bc0b-b8c9c65a17fb", "embedding": null, "metadata": {"window": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9cee65f-3e98-4f0d-a0bf-599fbd5eb50a", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10\npercent; and\nAdjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "838ea000b119db78926b0dc135722dba88ffe9b5d1d8cd2a2a35125b190aad1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "040ec0ed-e314-414f-a9c2-982f4a6a51b9", "node_type": "1", "metadata": {"window": "Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n"}, "hash": "2cf4d08f4547d3c18edfea94a1f09c093a3660e8e34abedce2e290b6cc49da1e", "class_name": "RelatedNodeInfo"}}, "text": "Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n", "start_char_idx": 2639, "end_char_idx": 3278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "040ec0ed-e314-414f-a9c2-982f4a6a51b9": {"__data__": {"id_": "040ec0ed-e314-414f-a9c2-982f4a6a51b9", "embedding": null, "metadata": {"window": "Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6ebbd7b-5b6c-46b2-bc0b-b8c9c65a17fb", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6\npercent.  Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9ffdcad252806714d9ca23f55688f7bdfb1b5d8697adbae07615b8af8755e49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "190c6daa-546f-44b2-b891-ad8af2686a71", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Confer ence Call & Slide Pr esentation\n4"}, "hash": "154fba6837bb3af05f83c89ad4dddfbbe1dff472c5c2e825eb3574241502909a", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n", "start_char_idx": 3278, "end_char_idx": 3493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "190c6daa-546f-44b2-b891-ad8af2686a71": {"__data__": {"id_": "190c6daa-546f-44b2-b891-ad8af2686a71", "embedding": null, "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Confer ence Call & Slide Pr esentation\n4", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ee6320da280fe9e84004f136693db8712df59b8460daa640360772944d0311", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "040ec0ed-e314-414f-a9c2-982f4a6a51b9", "node_type": "1", "metadata": {"window": "Excluding certain contributions related to C OVID-19, adjusted consolidated operating income growth to be in the\nrange of 11 to 13 percent, up from the previous range of 7 to 9 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "816824def20a0166b2f2a3c26633aa95432b7b68360da17fad252bc95f9bafec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "936b9e8d-bfcb-48b7-8a19-06076b2fed7b", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "The Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "0d6c4663c60c9a5f15e81d1c150121d1b612efa8b01ce84eddf56dc5f71b9755", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\n4", "start_char_idx": 3493, "end_char_idx": 3533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "936b9e8d-bfcb-48b7-8a19-06076b2fed7b": {"__data__": {"id_": "936b9e8d-bfcb-48b7-8a19-06076b2fed7b", "embedding": null, "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "The Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "190c6daa-546f-44b2-b891-ad8af2686a71", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 9 to 11 percent, up from the\nprevious range of 4 to 7 percent.  Expectations for segment operating income growth excluding exclusive C OVID-19\ntherapy contributions to be in the range of 12 to 14 percent, up from the previous range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the\nprevious range of 1 to 4 percent;\nNet interest expense to be in the range of $185 to $215 million, down from the previous range of $210 to $230 million; and\nFor additional details regarding updated guidance expectations on a constant currency and ex-C OVID-19 contribution basis,\nplease refer to our slide presentation for investors.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to\nstockholders of record at the close of business on February 9, 2024.\n Confer ence Call & Slide Pr esentation\n4", "original_text": "Confer ence Call & Slide Pr esentation\n4", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d37d3fcf1eb875b4e2a9662bb526baa17d751015c797bcf8a9152e0a575ddfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "122d7c20-7e6b-48b1-a71a-185a233e0e92", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on January 31, 2024. "}, "hash": "a842357c98a2426773e03ee0b9f901dd5fd675da656c2fbb90518e77de924066", "class_name": "RelatedNodeInfo"}}, "text": "The Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 0, "end_char_idx": 76, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "122d7c20-7e6b-48b1-a71a-185a233e0e92": {"__data__": {"id_": "122d7c20-7e6b-48b1-a71a-185a233e0e92", "embedding": null, "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on January 31, 2024. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "936b9e8d-bfcb-48b7-8a19-06076b2fed7b", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "The Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3b18400ffdd0138507ff70ec169c8fdc048e8cf951722dd429edbe1cfa57142", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de45eb66-ed9d-4f09-84bf-d436d3f3a082", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com . "}, "hash": "3bf4d28dddf2441cf28bf4644deeaa447cb55dc614911290fe7eb818bd7d372e", "class_name": "RelatedNodeInfo"}}, "text": "ET on January 31, 2024. ", "start_char_idx": 76, "end_char_idx": 100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de45eb66-ed9d-4f09-84bf-d436d3f3a082": {"__data__": {"id_": "de45eb66-ed9d-4f09-84bf-d436d3f3a082", "embedding": null, "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com . ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "122d7c20-7e6b-48b1-a71a-185a233e0e92", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on January 31, 2024. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce4880074fb59722261435c3c0ca6eaabe24f2d76e738b5251880b74bcb62e80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42dd1bbf-7a5d-4c42-979b-bcc11b496c6e", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. "}, "hash": "c7f82a1acce9e53d7297ed744144ab55986a65f2cf8242b8a79156745aa5a018", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com . ", "start_char_idx": 100, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42dd1bbf-7a5d-4c42-979b-bcc11b496c6e": {"__data__": {"id_": "42dd1bbf-7a5d-4c42-979b-bcc11b496c6e", "embedding": null, "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de45eb66-ed9d-4f09-84bf-d436d3f3a082", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com . ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c42fbd78f9800eabea6930f753d245cdf0392ac8ba552814598b0af4f0b067c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7389a997-000b-4395-8884-2f59578003cd", "node_type": "1", "metadata": {"window": "ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. "}, "hash": "cde738603429cb41a11f3b81df5fe682055cceaa6ffebd3d5f97348acfa25b2b", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "start_char_idx": 207, "end_char_idx": 446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7389a997-000b-4395-8884-2f59578003cd": {"__data__": {"id_": "7389a997-000b-4395-8884-2f59578003cd", "embedding": null, "metadata": {"window": "ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42dd1bbf-7a5d-4c42-979b-bcc11b496c6e", "node_type": "1", "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1745713770a38f1777357d33cf50d8fdef7fe98b89d42564057f7b390407ac1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2f0954c-b35f-4cbb-a712-dd4a1702290f", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 457478. "}, "hash": "1351e8f2400d02dd128cfce26075945662c66aae759b574ded5b969dfa65c289", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "start_char_idx": 446, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2f0954c-b35f-4cbb-a712-dd4a1702290f": {"__data__": {"id_": "c2f0954c-b35f-4cbb-a712-dd4a1702290f", "embedding": null, "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 457478. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7389a997-000b-4395-8884-2f59578003cd", "node_type": "1", "metadata": {"window": "ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1e0898549dee1f029780342650b061ec59e4c4e00d5ce226607bac146112d02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c545ea75-f9ec-4d0a-9748-4ab4a0fd66d9", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com . "}, "hash": "6452abdae45508d53ddaeea7c1be3c1e9bee8edf4d28fd34d03dcc7de61161ce", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 457478. ", "start_char_idx": 514, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c545ea75-f9ec-4d0a-9748-4ab4a0fd66d9": {"__data__": {"id_": "c545ea75-f9ec-4d0a-9748-4ab4a0fd66d9", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com . ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2f0954c-b35f-4cbb-a712-dd4a1702290f", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 457478. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b369324360cd85aad36327d902e9170fbe4f7fd4c3c84919c3d16c634335398", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5051af5-445d-4d26-a8e3-2ab5f2636e48", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "9efc4cc6a9f9b31faa29e6b4d2dacb437eb53e8b2bb84f1695e70820c2f8cc69", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com . ", "start_char_idx": 559, "end_char_idx": 646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5051af5-445d-4d26-a8e3-2ab5f2636e48": {"__data__": {"id_": "c5051af5-445d-4d26-a8e3-2ab5f2636e48", "embedding": null, "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c545ea75-f9ec-4d0a-9748-4ab4a0fd66d9", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com . ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25a3e9db21925f9fcd0800b509472eea2d060673610bf37fe61034a29d0e0df1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9897959-cdb3-4830-9f04-8ae61de1fa07", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "618c974f624fa15cdc44cad85ceee06dcfb593dd0c12c57e5f23f249c0dd0ee6", "class_name": "RelatedNodeInfo"}}, "text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 646, "end_char_idx": 769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9897959-cdb3-4830-9f04-8ae61de1fa07": {"__data__": {"id_": "d9897959-cdb3-4830-9f04-8ae61de1fa07", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5051af5-445d-4d26-a8e3-2ab5f2636e48", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d186d5df6783ec009fea154d8dcbb332438e59f8ab15b39a35bab466a4e5a2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c704000d-de3d-4eef-a706-7af740282ab5", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. "}, "hash": "77eb969ee02e8649608777c08fd4edcc9422536f218ab7349b94c0319884ea07", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 769, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c704000d-de3d-4eef-a706-7af740282ab5": {"__data__": {"id_": "c704000d-de3d-4eef-a706-7af740282ab5", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9897959-cdb3-4830-9f04-8ae61de1fa07", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 457478.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19e72e2eba3d2842b216b75c97c3e156258422c6372540545ac0d8528389833c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f212edaf-4249-4837-8cb4-a9c8c84d0644", "node_type": "1", "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. "}, "hash": "280f25b81fba3300f7f7447596821e1433f7a612add9050dfa6bebe6a693c943", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 839, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f212edaf-4249-4837-8cb4-a9c8c84d0644": {"__data__": {"id_": "f212edaf-4249-4837-8cb4-a9c8c84d0644", "embedding": null, "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c704000d-de3d-4eef-a706-7af740282ab5", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com .  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ab01365467de5db4c7dbcc7355834f517a2e0cdba708d1868889adc8bfcf89f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ccc53e3-a503-431e-a1ff-7a3996533257", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n", "original_text": "T o access the telephone\nreplay from within the U.S. "}, "hash": "c74454049d5ee3fe9cfb771a7797858290735ef6335db5971f40d05a140ac627", "class_name": "RelatedNodeInfo"}}, "text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "start_char_idx": 998, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ccc53e3-a503-431e-a1ff-7a3996533257": {"__data__": {"id_": "2ccc53e3-a503-431e-a1ff-7a3996533257", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n", "original_text": "T o access the telephone\nreplay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f212edaf-4249-4837-8cb4-a9c8c84d0644", "node_type": "1", "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5ae089a780c641d6871a803eaf097241cee3cd696209de901c1abe61608e12b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71d0612c-6d7c-4d7e-822e-8c311eca54d7", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "b9685ce4ab4f19da457833fcc450e4b06d90dc374935f2aa59b5e8b9671feaa4", "class_name": "RelatedNodeInfo"}}, "text": "T o access the telephone\nreplay from within the U.S. ", "start_char_idx": 1140, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71d0612c-6d7c-4d7e-822e-8c311eca54d7": {"__data__": {"id_": "71d0612c-6d7c-4d7e-822e-8c311eca54d7", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ccc53e3-a503-431e-a1ff-7a3996533257", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n", "original_text": "T o access the telephone\nreplay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8697c5af1546a74324ab65c4f582a3380369f5bf030cfcb511fd3719be6f544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2152c4d-5af8-4e8e-b176-c8c1ab07eb1d", "node_type": "1", "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United S tates, dial +1 (929) 458-6194. "}, "hash": "c58764fd88e288a961f909e163ab487ee890970670fd3ea87d26477f72beb195", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 1193, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2152c4d-5af8-4e8e-b176-c8c1ab07eb1d": {"__data__": {"id_": "a2152c4d-5af8-4e8e-b176-c8c1ab07eb1d", "embedding": null, "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United S tates, dial +1 (929) 458-6194. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71d0612c-6d7c-4d7e-822e-8c311eca54d7", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78b3bd52a4cf56bd0132dda6fb8fec1f0eca1391e0e5d86fe775b222ed37cdd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3342b03-b3be-43d5-93be-ac323380d63f", "node_type": "1", "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "The access\ncode for the replay is 308642.\n"}, "hash": "5b0bba9beff9fa605bd2a1f5ed1ed1679c984fc1a2902f40e0099f97ff8207fa", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United S tates, dial +1 (929) 458-6194. ", "start_char_idx": 1226, "end_char_idx": 1283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3342b03-b3be-43d5-93be-ac323380d63f": {"__data__": {"id_": "a3342b03-b3be-43d5-93be-ac323380d63f", "embedding": null, "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "The access\ncode for the replay is 308642.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2152c4d-5af8-4e8e-b176-c8c1ab07eb1d", "node_type": "1", "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United S tates, dial +1 (929) 458-6194. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c76db6ca69cd4025d0eb7f2f5c739b1cd4bc7abe04abac1aaf9c5fe91e2001f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ff000ee-28bb-4b36-925b-41d39d60a847", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n"}, "hash": "9045dc7bb1eead2772d25fb51c80f57be75538e7e33169380994b9264626d9f5", "class_name": "RelatedNodeInfo"}}, "text": "The access\ncode for the replay is 308642.\n", "start_char_idx": 1283, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ff000ee-28bb-4b36-925b-41d39d60a847": {"__data__": {"id_": "6ff000ee-28bb-4b36-925b-41d39d60a847", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3342b03-b3be-43d5-93be-ac323380d63f", "node_type": "1", "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "The access\ncode for the replay is 308642.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "776574ac58bfed1473b3a93278ae38f961504c3de77d9d60714c0957fcfd7eec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21e57375-3914-43c6-abc9-4d9b9c2decae", "node_type": "1", "metadata": {"window": "From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "8e9580de0173dd3b96c17cad2d5f6364c2bd3f559880c6f50e6b2297fcd0df4c", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n", "start_char_idx": 1325, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21e57375-3914-43c6-abc9-4d9b9c2decae": {"__data__": {"id_": "21e57375-3914-43c6-abc9-4d9b9c2decae", "embedding": null, "metadata": {"window": "From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ff000ee-28bb-4b36-925b-41d39d60a847", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "191f351feeecc1364b2ba8dc3ca5d9626a77c9cd0ccd019d7542d02441172bea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9f4eb73-408d-4ab5-8530-097a203d55a1", "node_type": "1", "metadata": {"window": "The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. "}, "hash": "65f339df19bd9abe6565f731793aebf304fe840dbc3e7c636d194ab0eff51e71", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 1493, "end_char_idx": 1622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9f4eb73-408d-4ab5-8530-097a203d55a1": {"__data__": {"id_": "b9f4eb73-408d-4ab5-8530-097a203d55a1", "embedding": null, "metadata": {"window": "The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21e57375-3914-43c6-abc9-4d9b9c2decae", "node_type": "1", "metadata": {"window": "From outside the United S tates, dial +1 (929) 458-6194.  The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e70663f41674c12c9c0d50a2e2c6c14061dfeb74bd9d049327964f9c96278344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10ae0ec4-46e6-4541-aa29-17cd4d93f2b8", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n"}, "hash": "128a78508d9af65187a5c194d7c44fb3b766f1960df749021ce4ca6babb4b1b7", "class_name": "RelatedNodeInfo"}}, "text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "start_char_idx": 1622, "end_char_idx": 1774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10ae0ec4-46e6-4541-aa29-17cd4d93f2b8": {"__data__": {"id_": "10ae0ec4-46e6-4541-aa29-17cd4d93f2b8", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9f4eb73-408d-4ab5-8530-097a203d55a1", "node_type": "1", "metadata": {"window": "The access\ncode for the replay is 308642.\n Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "967447cbdab44029eab29810679c2b6da7fc9a231dd544858787c4e58dc58cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a755df30-6d53-4bf5-906d-9252fe5c6f27", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. "}, "hash": "4a25185a75d4b3af413da6a71b8e01ac980a9e5efc53ce4dead13d4969136070", "class_name": "RelatedNodeInfo"}}, "text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "start_char_idx": 1774, "end_char_idx": 1895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a755df30-6d53-4bf5-906d-9252fe5c6f27": {"__data__": {"id_": "a755df30-6d53-4bf5-906d-9252fe5c6f27", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10ae0ec4-46e6-4541-aa29-17cd4d93f2b8", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ent\nCencora management will be attending the following investor event in the coming months:\nBarclays Global Healthcare Conference March 14, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6881076c6ba5451632cf8e7ec0ccdce31f00ecb9f97560aadddb296d86d9aca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef46d772-00a5-4777-a4ca-345469ec52e2", "node_type": "1", "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. "}, "hash": "ce0d6f5a21e058edaf7fcceaec4e1c2f20aacaec29289ee298832dd911e99742", "class_name": "RelatedNodeInfo"}}, "text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "start_char_idx": 1895, "end_char_idx": 2013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef46d772-00a5-4777-a4ca-345469ec52e2": {"__data__": {"id_": "ef46d772-00a5-4777-a4ca-345469ec52e2", "embedding": null, "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a755df30-6d53-4bf5-906d-9252fe5c6f27", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c29e9517daf57c113788c840ac3bfbdbbad33767e8102875ab40065c76aa2322", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb2ac460-437b-4f24-a659-d8a88fba779f", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. "}, "hash": "c1e84bb5f3c06763a7af5eacd8775e7e9d14ae2290c35a3eeae5a53d889b0689", "class_name": "RelatedNodeInfo"}}, "text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 2013, "end_char_idx": 2187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb2ac460-437b-4f24-a659-d8a88fba779f": {"__data__": {"id_": "bb2ac460-437b-4f24-a659-d8a88fba779f", "embedding": null, "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef46d772-00a5-4777-a4ca-345469ec52e2", "node_type": "1", "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd1f0429f09b032589480874083fdc880aedc8d691e9d711f616bbae5db8d390", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dd3a4df-86d9-47c6-927a-803f3129f125", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). "}, "hash": "0dec85da0fa9b184431cf8ce5d1b12f4bb3109aaf7cf7208f93bae37c74b20db", "class_name": "RelatedNodeInfo"}}, "text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "start_char_idx": 2187, "end_char_idx": 2309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dd3a4df-86d9-47c6-927a-803f3129f125": {"__data__": {"id_": "4dd3a4df-86d9-47c6-927a-803f3129f125", "embedding": null, "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb2ac460-437b-4f24-a659-d8a88fba779f", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f293d8b2e9acd231e78c31b2252007ceec98eb05a51a1c990759892eb07e079", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff6d180c-b880-4b02-8bf4-731375eb17b1", "node_type": "1", "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. "}, "hash": "b3ec51a7d2d761e7e83f68fea8216c4ec2dc03ea0caf4007787ea04508f433fc", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "start_char_idx": 2309, "end_char_idx": 2680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff6d180c-b880-4b02-8bf4-731375eb17b1": {"__data__": {"id_": "ff6d180c-b880-4b02-8bf4-731375eb17b1", "embedding": null, "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dd3a4df-86d9-47c6-927a-803f3129f125", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df0741a94f30d30bb410f11bef8179a534394129cdc1058aa597d0c96d8f61e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cf3cd46-3178-4ad7-9ad4-011d62b65fb0", "node_type": "1", "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "5e06346399805fee268ed12bf2a4013f2d82be81894033fa074577cd5e4f7170", "class_name": "RelatedNodeInfo"}}, "text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "start_char_idx": 2680, "end_char_idx": 3125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cf3cd46-3178-4ad7-9ad4-011d62b65fb0": {"__data__": {"id_": "7cf3cd46-3178-4ad7-9ad4-011d62b65fb0", "embedding": null, "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff6d180c-b880-4b02-8bf4-731375eb17b1", "node_type": "1", "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: W e are united in our\nresponsibility to create healthier futures.  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "original_text": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ad218dbae58c81c89265713bd0ec61d5e4c05fbd63b866d06d57199608e9d93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8d072e9-f01f-4991-8c16-5ee8e3881290", "node_type": "1", "metadata": {"window": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. "}, "hash": "e63d53f676fbf743491f5d321a6f563baa7acc42546a52cf3d1f0c70a50313a1", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 3125, "end_char_idx": 3287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8d072e9-f01f-4991-8c16-5ee8e3881290": {"__data__": {"id_": "b8d072e9-f01f-4991-8c16-5ee8e3881290", "embedding": null, "metadata": {"window": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cf3cd46-3178-4ad7-9ad4-011d62b65fb0", "node_type": "1", "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7428ef93a49c3bc36df3197a96de48d7e89999032b6d86e4ad179362be78fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c7f9c5c-bf63-4d8b-924f-bac0f41ce395", "node_type": "1", "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. "}, "hash": "bc4cad6d0fa631fa6c20f0cf9b626497073fe3876a0ef60b9c19bb2e0abc69ae", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "start_char_idx": 3287, "end_char_idx": 3486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c7f9c5c-bf63-4d8b-924f-bac0f41ce395": {"__data__": {"id_": "2c7f9c5c-bf63-4d8b-924f-bac0f41ce395", "embedding": null, "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8d072e9-f01f-4991-8c16-5ee8e3881290", "node_type": "1", "metadata": {"window": "Learn more at investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae2f42df99f56c626e87f34d55b9f74177f9e5ac3d254076dd3c4af43af7a039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a56dc27-0721-43a7-af6c-a801a6ab5258", "node_type": "1", "metadata": {"window": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n"}, "hash": "64505bc1aa5f2881df88d80d4082e40a76bf41a21b215ac1f0abea821f00f042", "class_name": "RelatedNodeInfo"}}, "text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 3486, "end_char_idx": 3914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a56dc27-0721-43a7-af6c-a801a6ab5258": {"__data__": {"id_": "9a56dc27-0721-43a7-af6c-a801a6ab5258", "embedding": null, "metadata": {"window": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c7f9c5c-bf63-4d8b-924f-bac0f41ce395", "node_type": "1", "metadata": {"window": "W ords such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17002861eeda0c28d1485ab5b20ac46856209f1225ba7d68a5ca5979c47b8c0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a26ad67-cd3c-433f-80f5-f657dfc9b5ef", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "5"}, "hash": "44373af56a70002dc4ed1b77a5411af5ccfceb7fbd3250f17363d83315079f09", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "start_char_idx": 3914, "end_char_idx": 4063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a26ad67-cd3c-433f-80f5-f657dfc9b5ef": {"__data__": {"id_": "8a26ad67-cd3c-433f-80f5-f657dfc9b5ef", "embedding": null, "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "5", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f2cc6bc05123c7cfae322c8196bf658d719ded1cfc843ca932aba06d071256", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a56dc27-0721-43a7-af6c-a801a6ab5258", "node_type": "1", "metadata": {"window": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "469a8edc78ef00e0d7971ea0c60ecf7274ef693f98bca06699c57a1e923689c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be7dffdf-6ca7-4933-8c51-192e1ba13100", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "\u00a0\nCENC ORA, INC.\n"}, "hash": "a37f4f462fbe8407342b1c83c8ef49fee4c7aa7274cb293dff4edb2f28de81dd", "class_name": "RelatedNodeInfo"}}, "text": "5", "start_char_idx": 506, "end_char_idx": 507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be7dffdf-6ca7-4933-8c51-192e1ba13100": {"__data__": {"id_": "be7dffdf-6ca7-4933-8c51-192e1ba13100", "embedding": null, "metadata": {"window": "\u00a0\nCENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "\u00a0\nCENC ORA, INC.\n", "page_label": "6", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c45ebcc8-9497-4075-9cd5-44ecc708ab11", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98bd2bc0fdf4171ad790b5e2dd87bd4e9dbfcdaea36aa04908ae6382cd4c3af2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a26ad67-cd3c-433f-80f5-f657dfc9b5ef", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included in the \u201cRisk F actors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed\nby the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any\nforward-looking statements, except as required by the federal securities laws.\n 5", "original_text": "5", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c7da1897b596f22ad669c88027d79b2b6d3b8abf0c916f2e168b5d4c5950c1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da32d30d-ef22-4b7f-a424-a32d3f0fb6ed", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6"}, "hash": "c4ee764458771f2472073f19e9582d974c7a6fa6bbfba4fa70d6931ed8a72fbb", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\nCENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 17, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da32d30d-ef22-4b7f-a424-a32d3f0fb6ed": {"__data__": {"id_": "da32d30d-ef22-4b7f-a424-a32d3f0fb6ed", "embedding": null, "metadata": {"window": "\u00a0\nCENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c45ebcc8-9497-4075-9cd5-44ecc708ab11", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98bd2bc0fdf4171ad790b5e2dd87bd4e9dbfcdaea36aa04908ae6382cd4c3af2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be7dffdf-6ca7-4933-8c51-192e1ba13100", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "\u00a0\nCENC ORA, INC.\n", "page_label": "6", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39dd9235d44c951e8a0fca383c78c07f2657a160c47c52eb8ff6b337f72e994e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c75d8b03-b331-444b-9b34-0e1ed7aac5cc", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n", "original_text": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0"}, "hash": "c260045b26d5937bb6e942cbe72f2ef45ca9f45c072dc03b67970df50d6a8217", "class_name": "RelatedNodeInfo"}}, "text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "start_char_idx": 17, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c75d8b03-b331-444b-9b34-0e1ed7aac5cc": {"__data__": {"id_": "c75d8b03-b331-444b-9b34-0e1ed7aac5cc", "embedding": null, "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n", "original_text": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de5c23ed3dc33c3145b1cf4b82f768c64bd73cc5875bdea4be0247105fb538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da32d30d-ef22-4b7f-a424-a32d3f0fb6ed", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3cc86db2bbea619a8df9fdb84d61133b3db9889aad89cb0a62f851cb8e47ec46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b1056e6-c638-46f5-9128-91b029e3ecdd", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n", "original_text": "$601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023. "}, "hash": "6f96e66fb24933374642f99a75cf5fe5558ecbdd59937b5dd6b89c0da3d77958", "class_name": "RelatedNodeInfo"}}, "text": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "start_char_idx": 0, "end_char_idx": 373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b1056e6-c638-46f5-9128-91b029e3ecdd": {"__data__": {"id_": "3b1056e6-c638-46f5-9128-91b029e3ecdd", "embedding": null, "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n", "original_text": "$601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023. ", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de5c23ed3dc33c3145b1cf4b82f768c64bd73cc5875bdea4be0247105fb538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c75d8b03-b331-444b-9b34-0e1ed7aac5cc", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n", "original_text": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95d51a43d4d03a2644270eb30c09886c3794fb49c080e8c49537a684e0464ced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "286ee9f8-d878-4d34-93d7-28dca11c3d39", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n"}, "hash": "419181a67964f09cb21c7b4bd905ae2d4e3bd554acca851a0393123027e5c7ae", "class_name": "RelatedNodeInfo"}}, "text": "$601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023. ", "start_char_idx": 373, "end_char_idx": 958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "286ee9f8-d878-4d34-93d7-28dca11c3d39": {"__data__": {"id_": "286ee9f8-d878-4d34-93d7-28dca11c3d39", "embedding": null, "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de5c23ed3dc33c3145b1cf4b82f768c64bd73cc5875bdea4be0247105fb538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b1056e6-c638-46f5-9128-91b029e3ecdd", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n", "original_text": "$601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023. ", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c677289c3fe0570b66a18113df7fa971e8c76f8f539af0386e41e86dba94f62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "674a12e6-dcc8-4706-8fed-cff0cf29e1e6", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n"}, "hash": "b80c7471f5c3a71d7548687594ee6087cc314b34004ce4207ff331eb2bf3516a", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n", "start_char_idx": 958, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "674a12e6-dcc8-4706-8fed-cff0cf29e1e6": {"__data__": {"id_": "674a12e6-dcc8-4706-8fed-cff0cf29e1e6", "embedding": null, "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de5c23ed3dc33c3145b1cf4b82f768c64bd73cc5875bdea4be0247105fb538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "286ee9f8-d878-4d34-93d7-28dca11c3d39", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d94468391dd37e302b213f72060a1d6c1a19dcaf9fd645c00b6912676eec458", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d30371a8-9f58-40d9-9dde-5a21022b48fc", "node_type": "1", "metadata": {"window": "$601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "CENC ORA, INC.\n"}, "hash": "5d9f2acaa5344e5a27b8a4999bfb598a6c3c5edfb6452db48ec29bd409e002cd", "class_name": "RelatedNodeInfo"}}, "text": "2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n", "start_char_idx": 1168, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d30371a8-9f58-40d9-9dde-5a21022b48fc": {"__data__": {"id_": "d30371a8-9f58-40d9-9dde-5a21022b48fc", "embedding": null, "metadata": {"window": "$601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "CENC ORA, INC.\n", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de5c23ed3dc33c3145b1cf4b82f768c64bd73cc5875bdea4be0247105fb538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "674a12e6-dcc8-4706-8fed-cff0cf29e1e6", "node_type": "1", "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4de45e5f65b65c506bc9b2384cf2c40bb2b476930786e2e1c798919d6375484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69da5285-393a-4103-9869-ddc5c4d7697f", "node_type": "1", "metadata": {"window": "Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "7"}, "hash": "262d83685ac56710cf2fe61c7986e94ba2b260f0065eae106035bf62207a2762", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 1479, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69da5285-393a-4103-9869-ddc5c4d7697f": {"__data__": {"id_": "69da5285-393a-4103-9869-ddc5c4d7697f", "embedding": null, "metadata": {"window": "Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "7", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de5c23ed3dc33c3145b1cf4b82f768c64bd73cc5875bdea4be0247105fb538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d30371a8-9f58-40d9-9dde-5a21022b48fc", "node_type": "1", "metadata": {"window": "$601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "CENC ORA, INC.\n", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e1056f8d521bca4465b9449896a05dc61f7522afab975a25b4c0e1cbe685940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b8eb401-6fd5-438b-bcd5-7d1ebe96237e", "node_type": "1", "metadata": {"window": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8"}, "hash": "a51f87289ab4b351d855a382a032680b4b5a2cecb343e858bd2e730e5d668eab", "class_name": "RelatedNodeInfo"}}, "text": "7", "start_char_idx": 29, "end_char_idx": 30, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b8eb401-6fd5-438b-bcd5-7d1ebe96237e": {"__data__": {"id_": "2b8eb401-6fd5-438b-bcd5-7d1ebe96237e", "embedding": null, "metadata": {"window": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "page_label": "8", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cce6d223-032b-4099-8a5f-acb07bd5f1c5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7c7df8eb9a7d22f8897debc3d3a2fc121c9aab766d40f716fcb52407b240c6f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69da5285-393a-4103-9869-ddc5c4d7697f", "node_type": "1", "metadata": {"window": "Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n CENC ORA, INC.\n 7", "original_text": "7", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c077341bd55cdf74440e636094f10e9b25925f8e94d615069c47c766b9c215fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de959daf-1918-49f8-881f-0f555b397209", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n", "original_text": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "438f01c8a7fe5a57fa82a26eaae26f10279932bef4e5b3447c2995370ccdef12", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "start_char_idx": 0, "end_char_idx": 1351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de959daf-1918-49f8-881f-0f555b397209": {"__data__": {"id_": "de959daf-1918-49f8-881f-0f555b397209", "embedding": null, "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n", "original_text": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ef02d05663e27f6bcbdbd17785618be2e216f6d511da5e0eead9df908bf3165", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b8eb401-6fd5-438b-bcd5-7d1ebe96237e", "node_type": "1", "metadata": {"window": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "page_label": "8", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "224c3ec13427a0d802a0d340ad457995c50c17edb927bb12a8cec7b3608c0fe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56b73020-09a7-4d9f-b269-5c1e6651029b", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n"}, "hash": "5c6eb63538643553eee672b18ac5af164f42ee59e5ae324e4fee812466566ca7", "class_name": "RelatedNodeInfo"}}, "text": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56b73020-09a7-4d9f-b269-5c1e6651029b": {"__data__": {"id_": "56b73020-09a7-4d9f-b269-5c1e6651029b", "embedding": null, "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ef02d05663e27f6bcbdbd17785618be2e216f6d511da5e0eead9df908bf3165", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de959daf-1918-49f8-881f-0f555b397209", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n", "original_text": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35d58f8815306eab07b8b686e09e36aa682fc917824f223995d832b75462f336", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edf289cb-61b9-4d88-813f-403785d70887", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n"}, "hash": "58338ca07e46d9e3f93e8c4b3b5b8115a13538ea371faa27938f6f777b76afec", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n", "start_char_idx": 602, "end_char_idx": 1129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edf289cb-61b9-4d88-813f-403785d70887": {"__data__": {"id_": "edf289cb-61b9-4d88-813f-403785d70887", "embedding": null, "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ef02d05663e27f6bcbdbd17785618be2e216f6d511da5e0eead9df908bf3165", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56b73020-09a7-4d9f-b269-5c1e6651029b", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2957e56dd552c57849d041e68d00ee3533b26c11b1c6c8a90202eab1c539875", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3552026b-ae7e-4c7e-8911-f985f70f119d", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "3The sum of the components does not equal the total due to rounding.\n"}, "hash": "46a44eec5d9781f2c89c24c6004d778be792342f6a147197475c2c672153be30", "class_name": "RelatedNodeInfo"}}, "text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n", "start_char_idx": 1129, "end_char_idx": 1312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3552026b-ae7e-4c7e-8911-f985f70f119d": {"__data__": {"id_": "3552026b-ae7e-4c7e-8911-f985f70f119d", "embedding": null, "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "3The sum of the components does not equal the total due to rounding.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ef02d05663e27f6bcbdbd17785618be2e216f6d511da5e0eead9df908bf3165", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edf289cb-61b9-4d88-813f-403785d70887", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e075e3567972cd01f22373447dbfed7296f28880b794237bac055ba5d63c6ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b7fd741-f7a0-4657-b6ab-7e3451d817a9", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "9"}, "hash": "58c148a1c296ecae1529634062c07469c2f4c0886ac9d6f503613eeb97f42b94", "class_name": "RelatedNodeInfo"}}, "text": "3The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 1312, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b7fd741-f7a0-4657-b6ab-7e3451d817a9": {"__data__": {"id_": "5b7fd741-f7a0-4657-b6ab-7e3451d817a9", "embedding": null, "metadata": {"window": "prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "9", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ef02d05663e27f6bcbdbd17785618be2e216f6d511da5e0eead9df908bf3165", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3552026b-ae7e-4c7e-8911-f985f70f119d", "node_type": "1", "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "3The sum of the components does not equal the total due to rounding.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb4002427bc055e67fa4f05c2a26af4cda1c44ef75e4161c1a7ee23c8e144815", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9286689-fe56-4f66-a454-2605fa62ea78", "node_type": "1", "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n"}, "hash": "fece9d32bb6b26384f678a0b62956128f89c7586bf5f44ddb93afe944b0fa9fd", "class_name": "RelatedNodeInfo"}}, "text": "9", "start_char_idx": 74, "end_char_idx": 75, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9286689-fe56-4f66-a454-2605fa62ea78": {"__data__": {"id_": "d9286689-fe56-4f66-a454-2605fa62ea78", "embedding": null, "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6d608a1-af96-4d54-999d-b63c25fc36ca", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53311bbcbc7551d2f27f1dff89e4891b2fd506a1957d9a532cb82a1a85b7958f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b7fd741-f7a0-4657-b6ab-7e3451d817a9", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n 9", "original_text": "9", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "389fafc0ea6d6c5c5a46445ef7d10fd72ba129c4b5244362246675235a42b1db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e96e3fb-7716-471d-967b-dccde8aa7823", "node_type": "1", "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "CENC ORA, INC.\n"}, "hash": "3e30ad1557a31d99bd9d664a63c311a0686592ae7e7fa71de6fc7df15f23fa77", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e96e3fb-7716-471d-967b-dccde8aa7823": {"__data__": {"id_": "0e96e3fb-7716-471d-967b-dccde8aa7823", "embedding": null, "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "CENC ORA, INC.\n", "page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6d608a1-af96-4d54-999d-b63c25fc36ca", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53311bbcbc7551d2f27f1dff89e4891b2fd506a1957d9a532cb82a1a85b7958f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9286689-fe56-4f66-a454-2605fa62ea78", "node_type": "1", "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea9a79c1db438837cb78f517eb41c961d270740a68ed68bb1a00bfcd4af60308", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3af2534a-0d9d-48f8-b4b0-035edc402346", "node_type": "1", "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10"}, "hash": "a2335cccb7794537e00e0dbcf27fc311a424224cfb087186d1df5b960ff0daf1", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 181, "end_char_idx": 196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3af2534a-0d9d-48f8-b4b0-035edc402346": {"__data__": {"id_": "3af2534a-0d9d-48f8-b4b0-035edc402346", "embedding": null, "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6d608a1-af96-4d54-999d-b63c25fc36ca", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53311bbcbc7551d2f27f1dff89e4891b2fd506a1957d9a532cb82a1a85b7958f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e96e3fb-7716-471d-967b-dccde8aa7823", "node_type": "1", "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "CENC ORA, INC.\n", "page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da0bb19f8b76999895eaac35cf584ea460fc4b10a51d272bc479984de0f179fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "567574be-f297-4af8-bd53-2cf33b66cb85", "node_type": "1", "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n"}, "hash": "c1f10d8c71318d499c51563c1e85d4f033adc18ccb1c54c55f0f0a4c363b7633", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "start_char_idx": 196, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "567574be-f297-4af8-bd53-2cf33b66cb85": {"__data__": {"id_": "567574be-f297-4af8-bd53-2cf33b66cb85", "embedding": null, "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "372c63ac-47ac-4945-bc66-9bfc697c973c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a87c89ada0cb503c2afce408ee9a045f5fe99427601646d7567fa8469935a832", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3af2534a-0d9d-48f8-b4b0-035edc402346", "node_type": "1", "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a782f17664b0763fd4ed01791ca62448f47f0437974e6e05184dd671ea917e67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e83fcff-4482-4b57-88e4-9c17c27bae9b", "node_type": "1", "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "6e906095f445931ac0edf99fd51aca4e281011f0af3185e66d196e5a90fd6c98", "class_name": "RelatedNodeInfo"}}, "text": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e83fcff-4482-4b57-88e4-9c17c27bae9b": {"__data__": {"id_": "0e83fcff-4482-4b57-88e4-9c17c27bae9b", "embedding": null, "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "372c63ac-47ac-4945-bc66-9bfc697c973c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a87c89ada0cb503c2afce408ee9a045f5fe99427601646d7567fa8469935a832", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "567574be-f297-4af8-bd53-2cf33b66cb85", "node_type": "1", "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97f994afb47ca32f750c542b75b8ad056aaa4bb7fe0c470de775c4b29795bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f218db4d-1e9e-4064-bf37-fec27509c100", "node_type": "1", "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "11"}, "hash": "b52b97fb681fab665a32792c2f9108d54efa769ad6734e48bb7544605d88857d", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 1092, "end_char_idx": 1269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f218db4d-1e9e-4064-bf37-fec27509c100": {"__data__": {"id_": "f218db4d-1e9e-4064-bf37-fec27509c100", "embedding": null, "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "11", "page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "372c63ac-47ac-4945-bc66-9bfc697c973c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a87c89ada0cb503c2afce408ee9a045f5fe99427601646d7567fa8469935a832", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e83fcff-4482-4b57-88e4-9c17c27bae9b", "node_type": "1", "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e24e77a4bb0e5acea840467386556cc3b41d9d474bb404b44abb3390997b93c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c2a2ec3-4c3a-4901-b946-8e27c898ab60", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "\u00a0\nCENC ORA, INC.\n"}, "hash": "757517f4e152970008380097042bb1d9ecfbaf0d072aec351a9de5a2f47eab08", "class_name": "RelatedNodeInfo"}}, "text": "11", "start_char_idx": 1269, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c2a2ec3-4c3a-4901-b946-8e27c898ab60": {"__data__": {"id_": "9c2a2ec3-4c3a-4901-b946-8e27c898ab60", "embedding": null, "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "\u00a0\nCENC ORA, INC.\n", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc1c3ca888d63878f2d7eb0388844c2f0d20a33391afcd48c3323bbb140a8950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f218db4d-1e9e-4064-bf37-fec27509c100", "node_type": "1", "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "11", "page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1f135cbb1435c4bacb6e371884bafee38b89e3aba2b2ffc4777cf6744f28d37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "916a0d52-6be1-4710-b0d0-ed8e7d955e37", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. "}, "hash": "28423cef8e13566819f432242e5f50894e2f729b642cfb3d529118fecd61a085", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\nCENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 17, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "916a0d52-6be1-4710-b0d0-ed8e7d955e37": {"__data__": {"id_": "916a0d52-6be1-4710-b0d0-ed8e7d955e37", "embedding": null, "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc1c3ca888d63878f2d7eb0388844c2f0d20a33391afcd48c3323bbb140a8950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c2a2ec3-4c3a-4901-b946-8e27c898ab60", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "\u00a0\nCENC ORA, INC.\n", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6419a3cc7704a97fc36ff947cf7db64f7a715d12bcd46f05304f02a4cd39922f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b74c5df6-d1d3-4f28-9434-b030ee45dabb", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. "}, "hash": "25759c3b161d0e9059186b91f2483e885785f58d30edcb5589ccc716bf66f292", "class_name": "RelatedNodeInfo"}}, "text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "start_char_idx": 17, "end_char_idx": 150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b74c5df6-d1d3-4f28-9434-b030ee45dabb": {"__data__": {"id_": "b74c5df6-d1d3-4f28-9434-b030ee45dabb", "embedding": null, "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc1c3ca888d63878f2d7eb0388844c2f0d20a33391afcd48c3323bbb140a8950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "916a0d52-6be1-4710-b0d0-ed8e7d955e37", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3db5c14b5cbf0a9a92ad971eea2004b960233dc7a0dc1e44752cb2c9243b72e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a9557ba-cb7a-4d66-aeb8-63a9c76f49b2", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12"}, "hash": "e5fa3f18bb7c6755c255e45f3d0fc59269a13a7337044fddb352dbea45d5ee6c", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "start_char_idx": 150, "end_char_idx": 464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a9557ba-cb7a-4d66-aeb8-63a9c76f49b2": {"__data__": {"id_": "4a9557ba-cb7a-4d66-aeb8-63a9c76f49b2", "embedding": null, "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc1c3ca888d63878f2d7eb0388844c2f0d20a33391afcd48c3323bbb140a8950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b74c5df6-d1d3-4f28-9434-b030ee45dabb", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbe181362b23f2e107c516626d6cdc8a28d6ded78b236bd6edba585f5d612958", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "760b2366-f13a-46c1-b76e-ef4b8063ca24", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "7118d20c010bf7373afa98709cf0b0420dbbf712046b5057512f591117b513a4", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "start_char_idx": 464, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "760b2366-f13a-46c1-b76e-ef4b8063ca24": {"__data__": {"id_": "760b2366-f13a-46c1-b76e-ef4b8063ca24", "embedding": null, "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eb2ebcedf48bdbf8598d270cecc85f27b6992cdf0511af8a19d68f79bf98078", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a9557ba-cb7a-4d66-aeb8-63a9c76f49b2", "node_type": "1", "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67e5e69c1dab6957d9401203e6a73bf726336f9bf9350cfe97cf00a4e9092884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebedd894-4587-4b80-8d8e-ad0648f5ad15", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "ed2370f60cf37cda46a2351ee2df877003f708a6c617ba698d44aff3ca6c9fa6", "class_name": "RelatedNodeInfo"}}, "text": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebedd894-4587-4b80-8d8e-ad0648f5ad15": {"__data__": {"id_": "ebedd894-4587-4b80-8d8e-ad0648f5ad15", "embedding": null, "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eb2ebcedf48bdbf8598d270cecc85f27b6992cdf0511af8a19d68f79bf98078", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "760b2366-f13a-46c1-b76e-ef4b8063ca24", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b28446d0cc56d882ad5c3415fb34a087229c90b449d5efce55c6480aa848dbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ce8742f-aca9-4cfc-b457-86c82fb5000a", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "16d33876d3c3055d938dcef44047d16dfb7ab2219cc5d568ec24d0ff8e7aaff8", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 313, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ce8742f-aca9-4cfc-b457-86c82fb5000a": {"__data__": {"id_": "1ce8742f-aca9-4cfc-b457-86c82fb5000a", "embedding": null, "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eb2ebcedf48bdbf8598d270cecc85f27b6992cdf0511af8a19d68f79bf98078", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebedd894-4587-4b80-8d8e-ad0648f5ad15", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9834350c7faebd451af895c7b1de7c0e5805d642fd99331ac3d2cbb307554172", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05552a8d-f47a-465f-a596-75f8c63520ae", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13"}, "hash": "3870defad8179ced7d33cbc247513632b95725f6a1d6da84735635d298cbf03b", "class_name": "RelatedNodeInfo"}}, "text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 637, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05552a8d-f47a-465f-a596-75f8c63520ae": {"__data__": {"id_": "05552a8d-f47a-465f-a596-75f8c63520ae", "embedding": null, "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eb2ebcedf48bdbf8598d270cecc85f27b6992cdf0511af8a19d68f79bf98078", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ce8742f-aca9-4cfc-b457-86c82fb5000a", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1c03bcfe21f62a720605d21de4b75c68454f999330fba7abcd1c80aae0159b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06fec38a-0ae0-43ac-953c-621d3bfb0cd4", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n"}, "hash": "159724f3089a2347413172db789926035d7300a72299bc49c6b63a76490c4b4d", "class_name": "RelatedNodeInfo"}}, "text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "start_char_idx": 784, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06fec38a-0ae0-43ac-953c-621d3bfb0cd4": {"__data__": {"id_": "06fec38a-0ae0-43ac-953c-621d3bfb0cd4", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdc8970d-6d35-4af7-868f-f6f4562a32da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebaac07e5bb86e70fbe452652eea607ded8a4de1cf7576bdccbb76355807f3eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05552a8d-f47a-465f-a596-75f8c63520ae", "node_type": "1", "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "462c721675fd854d0320713f1824150597e3fdd3be08768b02472861207a7315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5330729-80c9-43dd-88c7-d63bdf9c3dcd", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "CENC ORA, INC.\n"}, "hash": "46d85ef019c002fa71848ae556f10eafbccf3950ad96d2b556c7311ec564ae85", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5330729-80c9-43dd-88c7-d63bdf9c3dcd": {"__data__": {"id_": "b5330729-80c9-43dd-88c7-d63bdf9c3dcd", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "CENC ORA, INC.\n", "page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdc8970d-6d35-4af7-868f-f6f4562a32da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebaac07e5bb86e70fbe452652eea607ded8a4de1cf7576bdccbb76355807f3eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06fec38a-0ae0-43ac-953c-621d3bfb0cd4", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed9175ac2f7b85faca2fe1c037bec398ffa376af55d4693a2b69b7c893144ed8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2f33c94-4334-4d30-a47a-d3e74eb1f016", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14"}, "hash": "b820e489665408d0bb62fa44ee71c869ca9b0648cbf311954a91b694d01b8946", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 179, "end_char_idx": 194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2f33c94-4334-4d30-a47a-d3e74eb1f016": {"__data__": {"id_": "f2f33c94-4334-4d30-a47a-d3e74eb1f016", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cdc8970d-6d35-4af7-868f-f6f4562a32da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebaac07e5bb86e70fbe452652eea607ded8a4de1cf7576bdccbb76355807f3eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5330729-80c9-43dd-88c7-d63bdf9c3dcd", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "CENC ORA, INC.\n", "page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5226960278c606d3eecacf87c31dc75570cbb774fe4183e6d88fc0b30fffbc0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c14bc8b-2999-4c9e-bc2f-8f6e4d902659", "node_type": "1", "metadata": {"window": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "original_text": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n"}, "hash": "57c4339b3be110cfc9a34fc98c0c61ee8776c56de412806da0c46c6a32260def", "class_name": "RelatedNodeInfo"}}, "text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "start_char_idx": 194, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c14bc8b-2999-4c9e-bc2f-8f6e4d902659": {"__data__": {"id_": "0c14bc8b-2999-4c9e-bc2f-8f6e4d902659", "embedding": null, "metadata": {"window": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "original_text": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n", "page_label": "15", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a36f69b-81ad-4fc2-bb42-f0f8e2999c9d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4184eac637d27fc1172667455650a16201fdab1aaec99f9888e7a9dc671312", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2f33c94-4334-4d30-a47a-d3e74eb1f016", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90fdcc0e98f94296ab74de59b1854792d934ce4d8d1512ca442ed691a462dfaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04893a0d-db67-47de-95ca-3d6ce9bb9b2c", "node_type": "1", "metadata": {"window": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15"}, "hash": "406b98655d41dde8d0a53fda91178ba7aec7fa659bd66a957212384b3d32cbcb", "class_name": "RelatedNodeInfo"}}, "text": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04893a0d-db67-47de-95ca-3d6ce9bb9b2c": {"__data__": {"id_": "04893a0d-db67-47de-95ca-3d6ce9bb9b2c", "embedding": null, "metadata": {"window": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "page_label": "15", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a36f69b-81ad-4fc2-bb42-f0f8e2999c9d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4184eac637d27fc1172667455650a16201fdab1aaec99f9888e7a9dc671312", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c14bc8b-2999-4c9e-bc2f-8f6e4d902659", "node_type": "1", "metadata": {"window": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "original_text": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n", "page_label": "15", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf8209263484f7fd68e9ae9f01d50a7d218f22b7ca43d593afa96cb203f99d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e1ae334-fdca-4f65-8faf-9368a28adf85", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "original_text": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16"}, "hash": "dcc4e9e2f467fc4c52514eb7724d1a393615764119a6e05f3d453f36268d7cb9", "class_name": "RelatedNodeInfo"}}, "text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "start_char_idx": 665, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e1ae334-fdca-4f65-8faf-9368a28adf85": {"__data__": {"id_": "1e1ae334-fdca-4f65-8faf-9368a28adf85", "embedding": null, "metadata": {"window": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "original_text": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "page_label": "16", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7b0f02bf-ba5a-4454-a868-8c9d00be715d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41f46435762a32ad2480836c171f0830119658ac2d1b11b7607709723b6ea948", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04893a0d-db67-47de-95ca-3d6ce9bb9b2c", "node_type": "1", "metadata": {"window": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "page_label": "15", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cd94ecaec9a9a7e496ca701e417f8ed33c7d46532350d197257b4245d595ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3bc79ff-2f29-41c3-9502-d5dbb0b4f48a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n"}, "hash": "7387d5cffda99dd7d34286c3aae89230d66c5044ff91ce4e3372b7ef3e1cd88c", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "start_char_idx": 0, "end_char_idx": 1151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3bc79ff-2f29-41c3-9502-d5dbb0b4f48a": {"__data__": {"id_": "e3bc79ff-2f29-41c3-9502-d5dbb0b4f48a", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bea30be9-32da-4ef1-8f76-de870e77be9a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a555bc1caafbd31980f3f37a37b1ab845f846ad6598b617c82fa12d423599c4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e1ae334-fdca-4f65-8faf-9368a28adf85", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "original_text": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "page_label": "16", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0c15d87b35d62e9ae916cf0a460c45de8aaa9719cf5ceccc656b450e8295087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3729e6a-4222-4d55-b8ec-a53ac05d2115", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "908f8961836731d755b9d691fc76f0d0fb7946443b4fe5bf3ba0e6a1d536bc11", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "start_char_idx": 0, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3729e6a-4222-4d55-b8ec-a53ac05d2115": {"__data__": {"id_": "a3729e6a-4222-4d55-b8ec-a53ac05d2115", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bea30be9-32da-4ef1-8f76-de870e77be9a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a555bc1caafbd31980f3f37a37b1ab845f846ad6598b617c82fa12d423599c4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3bc79ff-2f29-41c3-9502-d5dbb0b4f48a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d6d4338d02a91dc50c235ef391707b6afa1ef40ea80eec2b1b36fbdbbbeba0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b884219d-f0b8-4e4e-9472-15eb1f0b4098", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "0c1b5ba49238d061a1379283dfa3cf5ee9187b178beea140328f194fb20feaeb", "class_name": "RelatedNodeInfo"}}, "text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 531, "end_char_idx": 1344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b884219d-f0b8-4e4e-9472-15eb1f0b4098": {"__data__": {"id_": "b884219d-f0b8-4e4e-9472-15eb1f0b4098", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bea30be9-32da-4ef1-8f76-de870e77be9a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a555bc1caafbd31980f3f37a37b1ab845f846ad6598b617c82fa12d423599c4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3729e6a-4222-4d55-b8ec-a53ac05d2115", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d1decea060f5f22ffdbc2d1138b156f32d3064c6c67726ca6a7b7e07b64c801", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9edd26c-3575-4e32-91a6-b9b5f4688ec1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "14cef49b84f0495dc630ddcf43e5c0d392eedbadd2b5f710c6717775740a2fa5", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1344, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9edd26c-3575-4e32-91a6-b9b5f4688ec1": {"__data__": {"id_": "f9edd26c-3575-4e32-91a6-b9b5f4688ec1", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bea30be9-32da-4ef1-8f76-de870e77be9a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a555bc1caafbd31980f3f37a37b1ab845f846ad6598b617c82fa12d423599c4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b884219d-f0b8-4e4e-9472-15eb1f0b4098", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3efa0072a4407ca28fa2ececb9dc6825da461fa65448a7650b78ff8c9a431df0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9967efd-b014-40f5-b823-89ca28672c9c", "node_type": "1", "metadata": {"window": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "b3003e94f011c19b443034a2c7d525227e5b4e7cd46d627fe6e783d5afb1b6be", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1459, "end_char_idx": 1599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9967efd-b014-40f5-b823-89ca28672c9c": {"__data__": {"id_": "f9967efd-b014-40f5-b823-89ca28672c9c", "embedding": null, "metadata": {"window": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bea30be9-32da-4ef1-8f76-de870e77be9a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a555bc1caafbd31980f3f37a37b1ab845f846ad6598b617c82fa12d423599c4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9edd26c-3575-4e32-91a6-b9b5f4688ec1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe720bf199f87d9c1fc203a90bf3600e9837d986a8fa90e655873d24effbbd0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69299d4a-a253-43c9-89ca-94bd72e7eeaa", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17"}, "hash": "8d5d149d018f6da9fb16cbe72c2461b5b94eece185166fe0df44ac88b5475c81", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1599, "end_char_idx": 1718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69299d4a-a253-43c9-89ca-94bd72e7eeaa": {"__data__": {"id_": "69299d4a-a253-43c9-89ca-94bd72e7eeaa", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bea30be9-32da-4ef1-8f76-de870e77be9a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a555bc1caafbd31980f3f37a37b1ab845f846ad6598b617c82fa12d423599c4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9967efd-b014-40f5-b823-89ca28672c9c", "node_type": "1", "metadata": {"window": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78cead0d8ee1faa6404de021635536fa14f355281710c7fa9d0c27a51f5ddd4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a1de299-5ed2-48d5-b7df-fb707600c8bd", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "original_text": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "d0949f6e31c6eab7f9e10cb6d8eda22cb72bef09feff5705e6820d1bc7603b24", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "start_char_idx": 1718, "end_char_idx": 1834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a1de299-5ed2-48d5-b7df-fb707600c8bd": {"__data__": {"id_": "1a1de299-5ed2-48d5-b7df-fb707600c8bd", "embedding": null, "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "original_text": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69299d4a-a253-43c9-89ca-94bd72e7eeaa", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\n17", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "264b127354f1f5f7341e5f42a28526bc16fd47cbc798bb20537c396a2ed0e633", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4244df3b-bfaa-4020-bd81-56e7fb5abe6f", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "16626a043714d2f62973a884050114f8476264c62e360195a0403f6b18f35bd8", "class_name": "RelatedNodeInfo"}}, "text": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 0, "end_char_idx": 105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4244df3b-bfaa-4020-bd81-56e7fb5abe6f": {"__data__": {"id_": "4244df3b-bfaa-4020-bd81-56e7fb5abe6f", "embedding": null, "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a1de299-5ed2-48d5-b7df-fb707600c8bd", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "original_text": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f3c600be96549f6e5ec8cbb84381c169daa7a8d2db3fb403c9db54723de920", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bf15959-015b-40d0-b260-8353baeaffa1", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "6c8a0d49b1266b998b111ae804769054977f82e8593c2c5b01f4f69edea60d1b", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 105, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bf15959-015b-40d0-b260-8353baeaffa1": {"__data__": {"id_": "2bf15959-015b-40d0-b260-8353baeaffa1", "embedding": null, "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4244df3b-bfaa-4020-bd81-56e7fb5abe6f", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3277534d9ad730e40b9725d69040ada9b1bbe6c4802948045970b4ea743e6a2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd1947a2-be8b-4771-9854-c90eaf41deba", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. "}, "hash": "8a501a31d9f7c50f9af30b5526d0151fcbd3eef184ead2d8d2779bbcac1eb1d5", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 287, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd1947a2-be8b-4771-9854-c90eaf41deba": {"__data__": {"id_": "fd1947a2-be8b-4771-9854-c90eaf41deba", "embedding": null, "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bf15959-015b-40d0-b260-8353baeaffa1", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41920e00f4dcb24ee20a3580cdb33c7457415135ae530e6f3ad6b0d78bf095fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22fb38ef-6e0f-4736-9001-bc90d29f1eb3", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "6064a743efeb48278590db02b3e37be22989a9c44bd27125b2332fc864f636d0", "class_name": "RelatedNodeInfo"}}, "text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "start_char_idx": 568, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22fb38ef-6e0f-4736-9001-bc90d29f1eb3": {"__data__": {"id_": "22fb38ef-6e0f-4736-9001-bc90d29f1eb3", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd1947a2-be8b-4771-9854-c90eaf41deba", "node_type": "1", "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a0367b33d399b1187f3a21b0d985f406e525fac89672a0c435a8aae702eb8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bfd451c-cf9d-42e7-b468-91082465bfa0", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "c07b9a11bb4c3f35bd06acec27e76e3db775d4b070e776c90c2a8352c07e40ad", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 894, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bfd451c-cf9d-42e7-b468-91082465bfa0": {"__data__": {"id_": "4bfd451c-cf9d-42e7-b468-91082465bfa0", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22fb38ef-6e0f-4736-9001-bc90d29f1eb3", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7823d83d828e50adaa6e23f3afa6c9ad396367de5b55fd7771ebb0a0900b3e31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0d42781-2e50-47a4-9c09-5a0150e0bec8", "node_type": "1", "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses. ", "original_text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "4637c2b39672f76291fca086ec04aa77bddf9742fdd551d9d30da092a3ffec33", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 979, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0d42781-2e50-47a4-9c09-5a0150e0bec8": {"__data__": {"id_": "e0d42781-2e50-47a4-9c09-5a0150e0bec8", "embedding": null, "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses. ", "original_text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bfd451c-cf9d-42e7-b468-91082465bfa0", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5285a1f2f03b5ef3d8b70e1a19ce33d14cfd10eaf32bc547c4266019095b7e17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e6b2f0f-5fa1-4903-9299-0dd4f1cbd9d2", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "7849de93908de1ef5ffb974d897e40c7743205f333108a162f2382a814fe7ff3", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 1136, "end_char_idx": 1339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e6b2f0f-5fa1-4903-9299-0dd4f1cbd9d2": {"__data__": {"id_": "9e6b2f0f-5fa1-4903-9299-0dd4f1cbd9d2", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0d42781-2e50-47a4-9c09-5a0150e0bec8", "node_type": "1", "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses. ", "original_text": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a95ef92efdacde62cab46984ab459ed2385381d7c20e510a7ee09b17c65065a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a7e280f-c47e-4ce9-8e15-c7cc39c6c8bc", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n"}, "hash": "3235336c3436ca9891b088a3be35106957ad98d3fe659687b08f834c86708e59", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 1339, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a7e280f-c47e-4ce9-8e15-c7cc39c6c8bc": {"__data__": {"id_": "0a7e280f-c47e-4ce9-8e15-c7cc39c6c8bc", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e6b2f0f-5fa1-4903-9299-0dd4f1cbd9d2", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0f1e6b1e4daf4c29a9716e51d3db241d0425bd2b3fe059457796b9cf658cf0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23ec2166-b97f-41ac-943e-3db2b41f7abd", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses. "}, "hash": "842b4366a0e9a208170384143c74e0a3dcce9b1c3209a850a9ca2bc0370c3101", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "start_char_idx": 1635, "end_char_idx": 1817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23ec2166-b97f-41ac-943e-3db2b41f7abd": {"__data__": {"id_": "23ec2166-b97f-41ac-943e-3db2b41f7abd", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a7e280f-c47e-4ce9-8e15-c7cc39c6c8bc", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1687b446ffb3bd56535dec3accb534a6e11ba42986b2a90ca63717bd79d5525e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f3b5414-a4c8-4258-bd02-bc94a292d616", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "original_text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. "}, "hash": "bf36d582638de42e31971f6ef77478beb55485944d1b62a71fd27fc6a4c112d2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses. ", "start_char_idx": 1817, "end_char_idx": 2142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f3b5414-a4c8-4258-bd02-bc94a292d616": {"__data__": {"id_": "7f3b5414-a4c8-4258-bd02-bc94a292d616", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "original_text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23ec2166-b97f-41ac-943e-3db2b41f7abd", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, LIFO expense (credit), and Turkey highly inflationary impact are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9526a86edee30e8535d85902756c3c0d8cfa1ffd6132a391c9bf9a8d20e5722", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e4a39cc-25c9-4e31-9ee9-2d8d66f86e9a", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. "}, "hash": "0f9656d3fdcce782f33d0ad3adfcc60f7e927a396537725dc49b70883d229374", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 2142, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e4a39cc-25c9-4e31-9ee9-2d8d66f86e9a": {"__data__": {"id_": "3e4a39cc-25c9-4e31-9ee9-2d8d66f86e9a", "embedding": null, "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f3b5414-a4c8-4258-bd02-bc94a292d616", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "original_text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5edb7c74bf37efcfb12c49810b0e484ce9c5cd12f45bde00da0d2843c4bf3317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b44de64-be2e-47a4-ac8b-16dce5be0959", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities. "}, "hash": "5ff8b7c383b9255f0abd11daa71aa8c8c39381114aa52e95b5fc8909db9da962", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "start_char_idx": 2238, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b44de64-be2e-47a4-ac8b-16dce5be0959": {"__data__": {"id_": "0b44de64-be2e-47a4-ac8b-16dce5be0959", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e4a39cc-25c9-4e31-9ee9-2d8d66f86e9a", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3932cfa075bdbcd5d59276e787f85dd9f08a7f120ea90fd04998cda2535ff9e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d200113-aa10-4a6a-8f7a-c822bdd5863f", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n"}, "hash": "ae9784106ddb2f19369566ddd1f64a9d2c8710372cfe28f6aaf6f9743a10a798", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities. ", "start_char_idx": 2399, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d200113-aa10-4a6a-8f7a-c822bdd5863f": {"__data__": {"id_": "7d200113-aa10-4a6a-8f7a-c822bdd5863f", "embedding": null, "metadata": {"window": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b44de64-be2e-47a4-ac8b-16dce5be0959", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; and restructuring and other expenses.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9929b0d99e3c461ec384f5882152d3008a7fbe29091cba40a8b191ced31c2bbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cea133d5-66a6-4f90-835e-1ec1234f2bf7", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "4bee002d3846f88f902c1100823569c0eecbbe590491412167ce9df18373f6aa", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "start_char_idx": 2570, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cea133d5-66a6-4f90-835e-1ec1234f2bf7": {"__data__": {"id_": "cea133d5-66a6-4f90-835e-1ec1234f2bf7", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d200113-aa10-4a6a-8f7a-c822bdd5863f", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a24fd996614d08c3e8913ac0161377693c845a4256cbf16bd98be8ba9bc24a2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "799d8f7a-b529-47bb-bf2b-62664bcc6d7f", "node_type": "1", "metadata": {"window": "W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "5af972c2510955041ee09d7c81fc0f61e74e8f5cfce2504bdbf130db58db85bd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 2827, "end_char_idx": 3076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "799d8f7a-b529-47bb-bf2b-62664bcc6d7f": {"__data__": {"id_": "799d8f7a-b529-47bb-bf2b-62664bcc6d7f", "embedding": null, "metadata": {"window": "W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cea133d5-66a6-4f90-835e-1ec1234f2bf7", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa4140646b1a8d85437ef88f37afe01ccdc491d5453bc0529f791b5002a090a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aad84d13-db91-4c8d-8173-997d518c4a95", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "756a0f887bd46ec7e1d4f93e408da188f3930e15b0cf711169fe4cb4cc2951ff", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 3076, "end_char_idx": 3169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aad84d13-db91-4c8d-8173-997d518c4a95": {"__data__": {"id_": "aad84d13-db91-4c8d-8173-997d518c4a95", "embedding": null, "metadata": {"window": "W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "799d8f7a-b529-47bb-bf2b-62664bcc6d7f", "node_type": "1", "metadata": {"window": "W e exclude acquisition-\nrelated deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or non-recurring\nbusiness activities.  W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a477ef5ca41fca0f4ea1672819952e79741936d55c9f039fa5a33f16a9729a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe137c23-ba8f-4803-916f-d31c40d2b762", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "663e7e97825a36077f32672efdb708bea70f61375020c1a77f3daf3f0b8e2bf6", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 3169, "end_char_idx": 3416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe137c23-ba8f-4803-916f-d31c40d2b762": {"__data__": {"id_": "fe137c23-ba8f-4803-916f-d31c40d2b762", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aad84d13-db91-4c8d-8173-997d518c4a95", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related expenses (credit) that is unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9aa4346b4bf2522236ec06224ad5e322e2e8074b87fe3164e17811bc9ec71a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a299f86e-e5b9-4042-8c81-a582272ec134", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "original_text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. "}, "hash": "b0f7efec792e90d86866096c51b1c18729a44e81b625d233efab77796b860767", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 3416, "end_char_idx": 3621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a299f86e-e5b9-4042-8c81-a582272ec134": {"__data__": {"id_": "a299f86e-e5b9-4042-8c81-a582272ec134", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "original_text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe137c23-ba8f-4803-916f-d31c40d2b762", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "276f72d3eaecee568482a365abb32dba3d8e160349da49c993d92656c40050b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e13316c-ba8d-4432-92cf-c92bbdb07fe5", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022. ", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n"}, "hash": "8446cafaa9e97333b7e771d7a5fa5be4e7c191e6814ef8eeebcc38ddd0d65f3f", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "start_char_idx": 3621, "end_char_idx": 3992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e13316c-ba8d-4432-92cf-c92bbdb07fe5": {"__data__": {"id_": "4e13316c-ba8d-4432-92cf-c92bbdb07fe5", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022. ", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a299f86e-e5b9-4042-8c81-a582272ec134", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "original_text": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e96f7a9519dae3a699d6abec5ecd9331173cbecb782ba02b5d39f091d4393ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48b319d1-9438-4c0f-ac96-45d169a552e6", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "515fb9afe3d0607b2532992200119fa9d591be0011fe4b7de158bcd07923783e", "class_name": "RelatedNodeInfo"}}, "text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "start_char_idx": 3992, "end_char_idx": 4157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48b319d1-9438-4c0f-ac96-45d169a552e6": {"__data__": {"id_": "48b319d1-9438-4c0f-ac96-45d169a552e6", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e13316c-ba8d-4432-92cf-c92bbdb07fe5", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022. ", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c0c3f1dc75138c473d1dc11ae4b69021e6e779abefdd5180520a86a0f7587e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e701e26-36bd-478d-bd3f-593c12f285e0", "node_type": "1", "metadata": {"window": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. "}, "hash": "e5d6efc31a6625b18a6bfecfe4d08bfc84dfd1946fcda66c018f74a1b7b0c1f7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 4157, "end_char_idx": 4395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e701e26-36bd-478d-bd3f-593c12f285e0": {"__data__": {"id_": "4e701e26-36bd-478d-bd3f-593c12f285e0", "embedding": null, "metadata": {"window": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48b319d1-9438-4c0f-ac96-45d169a552e6", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9e58ef5364b20ed1c046529105634ae4970adaf520317e5b7173552cdb9604c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ab0a1ad-7aeb-40b7-9801-dde4ac52f873", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022. "}, "hash": "8ec916fd83dac6852fdf0709b3a0cc7a006134ad42fe027f8a10e5402c30aefc", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "start_char_idx": 4395, "end_char_idx": 4487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ab0a1ad-7aeb-40b7-9801-dde4ac52f873": {"__data__": {"id_": "3ab0a1ad-7aeb-40b7-9801-dde4ac52f873", "embedding": null, "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e701e26-36bd-478d-bd3f-593c12f285e0", "node_type": "1", "metadata": {"window": "In addition, the loss on\nremeasurement of an equity investment, the recovery of a non-customer note receivable, a foreign currency gain, and the\ngain (loss) on the currency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform are excluded from\nadjusted income before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84137189be8750b08a470cfac049fbab372b1f7a470aafc743f78ac4941ebb39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a641f0fa-085c-4d0b-9c62-ceafff4f9e81", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n"}, "hash": "b69151e4118c260d8f30d5a32d1fa013f32ae895397b5f10fd05a1554b2ae7b8", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022. ", "start_char_idx": 4487, "end_char_idx": 4649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a641f0fa-085c-4d0b-9c62-ceafff4f9e81": {"__data__": {"id_": "a641f0fa-085c-4d0b-9c62-ceafff4f9e81", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ab0a1ad-7aeb-40b7-9801-dde4ac52f873", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8718384662943d6451c929fb93d87996b1615108c9e932054071f9e349a92e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7c16fd4-9a08-497c-acce-4853468f5d63", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. "}, "hash": "158abed63163b4cf7fcbda97d7ae077adb6e1fb332e5ecb11442c6dafafacfa1", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "start_char_idx": 4649, "end_char_idx": 4893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7c16fd4-9a08-497c-acce-4853468f5d63": {"__data__": {"id_": "b7c16fd4-9a08-497c-acce-4853468f5d63", "embedding": null, "metadata": {"window": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a641f0fa-085c-4d0b-9c62-ceafff4f9e81", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65ffd9d147a2d2ac8ced66e59819268ed9b70ee48ef217d532604bdd9bb5d4aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3dba3db-d573-49ee-8a87-b06cc9b17072", "node_type": "1", "metadata": {"window": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "8df798d71bd38aad84a2b423fa85db9e53b184f6a9dc45640838d7ab211a5b0f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "start_char_idx": 4893, "end_char_idx": 5082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3dba3db-d573-49ee-8a87-b06cc9b17072": {"__data__": {"id_": "a3dba3db-d573-49ee-8a87-b06cc9b17072", "embedding": null, "metadata": {"window": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7c16fd4-9a08-497c-acce-4853468f5d63", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) are also excluded from adjusted income tax expense.  Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "824178f91f8b7ed53d6431f93c3c3edd68a8fe88a69679d87e40939cd1761e3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed91153b-3718-4ad8-bacb-a737aa3646e6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "18"}, "hash": "2e7087c554097bc52a787b3213f5511bd3e2cc371a2fcfa3037dfbe47c11d116", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 5082, "end_char_idx": 5355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed91153b-3718-4ad8-bacb-a737aa3646e6": {"__data__": {"id_": "ed91153b-3718-4ad8-bacb-a737aa3646e6", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a67836c15a09216a565ed1a22fdb0b61f5007775ffc6c1bca0ebcc695776d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3dba3db-d573-49ee-8a87-b06cc9b17072", "node_type": "1", "metadata": {"window": "Further, certain expenses relating\nto 2020 S wiss tax reform are excluded from adjusted income tax expense for the three months ended December 31, 2023 and\n2022.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40f3fbe7ce5d3f2dedcb52866343183d43674bd749c65473adb344f2c106416d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4fb2b6c-0132-40f8-911f-beff09059274", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. "}, "hash": "324844b1f5b8ce57a205fbf2ad25dee49ecd50cfd1caa87fe7e516855ce6cea3", "class_name": "RelatedNodeInfo"}}, "text": "18", "start_char_idx": 5355, "end_char_idx": 5357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4fb2b6c-0132-40f8-911f-beff09059274": {"__data__": {"id_": "e4fb2b6c-0132-40f8-911f-beff09059274", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed91153b-3718-4ad8-bacb-a737aa3646e6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5f2bb01cc196ef979893fbbb6b629bd241086adba4f528015f3b0cc2dc950ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2891e2c-fb4a-4a4a-bbb6-30f8ce2a2180", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n"}, "hash": "8a8dcea323d069efacdc2c63215c6b24baeeef4ae252719506fa89eccbb97114", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "start_char_idx": 0, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2891e2c-fb4a-4a4a-bbb6-30f8ce2a2180": {"__data__": {"id_": "e2891e2c-fb4a-4a4a-bbb6-30f8ce2a2180", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4fb2b6c-0132-40f8-911f-beff09059274", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c745e9134bfc610fd29c5b2dc196d80427ef1d972e5b07404f113145597bb04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab0d3d85-832d-4822-8405-a50bc5f83940", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "3a5fc28e8d8bdb339a5c7c30d78226723cb95c179ea16932580cfe612ead42e4", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n", "start_char_idx": 214, "end_char_idx": 378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab0d3d85-832d-4822-8405-a50bc5f83940": {"__data__": {"id_": "ab0d3d85-832d-4822-8405-a50bc5f83940", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2891e2c-fb4a-4a4a-bbb6-30f8ce2a2180", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93386b55a9a27696d76c338a8e52c028d39292fa9614f27884559cdb6480aed4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40b8b73a-ddb7-417c-b725-c1edbe656da4", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "88379bb4f6132f1ce5e6b882934f168a78e15f149ba49987184b48ce29350a39", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 378, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40b8b73a-ddb7-417c-b725-c1edbe656da4": {"__data__": {"id_": "40b8b73a-ddb7-417c-b725-c1edbe656da4", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab0d3d85-832d-4822-8405-a50bc5f83940", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e372a222d156a096fdb79457c62e36a09139076747a193241738b206a7b8ccf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e143ebd0-c1b7-443a-ac8e-f1d8cabed7e7", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. "}, "hash": "483878d6694d2d389dedf35461859ea40e94ecebe969af1d6b64aa7f10b91bce", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 559, "end_char_idx": 803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e143ebd0-c1b7-443a-ac8e-f1d8cabed7e7": {"__data__": {"id_": "e143ebd0-c1b7-443a-ac8e-f1d8cabed7e7", "embedding": null, "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40b8b73a-ddb7-417c-b725-c1edbe656da4", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01bd41e24945ed4b8c8c52e29ca19179459a25fae80a1fd911e606bf6defc025", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6dd8bfd-16c2-46de-bdec-cf2527b4e436", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share. "}, "hash": "946b463b67ff38d30940c186ae002d8e89a2969e6cfec767c79c7d1d5ecf7b29", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 803, "end_char_idx": 1498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6dd8bfd-16c2-46de-bdec-cf2527b4e436": {"__data__": {"id_": "f6dd8bfd-16c2-46de-bdec-cf2527b4e436", "embedding": null, "metadata": {"window": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e143ebd0-c1b7-443a-ac8e-f1d8cabed7e7", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b548d516e5cb424f82a4a3b8f2f3e30a02e97cf057718b9df2eba8f8cf0f7b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c519122a-729a-4044-bbda-3d4afd83ae36", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million. ", "original_text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "1d5b734e51359b3b822e2654db80795721c25798097793fe6d9beb012b0e61aa", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share. ", "start_char_idx": 1498, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c519122a-729a-4044-bbda-3d4afd83ae36": {"__data__": {"id_": "c519122a-729a-4044-bbda-3d4afd83ae36", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million. ", "original_text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6dd8bfd-16c2-46de-bdec-cf2527b4e436", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bedeeab266760bdb197e1a27efe5406840906d22734cbad510c3f07f63a353e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca5e43c6-92c6-4dfe-82ac-dca517c5c9a1", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "d3c2c54a87030a38d842435a0b5b4c09e50e4ea892f0ded98c6d22db9e9f02e8", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 1769, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca5e43c6-92c6-4dfe-82ac-dca517c5c9a1": {"__data__": {"id_": "ca5e43c6-92c6-4dfe-82ac-dca517c5c9a1", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c519122a-729a-4044-bbda-3d4afd83ae36", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million. ", "original_text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a48cb072c5b13a34e848ed1146c2f6fbd24812038c403a473fc70103b7d0641", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92cb8332-cd4a-4298-8015-6f1a6be372a7", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "1fb17080d73ea18dbd00b515f2c3ca2e48ecd6938485fa772b4896edde0e5451", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 2123, "end_char_idx": 2396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92cb8332-cd4a-4298-8015-6f1a6be372a7": {"__data__": {"id_": "92cb8332-cd4a-4298-8015-6f1a6be372a7", "embedding": null, "metadata": {"window": "In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca5e43c6-92c6-4dfe-82ac-dca517c5c9a1", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); Turkey highly inflationary impact; acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses (credit); acquisition-related deal and integration\nexpenses; restructuring and other expenses; the loss on remeasurement of an equity investment; recovery of a non-customer\nnote receivable; and the gain (loss) on the currency remeasurement related to 2020 S wiss tax reform, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e012d86e0c5ac835b752642103e8c04836216107097f6b6ce8fe2b88a9713cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8450568a-f48c-41af-8bd8-280915e938a3", "node_type": "1", "metadata": {"window": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million. "}, "hash": "6a52ab07bddfd354c9205a559989937d5de7035dbe1ef26352c87e53531931ee", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 2396, "end_char_idx": 2634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8450568a-f48c-41af-8bd8-280915e938a3": {"__data__": {"id_": "8450568a-f48c-41af-8bd8-280915e938a3", "embedding": null, "metadata": {"window": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92cb8332-cd4a-4298-8015-6f1a6be372a7", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete\ntax expense (benefit), and the per share impact of certain expenses relating to 2020 S wiss tax reform for the three months\nended December 31, 2023 and 2022 are also excluded from adjusted diluted earnings per share.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa2f467655416c3e0e5c9d668781dc7902f03ce95c5e2c590ef526a7308542de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cca90de-45e0-4897-be82-71ac42034503", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n"}, "hash": "6c4bcbddace75a5f5933d8dd2c2170f54612fca6369ed8467e1c8d7cb9bbbb0b", "class_name": "RelatedNodeInfo"}}, "text": "For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million. ", "start_char_idx": 2634, "end_char_idx": 2910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cca90de-45e0-4897-be82-71ac42034503": {"__data__": {"id_": "7cca90de-45e0-4897-be82-71ac42034503", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8450568a-f48c-41af-8bd8-280915e938a3", "node_type": "1", "metadata": {"window": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cb6b5ed835a0125df215f1d92dc47f2995ae6608b59d0cdd03621c87135ecad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66e18f19-6b75-4e11-b3d3-7e9f0fcf60f3", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. "}, "hash": "d31ac865c897e606b0f5f9298cd110d7326121e6d1fb6ff205f8fd9df9e59192", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n", "start_char_idx": 2910, "end_char_idx": 3206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66e18f19-6b75-4e11-b3d3-7e9f0fcf60f3": {"__data__": {"id_": "66e18f19-6b75-4e11-b3d3-7e9f0fcf60f3", "embedding": null, "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cca90de-45e0-4897-be82-71ac42034503", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57dca6a8d3e4b73a79a3069ce89607c22ea52ee7d2a065c548386be590265e2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d1ae852-457a-4855-9c62-c0d9effac2f6", "node_type": "1", "metadata": {"window": "For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. "}, "hash": "0b2ef24c8fccc95d126101e9d1ab44227c9454b8f0da7ce51aabcb849fd3e497", "class_name": "RelatedNodeInfo"}}, "text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "start_char_idx": 3206, "end_char_idx": 3360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d1ae852-457a-4855-9c62-c0d9effac2f6": {"__data__": {"id_": "0d1ae852-457a-4855-9c62-c0d9effac2f6", "embedding": null, "metadata": {"window": "For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66e18f19-6b75-4e11-b3d3-7e9f0fcf60f3", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ba0487038019ba501a1b992b3bd3fbe6f510fc79269b57b4d20a67c6c4f313e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10d02673-1ba1-4958-9639-f289dedb2d50", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. "}, "hash": "b719860a1f0d517a546fac73556321d2bd4832767147f2b09ea54572f5b2012a", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "start_char_idx": 3360, "end_char_idx": 3515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10d02673-1ba1-4958-9639-f289dedb2d50": {"__data__": {"id_": "10d02673-1ba1-4958-9639-f289dedb2d50", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d1ae852-457a-4855-9c62-c0d9effac2f6", "node_type": "1", "metadata": {"window": "For the three months ended December 31, 2023, adjusted free cash flow of $762.7 million consisted of net cash\nprovided by operating activities of $885.2 million, minus capital expenditures of $74.2 million and the gains from antitrust\nlitigation settlements of $48.2 million.  The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c22566741536933e408295c42bc3a969b62e9a5314a2e4f84553668c7b17473a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8af1c89f-adfd-49cb-aeea-6680308f2718", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. "}, "hash": "836a013210f648ae88833c9cfb5df6a80e148e84ae5322f30390ae97b2027b0f", "class_name": "RelatedNodeInfo"}}, "text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "start_char_idx": 3515, "end_char_idx": 3693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8af1c89f-adfd-49cb-aeea-6680308f2718": {"__data__": {"id_": "8af1c89f-adfd-49cb-aeea-6680308f2718", "embedding": null, "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10d02673-1ba1-4958-9639-f289dedb2d50", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free\ncash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable\nsignificance of which cannot be determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bfda692168c5df59e0d3cde97e3ed9ca64c989dcc0967b577a593d2ec20cbe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cc1c7f0-65c1-4cfd-8a56-2ef541fa32bf", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. "}, "hash": "8747d81cd0deb9d57ca6c4dbc92afc210dbbd920cfdd4da316640f95e453da68", "class_name": "RelatedNodeInfo"}}, "text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "start_char_idx": 3693, "end_char_idx": 3849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cc1c7f0-65c1-4cfd-8a56-2ef541fa32bf": {"__data__": {"id_": "5cc1c7f0-65c1-4cfd-8a56-2ef541fa32bf", "embedding": null, "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8af1c89f-adfd-49cb-aeea-6680308f2718", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8543c84ae2270bba5d262e713cc066cbfafb1d14772f75e5feee5c4413fee78d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a5d214d-2ab3-4c37-be12-43fe558d6bd5", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n"}, "hash": "53d99f95cb17838e77897a2baae3cb6d641e9027795ce30d22a12d7fcda1c8c3", "class_name": "RelatedNodeInfo"}}, "text": "For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. ", "start_char_idx": 3849, "end_char_idx": 4246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a5d214d-2ab3-4c37-be12-43fe558d6bd5": {"__data__": {"id_": "5a5d214d-2ab3-4c37-be12-43fe558d6bd5", "embedding": null, "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cc1c7f0-65c1-4cfd-8a56-2ef541fa32bf", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "076963260c56134c8058b705e9d3faed82e4a75390e3a22eec2448a5e46be833", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f42739a-163e-4c23-8d54-b76a48daba1e", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "a245344760ea97c3bf527a42986df6ccd1e87fdbc0e657d03b1b0b780ecd272e", "class_name": "RelatedNodeInfo"}}, "text": "For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n", "start_char_idx": 4246, "end_char_idx": 4691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f42739a-163e-4c23-8d54-b76a48daba1e": {"__data__": {"id_": "9f42739a-163e-4c23-8d54-b76a48daba1e", "embedding": null, "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a5d214d-2ab3-4c37-be12-43fe558d6bd5", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United S tates reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0c5f57775d652e40bec53d965cdf3fdd5a91726d669fce547afd7a7c4af87cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "def3d3ec-4dd8-4eff-b76e-86bae985454a", "node_type": "1", "metadata": {"window": "For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "58cc6a51b393c45f650d5049211f1e3815f62ef9adcc4c0ad61348bf3da7f1b5", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 4691, "end_char_idx": 5141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "def3d3ec-4dd8-4eff-b76e-86bae985454a": {"__data__": {"id_": "def3d3ec-4dd8-4eff-b76e-86bae985454a", "embedding": null, "metadata": {"window": "For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f42739a-163e-4c23-8d54-b76a48daba1e", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c1edff9fe6039164dc429b32c45f80bd234d65a8f29a4be4a0ea642ef8d7e8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6dfdcda-e1ba-44db-ac7c-feb5c14f449e", "node_type": "1", "metadata": {"window": "For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "ca4c01ce1b78ae44d477377648ea87a32255f595fa1c3c90b348e1002c11b26a", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 5141, "end_char_idx": 5377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6dfdcda-e1ba-44db-ac7c-feb5c14f449e": {"__data__": {"id_": "e6dfdcda-e1ba-44db-ac7c-feb5c14f449e", "embedding": null, "metadata": {"window": "For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "def3d3ec-4dd8-4eff-b76e-86bae985454a", "node_type": "1", "metadata": {"window": "For the first\nquarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting\nin revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by\nforeign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million.  For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fa22528b74878128161984d3c23a9b06d6940b78cf02497cbaea2c55b201604", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d71a1a72-fe04-4319-a63f-41db2b7da32f", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n"}, "hash": "03d76460cc9f343523688aaf7bcff77991b9d83f827a8909728f3e840915e5a0", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 5377, "end_char_idx": 5693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d71a1a72-fe04-4319-a63f-41db2b7da32f": {"__data__": {"id_": "d71a1a72-fe04-4319-a63f-41db2b7da32f", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6dfdcda-e1ba-44db-ac7c-feb5c14f449e", "node_type": "1", "metadata": {"window": "For the first\nquarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by\nforeign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating\nincome of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a\nconstant currency basis of $194 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b783c77ff9c516031f8b9d3ab0e2324ffce003099dadd65f507def0918d5c8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4cacede-43ac-418a-a958-2903ff7ddc37", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "19"}, "hash": "549082f45e07691d8abb3c94cb2ffcf13d95f40af0696a1e180fd6cf97678f4b", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "start_char_idx": 5693, "end_char_idx": 5877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4cacede-43ac-418a-a958-2903ff7ddc37": {"__data__": {"id_": "a4cacede-43ac-418a-a958-2903ff7ddc37", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "19", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ffa6e04-827e-4171-b994-23d019284fcd", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a393f3036fe1c0b58991bc1b6c0b3cb55486666bb36662ad44b5b054c5092d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d71a1a72-fe04-4319-a63f-41db2b7da32f", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "234e0c736f34e882beaff3dc65fd5636afbec6dd0a7b9ffe24e32f1ae6c3d2ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aabad694-16d4-4d26-a5bc-e3f9766d2ade", "node_type": "1", "metadata": {"window": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n20", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n20"}, "hash": "6a7e7fc39b9b940ef0f82054c5489dbb89305cc0bc1261196ec1a97fff668b14", "class_name": "RelatedNodeInfo"}}, "text": "19", "start_char_idx": 3977, "end_char_idx": 3979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aabad694-16d4-4d26-a5bc-e3f9766d2ade": {"__data__": {"id_": "aabad694-16d4-4d26-a5bc-e3f9766d2ade", "embedding": null, "metadata": {"window": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n20", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n20", "page_label": "20", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "38384c4a-c687-41ca-a7e1-32efa5a1015a", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e426bc0fa88a3aebb9f83f7653d96a22df1fb068b928dc6cbfe73856eec06c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4cacede-43ac-418a-a958-2903ff7ddc37", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n 19", "original_text": "19", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8107cf658656bdd2a50e5d0e84088b520d525df15ff848bebfc686758b4a75bb", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n20", "start_char_idx": 0, "end_char_idx": 146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"84d029b5-1235-4b6b-a948-258149099077": {"doc_hash": "7a42e3a4ee0c09b28aa05d0890e3be591d29a15cf4012f1b568c0a64acacfe0d", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "3632ed99-d63e-45f7-a8a8-f7e41a0a253c": {"doc_hash": "e4c1cd6321300cce693ef9d9aa8a428b79ebc4e5659d5f59f1e1d88908aead54", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "62f2883b-1023-47dc-96bf-d0e6650b9551": {"doc_hash": "ab93cc298c95dc201e5ffa089475e25fe22a732c5228a9067da9fc57afec8db7", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "aad4d32f-5033-42d8-b394-5879080777d2": {"doc_hash": "256e4576d54688a6fb252f19a855fc9f2d10bc20489fbaa6383e5d85de8ce7f6", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "501befc5-2790-4c7a-b5d7-aa4ac3433459": {"doc_hash": "1c376215cbb9eb1f9d5601b47c70d2d716d6c3ec5076e5b18ca1fa9b17f38a83", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "c2602981-c2e0-48b1-a358-9cde8aae5c5e": {"doc_hash": "538062e948ddedceaa38fcaaacff346fbf73fcaeb0e693f66b9820feaaf968c2", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "7b7e580d-2a90-4d2d-986a-3f39122d1204": {"doc_hash": "9630563b03f6c3b1e0e85a2077379ef1672a7db0db046fd96cad02892b051315", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "42c5ec67-ee86-4b05-9bd1-4378b903197d": {"doc_hash": "7fc977eebe496cdda19019ccc6063ad8d0892ee751764cf8b1271815a3243d5e", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "7223bde6-9eed-410c-862b-02b532dcf3df": {"doc_hash": "78bcac36056f301b2e9f2ae42856bd16f9a52d33ccb2c5ef402addca616523db", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "a9cac26d-1faf-4848-afd3-32d600d084e1": {"doc_hash": "e183932065a7003640a00cf50e9606b1724e840bef00da218dee861f021fa9d6", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "7506e5f0-3795-4934-a29e-659717edc616": {"doc_hash": "c0cf7901b37423a7d2fd8ba0ea01306ec9b08a3445dca61562120f2c3de14f18", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "8f205d30-9323-43e7-bbce-fa53559188b2": {"doc_hash": "d51aafaa677d4948e8415010e1305943199fa7f3a769db67cc9fec396a348771", "ref_doc_id": "ec80978b-137f-4482-889d-7177d5e2d6bd"}, "910713d5-67b7-4518-ac75-e7e5e9345c4f": {"doc_hash": "316b2e51a6ee5750076cc0cff35631c21377a860ad857340c9b7accae6339553", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "e3364d98-7020-46dd-ba48-d049b3a8d6fb": {"doc_hash": "aff5ebb43c94d76fdb1f6fff677c49b9b0d15f94cec42b2996c0b9af5675eb19", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "f9be65c5-87df-46a7-bca1-46c93bc1cd4d": {"doc_hash": "82856b7823f956f91adb0cc0c3849efd634522edbcd455bddd37ad7bf1efa4c6", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "c6982918-f1dc-4f47-99f8-aff3491867c4": {"doc_hash": "edae1385127752d5f471cecff89fa76329d465a9ddf5154d0454818db9ad0cfc", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "fed69b32-cd74-47b8-bd7b-1df889def60d": {"doc_hash": "4a48a62ec620973de3fe511c25f1b50c3ba1acbb27c4cb7a39e8e14ea048d08f", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "9ca3cbc0-1c37-4937-827f-73898f30c908": {"doc_hash": "3fa806d2edd39972d5d42d09e7edb0fb62401dde18a1417654c6ab7889848262", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "ed9989f3-68ce-40b1-9ed5-20ff7f9de0af": {"doc_hash": "61d1794787966f1dd413911c290b9d747368dc91fafcc970d2255b8eb7f82a2d", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "2f3ea537-898d-4d65-a75b-0e3dbe9afadb": {"doc_hash": "5fdca543f9f735c63db2c96d05f1189be2f7655d431045b649cd860289f25bc6", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "ba015488-b4e1-47e3-b8f8-90524046c0ab": {"doc_hash": "1e13af0e31a5aca9205d174c31726847a8f53d2db35278f57806984b93bfb702", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "ce1db80d-6020-40e8-bf87-e0f3cb4b52f1": {"doc_hash": "716e0d0413ef76ca0a2ee99e6884ca757568d67d320175a31e91ba96ffd10ee9", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "0b87b31f-979c-49f9-ac74-fe41541fcf35": {"doc_hash": "988e91abe627b2de8967436d07d29a2a7f45e7b7c314a1b8e647deb3a64ec275", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "6714649b-793b-4bcc-a112-29df51a099fe": {"doc_hash": "b01111898684663aa22e7f46bec49874957dcba13ce14666cf7eb01579006e45", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "73a49c6e-66b9-4fe6-8fbc-a904261669c7": {"doc_hash": "83449f455fb7255b35965e72cf934a520bcd7f91fa5c50a85885103a865148a6", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "e7c2168b-1f56-4331-8f49-a2b79e89810c": {"doc_hash": "7a1acef2dfdecf368818036c0b555466a86e7badc5a3d542968dd490494df3d6", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "d8095d78-a4d0-4fff-9c8a-517abf14cc81": {"doc_hash": "ba8d0c36006a82a26cc73c177c37b951b665e1e5224e2522636e03ef05e8cf2b", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "55c01c78-0329-4fc9-b292-471c47d53a08": {"doc_hash": "b5915a746d3b093d47a77d8e4bfc4a90d77c5ed3a13c7e53b341035d1bea3f7c", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "033f471e-945d-414b-b4a1-f302c6473f13": {"doc_hash": "0a8f8e2867a67e6b87199d47bd5334618f1b807163843fba9dc5f262703e04fd", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "a09f03bd-c07d-4389-b092-b38d1c2f130e": {"doc_hash": "34e4249984c2a26365b27d19ff347514007410317ef3821467d3b1631c1d581f", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "ed336d73-2854-43ea-b6e8-9f42da7dd6dc": {"doc_hash": "a5da686cb451c0f78828aeb527568b4c12f0349b4d340d615d892713d96d2488", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "c711e221-a83f-4394-87ad-a033c60a883f": {"doc_hash": "c5f9ba83d18c6d85eab1faabab533b9670a84b3c68298669f9501604b501aa23", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "e4832a68-6a34-4cfc-ae8a-f1a3b06759fe": {"doc_hash": "f6ffac75bb0645622ebf69c3dfc48ae4784c78656d661f30865ed386df310b9a", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "c375f1ef-0d30-47a8-b6bb-f411e7771b8d": {"doc_hash": "2f67357e5c90fb4a0990199ca01467b6d23b88d7fe6cd773558c3b1bb632c345", "ref_doc_id": "07bd8210-72e7-4ac1-968d-a30965a836af"}, "576d7163-2b42-4866-9188-4cf36131c16e": {"doc_hash": "07e48daac2e0244045a386981d6b61e2068ea463d7fe4063beb0ee1b7422cebd", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "cc729b38-6e98-4c02-ace7-7f968d212a51": {"doc_hash": "54fcb6a856dcf64732b5cc20001266e791e19ea8ab239ecd3a14e2a7aa11b840", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "f06d75eb-cc52-46e2-b0ee-5229a91c72d0": {"doc_hash": "69a7a22d227c00bb5ce1f7851be7ba6d5cc529dad3b1be95203c94af2b0cb1a3", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "1779473a-735f-4ce4-88a7-f61305fe1ba4": {"doc_hash": "e8997118e145d023977c456acd27b7a4932cd66c9cb1e4291d6d955ef1ad26af", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "94c7a456-834a-4c1c-90b0-808b91f2bf1b": {"doc_hash": "897f3e892ba063ff45e260afb5101d693116787dcb1593642ef0280d6c74893a", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "739d0066-4c95-435f-a826-d9fd2995b306": {"doc_hash": "93af097ceaf57840c5e67dedf376b72f218190d078efb63917adfec3a97a8d1d", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "8132ccf2-f094-472a-935f-01d87cbee875": {"doc_hash": "c64e304af0d0c156ecba1d3aee91128210c68e51e94180d70f5d5e923c08d7e5", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "1cbcfdfe-d758-41a9-8a86-f849d73f6e88": {"doc_hash": "6309e1edd3f2bf71c707815273527ca4665e6959d485ddfd542ea9620c15fa3b", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "1fc906d2-95b0-4d6a-95a4-df4ec293465f": {"doc_hash": "68d3bc590014d5bc82566ef8bee97d930ed6211c08963628a1a47f01367112d3", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "079cd54f-3349-4df5-b386-fd8006f09d91": {"doc_hash": "2d975165f1d632a43afca5f4ee37103ebf1954a78325a20396b09d7ee0cfd9bf", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "e02e99f0-7a91-43c3-9938-0f530f37b0ea": {"doc_hash": "08bc39d5689699ddcac87a6352c78e84f25aa9e1ae225346f7a21e537427ba03", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "e59336fd-00de-4d36-88fa-831de139376f": {"doc_hash": "6dabf5beaee3d188a65f41ecea9f6c09b67323321fe527e2e4e1b899381664ba", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "217489dc-3299-48e6-b3f2-963a9d15bde4": {"doc_hash": "172ee7f6569f17618bb5ff3b55db32f931a1b1f39259d403b97a51c67fb1ab17", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "0c34ee94-592d-4f5b-98c9-b254af119bfc": {"doc_hash": "9c09efd5ef90436b99e7d80cd0f47af639e82c32dfb7949eff778eba3e043102", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "5677678b-0421-4409-8583-7935c47fc472": {"doc_hash": "d645277d7e816e8860aac0f04ba537b2b1e7e207aeca30ac7d9b0210009280bc", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "bec89659-dcf0-4024-bce1-406efa52f63d": {"doc_hash": "75eb2f7c25cfcfce2ebdd2f3a428a1e7c7be642bd73c5cd7f8b832db9383d8bc", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "be544d03-f78b-4e4d-83d0-b5151b0f5426": {"doc_hash": "c9145c8bebe2096898a6bbe2be48978e5d0619f0092862b50066be0671d3a53f", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "c8e1f8c4-e966-48a9-87e6-24ada0e97ba9": {"doc_hash": "1475e58eb0644c93d283ae5d74debaf77027b80ee936a842cae53c764030de85", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "0f7f75e6-fe9b-4e4e-88db-1d11efedc648": {"doc_hash": "99dc463275b24e1d12225efed7b425b53ed6d1890ecaeaa0c4794313274657dd", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "21cf16c9-caec-433d-a92f-036ef5ee7f23": {"doc_hash": "c9285ebcb29cff5b3f7d22989696d5ef7f7fb26009346b251de24872de92c901", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "9d815cc8-ed81-4b7a-8550-73feab3fd37c": {"doc_hash": "b5748b96265fb843661cb2a82f5d8ea039e7b82b16abf3cb1b115709099a81d0", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "4b29917c-b820-47d2-bc8f-27f8261a360f": {"doc_hash": "d3eb7f8981d520dc19b53ebaf37c94b4ff582caa1bee2f3358de568787de99be", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "d656d6cc-4edc-400c-b445-9578dda9694b": {"doc_hash": "740adbe1ab3f1243cb96fe41065aad097f79bf7184d9abe49ec3b95972f28720", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "f9961832-887a-4091-874d-081e7346b34d": {"doc_hash": "33d1741acc1dbffc9d32ccb03d0288cc34b8339b4d75249791ddbfbff2c4b273", "ref_doc_id": "a051485a-c1e5-4b47-94ab-19a5e3f83b18"}, "fd38e0f7-5f17-40f8-92f3-6720de87744c": {"doc_hash": "369c8e267d98898645054dfcfc6c68b5c97ec3ff7e23b0db97ae5f033f51fb29", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "c123bf81-6dd3-4069-a5f9-eb5a43d9a6aa": {"doc_hash": "f7418f617d5ed38e5c8a3a189f0f94a774fac22f539538e90d8104f6d8c55c68", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "b0b6bf1c-9d59-4459-882e-331b104bd8be": {"doc_hash": "7a4b0e9fbd25ebf78f5a5a0bab27d698003a7912f0f07a80ec41b28ce850f2b0", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "976bd4e5-7573-456c-a697-e80951802fa7": {"doc_hash": "0dd914edabe2a690d551ddd6622728072737956e5ba5d3de9deb9569cc234707", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "81d7be04-c27c-437b-bbdf-9763ee16ce28": {"doc_hash": "edd7028f81571ddc1b0824c62b0481a7bc6b10d450e941584566574c27f4ff7a", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "8b8981c3-674a-476d-9201-04add9428ec4": {"doc_hash": "ae59abad57dc16303c0beb593db81f99aa68d507225a288bf22134d3a01695a3", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "50934e2a-5449-49d4-b823-b4d8d1e65c62": {"doc_hash": "b32d5cd7b8bd343e87871f917da5054da8e5db6cc460a03d487bdfa92485841e", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "f6ff13f6-a333-4fe5-be0c-f5da68de995e": {"doc_hash": "e1749fe287b7b20e3289ab615a6072cd995a99fed8b089c56db00d3e61a06a10", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "58abbb71-1e45-4620-b6f6-a71816f03005": {"doc_hash": "c80e0e8031b3dc79ef706843e2de40315d704fe41903501d88d6e4a07ff62533", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "02d0af9e-db43-407a-99d4-0ec6f0cf6300": {"doc_hash": "2379260b5f0deb54f442629a31831503abf269de752898f1485515d6802fb2ed", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "fb06f4a9-433f-41c4-a17e-f36dd351e065": {"doc_hash": "d9e3887dc2955f1a5b5f6b607fe4013b45cd417741d08bbe812e46de39e349a6", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "0a1ee768-d38a-4b69-a665-37410a3eb3d1": {"doc_hash": "ac6cf9375bb3254ad99449a3d483cb0aa30c0b758c443cc48873045a8750a7ca", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "a1209509-d1f2-49ef-8083-1771eac74b10": {"doc_hash": "b29fe6e6170f1f15f4e58b3b624c6709f22d583080985ec6bc2b3e55f137297f", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "3821ce94-2fe1-4736-b551-af63d6142c43": {"doc_hash": "8e9121098b1a960e5402d935c484aad0d4562c4950c23427e9a883cbc892ce22", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "b9cee65f-3e98-4f0d-a0bf-599fbd5eb50a": {"doc_hash": "838ea000b119db78926b0dc135722dba88ffe9b5d1d8cd2a2a35125b190aad1b", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "c6ebbd7b-5b6c-46b2-bc0b-b8c9c65a17fb": {"doc_hash": "e9ffdcad252806714d9ca23f55688f7bdfb1b5d8697adbae07615b8af8755e49", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "040ec0ed-e314-414f-a9c2-982f4a6a51b9": {"doc_hash": "816824def20a0166b2f2a3c26633aa95432b7b68360da17fad252bc95f9bafec", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "190c6daa-546f-44b2-b891-ad8af2686a71": {"doc_hash": "2d37d3fcf1eb875b4e2a9662bb526baa17d751015c797bcf8a9152e0a575ddfd", "ref_doc_id": "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd"}, "936b9e8d-bfcb-48b7-8a19-06076b2fed7b": {"doc_hash": "f3b18400ffdd0138507ff70ec169c8fdc048e8cf951722dd429edbe1cfa57142", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "122d7c20-7e6b-48b1-a71a-185a233e0e92": {"doc_hash": "ce4880074fb59722261435c3c0ca6eaabe24f2d76e738b5251880b74bcb62e80", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "de45eb66-ed9d-4f09-84bf-d436d3f3a082": {"doc_hash": "c42fbd78f9800eabea6930f753d245cdf0392ac8ba552814598b0af4f0b067c6", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "42dd1bbf-7a5d-4c42-979b-bcc11b496c6e": {"doc_hash": "c1745713770a38f1777357d33cf50d8fdef7fe98b89d42564057f7b390407ac1", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "7389a997-000b-4395-8884-2f59578003cd": {"doc_hash": "a1e0898549dee1f029780342650b061ec59e4c4e00d5ce226607bac146112d02", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "c2f0954c-b35f-4cbb-a712-dd4a1702290f": {"doc_hash": "2b369324360cd85aad36327d902e9170fbe4f7fd4c3c84919c3d16c634335398", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "c545ea75-f9ec-4d0a-9748-4ab4a0fd66d9": {"doc_hash": "25a3e9db21925f9fcd0800b509472eea2d060673610bf37fe61034a29d0e0df1", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "c5051af5-445d-4d26-a8e3-2ab5f2636e48": {"doc_hash": "4d186d5df6783ec009fea154d8dcbb332438e59f8ab15b39a35bab466a4e5a2f", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "d9897959-cdb3-4830-9f04-8ae61de1fa07": {"doc_hash": "19e72e2eba3d2842b216b75c97c3e156258422c6372540545ac0d8528389833c", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "c704000d-de3d-4eef-a706-7af740282ab5": {"doc_hash": "8ab01365467de5db4c7dbcc7355834f517a2e0cdba708d1868889adc8bfcf89f", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "f212edaf-4249-4837-8cb4-a9c8c84d0644": {"doc_hash": "c5ae089a780c641d6871a803eaf097241cee3cd696209de901c1abe61608e12b", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "2ccc53e3-a503-431e-a1ff-7a3996533257": {"doc_hash": "e8697c5af1546a74324ab65c4f582a3380369f5bf030cfcb511fd3719be6f544", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "71d0612c-6d7c-4d7e-822e-8c311eca54d7": {"doc_hash": "78b3bd52a4cf56bd0132dda6fb8fec1f0eca1391e0e5d86fe775b222ed37cdd3", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "a2152c4d-5af8-4e8e-b176-c8c1ab07eb1d": {"doc_hash": "5c76db6ca69cd4025d0eb7f2f5c739b1cd4bc7abe04abac1aaf9c5fe91e2001f", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "a3342b03-b3be-43d5-93be-ac323380d63f": {"doc_hash": "776574ac58bfed1473b3a93278ae38f961504c3de77d9d60714c0957fcfd7eec", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "6ff000ee-28bb-4b36-925b-41d39d60a847": {"doc_hash": "191f351feeecc1364b2ba8dc3ca5d9626a77c9cd0ccd019d7542d02441172bea", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "21e57375-3914-43c6-abc9-4d9b9c2decae": {"doc_hash": "e70663f41674c12c9c0d50a2e2c6c14061dfeb74bd9d049327964f9c96278344", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "b9f4eb73-408d-4ab5-8530-097a203d55a1": {"doc_hash": "967447cbdab44029eab29810679c2b6da7fc9a231dd544858787c4e58dc58cb4", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "10ae0ec4-46e6-4541-aa29-17cd4d93f2b8": {"doc_hash": "d6881076c6ba5451632cf8e7ec0ccdce31f00ecb9f97560aadddb296d86d9aca", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "a755df30-6d53-4bf5-906d-9252fe5c6f27": {"doc_hash": "c29e9517daf57c113788c840ac3bfbdbbad33767e8102875ab40065c76aa2322", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "ef46d772-00a5-4777-a4ca-345469ec52e2": {"doc_hash": "fd1f0429f09b032589480874083fdc880aedc8d691e9d711f616bbae5db8d390", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "bb2ac460-437b-4f24-a659-d8a88fba779f": {"doc_hash": "7f293d8b2e9acd231e78c31b2252007ceec98eb05a51a1c990759892eb07e079", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "4dd3a4df-86d9-47c6-927a-803f3129f125": {"doc_hash": "df0741a94f30d30bb410f11bef8179a534394129cdc1058aa597d0c96d8f61e4", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "ff6d180c-b880-4b02-8bf4-731375eb17b1": {"doc_hash": "6ad218dbae58c81c89265713bd0ec61d5e4c05fbd63b866d06d57199608e9d93", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "7cf3cd46-3178-4ad7-9ad4-011d62b65fb0": {"doc_hash": "d7428ef93a49c3bc36df3197a96de48d7e89999032b6d86e4ad179362be78fc6", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "b8d072e9-f01f-4991-8c16-5ee8e3881290": {"doc_hash": "ae2f42df99f56c626e87f34d55b9f74177f9e5ac3d254076dd3c4af43af7a039", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "2c7f9c5c-bf63-4d8b-924f-bac0f41ce395": {"doc_hash": "17002861eeda0c28d1485ab5b20ac46856209f1225ba7d68a5ca5979c47b8c0c", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "9a56dc27-0721-43a7-af6c-a801a6ab5258": {"doc_hash": "469a8edc78ef00e0d7971ea0c60ecf7274ef693f98bca06699c57a1e923689c0", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "8a26ad67-cd3c-433f-80f5-f657dfc9b5ef": {"doc_hash": "0c7da1897b596f22ad669c88027d79b2b6d3b8abf0c916f2e168b5d4c5950c1f", "ref_doc_id": "00d4b34f-852a-41fa-9a65-39d4e89ad530"}, "be7dffdf-6ca7-4933-8c51-192e1ba13100": {"doc_hash": "39dd9235d44c951e8a0fca383c78c07f2657a160c47c52eb8ff6b337f72e994e", "ref_doc_id": "c45ebcc8-9497-4075-9cd5-44ecc708ab11"}, "da32d30d-ef22-4b7f-a424-a32d3f0fb6ed": {"doc_hash": "3cc86db2bbea619a8df9fdb84d61133b3db9889aad89cb0a62f851cb8e47ec46", "ref_doc_id": "c45ebcc8-9497-4075-9cd5-44ecc708ab11"}, "c75d8b03-b331-444b-9b34-0e1ed7aac5cc": {"doc_hash": "95d51a43d4d03a2644270eb30c09886c3794fb49c080e8c49537a684e0464ced", "ref_doc_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f"}, "3b1056e6-c638-46f5-9128-91b029e3ecdd": {"doc_hash": "8c677289c3fe0570b66a18113df7fa971e8c76f8f539af0386e41e86dba94f62", "ref_doc_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f"}, "286ee9f8-d878-4d34-93d7-28dca11c3d39": {"doc_hash": "1d94468391dd37e302b213f72060a1d6c1a19dcaf9fd645c00b6912676eec458", "ref_doc_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f"}, "674a12e6-dcc8-4706-8fed-cff0cf29e1e6": {"doc_hash": "b4de45e5f65b65c506bc9b2384cf2c40bb2b476930786e2e1c798919d6375484", "ref_doc_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f"}, "d30371a8-9f58-40d9-9dde-5a21022b48fc": {"doc_hash": "1e1056f8d521bca4465b9449896a05dc61f7522afab975a25b4c0e1cbe685940", "ref_doc_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f"}, "69da5285-393a-4103-9869-ddc5c4d7697f": {"doc_hash": "c077341bd55cdf74440e636094f10e9b25925f8e94d615069c47c766b9c215fd", "ref_doc_id": "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f"}, "2b8eb401-6fd5-438b-bcd5-7d1ebe96237e": {"doc_hash": "224c3ec13427a0d802a0d340ad457995c50c17edb927bb12a8cec7b3608c0fe0", "ref_doc_id": "cce6d223-032b-4099-8a5f-acb07bd5f1c5"}, "de959daf-1918-49f8-881f-0f555b397209": {"doc_hash": "35d58f8815306eab07b8b686e09e36aa682fc917824f223995d832b75462f336", "ref_doc_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99"}, "56b73020-09a7-4d9f-b269-5c1e6651029b": {"doc_hash": "c2957e56dd552c57849d041e68d00ee3533b26c11b1c6c8a90202eab1c539875", "ref_doc_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99"}, "edf289cb-61b9-4d88-813f-403785d70887": {"doc_hash": "5e075e3567972cd01f22373447dbfed7296f28880b794237bac055ba5d63c6ed", "ref_doc_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99"}, "3552026b-ae7e-4c7e-8911-f985f70f119d": {"doc_hash": "cb4002427bc055e67fa4f05c2a26af4cda1c44ef75e4161c1a7ee23c8e144815", "ref_doc_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99"}, "5b7fd741-f7a0-4657-b6ab-7e3451d817a9": {"doc_hash": "389fafc0ea6d6c5c5a46445ef7d10fd72ba129c4b5244362246675235a42b1db", "ref_doc_id": "c8b0a0e3-105f-46b3-bcdc-56e28620bc99"}, "d9286689-fe56-4f66-a454-2605fa62ea78": {"doc_hash": "ea9a79c1db438837cb78f517eb41c961d270740a68ed68bb1a00bfcd4af60308", "ref_doc_id": "c6d608a1-af96-4d54-999d-b63c25fc36ca"}, "0e96e3fb-7716-471d-967b-dccde8aa7823": {"doc_hash": "da0bb19f8b76999895eaac35cf584ea460fc4b10a51d272bc479984de0f179fc", "ref_doc_id": "c6d608a1-af96-4d54-999d-b63c25fc36ca"}, "3af2534a-0d9d-48f8-b4b0-035edc402346": {"doc_hash": "a782f17664b0763fd4ed01791ca62448f47f0437974e6e05184dd671ea917e67", "ref_doc_id": "c6d608a1-af96-4d54-999d-b63c25fc36ca"}, "567574be-f297-4af8-bd53-2cf33b66cb85": {"doc_hash": "b97f994afb47ca32f750c542b75b8ad056aaa4bb7fe0c470de775c4b29795bc6", "ref_doc_id": "372c63ac-47ac-4945-bc66-9bfc697c973c"}, "0e83fcff-4482-4b57-88e4-9c17c27bae9b": {"doc_hash": "e24e77a4bb0e5acea840467386556cc3b41d9d474bb404b44abb3390997b93c4", "ref_doc_id": "372c63ac-47ac-4945-bc66-9bfc697c973c"}, "f218db4d-1e9e-4064-bf37-fec27509c100": {"doc_hash": "a1f135cbb1435c4bacb6e371884bafee38b89e3aba2b2ffc4777cf6744f28d37", "ref_doc_id": "372c63ac-47ac-4945-bc66-9bfc697c973c"}, "9c2a2ec3-4c3a-4901-b946-8e27c898ab60": {"doc_hash": "6419a3cc7704a97fc36ff947cf7db64f7a715d12bcd46f05304f02a4cd39922f", "ref_doc_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0"}, "916a0d52-6be1-4710-b0d0-ed8e7d955e37": {"doc_hash": "3db5c14b5cbf0a9a92ad971eea2004b960233dc7a0dc1e44752cb2c9243b72e2", "ref_doc_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0"}, "b74c5df6-d1d3-4f28-9434-b030ee45dabb": {"doc_hash": "bbe181362b23f2e107c516626d6cdc8a28d6ded78b236bd6edba585f5d612958", "ref_doc_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0"}, "4a9557ba-cb7a-4d66-aeb8-63a9c76f49b2": {"doc_hash": "67e5e69c1dab6957d9401203e6a73bf726336f9bf9350cfe97cf00a4e9092884", "ref_doc_id": "f45b6f60-bad1-471d-a1bd-3255c08939f0"}, "760b2366-f13a-46c1-b76e-ef4b8063ca24": {"doc_hash": "7b28446d0cc56d882ad5c3415fb34a087229c90b449d5efce55c6480aa848dbe", "ref_doc_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d"}, "ebedd894-4587-4b80-8d8e-ad0648f5ad15": {"doc_hash": "9834350c7faebd451af895c7b1de7c0e5805d642fd99331ac3d2cbb307554172", "ref_doc_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d"}, "1ce8742f-aca9-4cfc-b457-86c82fb5000a": {"doc_hash": "d1c03bcfe21f62a720605d21de4b75c68454f999330fba7abcd1c80aae0159b7", "ref_doc_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d"}, "05552a8d-f47a-465f-a596-75f8c63520ae": {"doc_hash": "462c721675fd854d0320713f1824150597e3fdd3be08768b02472861207a7315", "ref_doc_id": "691a8102-2edb-468e-a2ea-ebf6e8c5e94d"}, "06fec38a-0ae0-43ac-953c-621d3bfb0cd4": {"doc_hash": "ed9175ac2f7b85faca2fe1c037bec398ffa376af55d4693a2b69b7c893144ed8", "ref_doc_id": "cdc8970d-6d35-4af7-868f-f6f4562a32da"}, "b5330729-80c9-43dd-88c7-d63bdf9c3dcd": {"doc_hash": "5226960278c606d3eecacf87c31dc75570cbb774fe4183e6d88fc0b30fffbc0a", "ref_doc_id": "cdc8970d-6d35-4af7-868f-f6f4562a32da"}, "f2f33c94-4334-4d30-a47a-d3e74eb1f016": {"doc_hash": "90fdcc0e98f94296ab74de59b1854792d934ce4d8d1512ca442ed691a462dfaa", "ref_doc_id": "cdc8970d-6d35-4af7-868f-f6f4562a32da"}, "0c14bc8b-2999-4c9e-bc2f-8f6e4d902659": {"doc_hash": "caf8209263484f7fd68e9ae9f01d50a7d218f22b7ca43d593afa96cb203f99d8", "ref_doc_id": "0a36f69b-81ad-4fc2-bb42-f0f8e2999c9d"}, "04893a0d-db67-47de-95ca-3d6ce9bb9b2c": {"doc_hash": "79cd94ecaec9a9a7e496ca701e417f8ed33c7d46532350d197257b4245d595ce", "ref_doc_id": "0a36f69b-81ad-4fc2-bb42-f0f8e2999c9d"}, "1e1ae334-fdca-4f65-8faf-9368a28adf85": {"doc_hash": "d0c15d87b35d62e9ae916cf0a460c45de8aaa9719cf5ceccc656b450e8295087", "ref_doc_id": "7b0f02bf-ba5a-4454-a868-8c9d00be715d"}, "e3bc79ff-2f29-41c3-9502-d5dbb0b4f48a": {"doc_hash": "81d6d4338d02a91dc50c235ef391707b6afa1ef40ea80eec2b1b36fbdbbbeba0", "ref_doc_id": "bea30be9-32da-4ef1-8f76-de870e77be9a"}, "a3729e6a-4222-4d55-b8ec-a53ac05d2115": {"doc_hash": "0d1decea060f5f22ffdbc2d1138b156f32d3064c6c67726ca6a7b7e07b64c801", "ref_doc_id": "bea30be9-32da-4ef1-8f76-de870e77be9a"}, "b884219d-f0b8-4e4e-9472-15eb1f0b4098": {"doc_hash": "3efa0072a4407ca28fa2ececb9dc6825da461fa65448a7650b78ff8c9a431df0", "ref_doc_id": "bea30be9-32da-4ef1-8f76-de870e77be9a"}, "f9edd26c-3575-4e32-91a6-b9b5f4688ec1": {"doc_hash": "fe720bf199f87d9c1fc203a90bf3600e9837d986a8fa90e655873d24effbbd0d", "ref_doc_id": "bea30be9-32da-4ef1-8f76-de870e77be9a"}, "f9967efd-b014-40f5-b823-89ca28672c9c": {"doc_hash": "78cead0d8ee1faa6404de021635536fa14f355281710c7fa9d0c27a51f5ddd4e", "ref_doc_id": "bea30be9-32da-4ef1-8f76-de870e77be9a"}, "69299d4a-a253-43c9-89ca-94bd72e7eeaa": {"doc_hash": "264b127354f1f5f7341e5f42a28526bc16fd47cbc798bb20537c396a2ed0e633", "ref_doc_id": "bea30be9-32da-4ef1-8f76-de870e77be9a"}, "1a1de299-5ed2-48d5-b7df-fb707600c8bd": {"doc_hash": "32f3c600be96549f6e5ec8cbb84381c169daa7a8d2db3fb403c9db54723de920", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "4244df3b-bfaa-4020-bd81-56e7fb5abe6f": {"doc_hash": "3277534d9ad730e40b9725d69040ada9b1bbe6c4802948045970b4ea743e6a2f", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "2bf15959-015b-40d0-b260-8353baeaffa1": {"doc_hash": "41920e00f4dcb24ee20a3580cdb33c7457415135ae530e6f3ad6b0d78bf095fd", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "fd1947a2-be8b-4771-9854-c90eaf41deba": {"doc_hash": "54a0367b33d399b1187f3a21b0d985f406e525fac89672a0c435a8aae702eb8d", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "22fb38ef-6e0f-4736-9001-bc90d29f1eb3": {"doc_hash": "7823d83d828e50adaa6e23f3afa6c9ad396367de5b55fd7771ebb0a0900b3e31", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "4bfd451c-cf9d-42e7-b468-91082465bfa0": {"doc_hash": "5285a1f2f03b5ef3d8b70e1a19ce33d14cfd10eaf32bc547c4266019095b7e17", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "e0d42781-2e50-47a4-9c09-5a0150e0bec8": {"doc_hash": "a95ef92efdacde62cab46984ab459ed2385381d7c20e510a7ee09b17c65065a7", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "9e6b2f0f-5fa1-4903-9299-0dd4f1cbd9d2": {"doc_hash": "f0f1e6b1e4daf4c29a9716e51d3db241d0425bd2b3fe059457796b9cf658cf0e", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "0a7e280f-c47e-4ce9-8e15-c7cc39c6c8bc": {"doc_hash": "1687b446ffb3bd56535dec3accb534a6e11ba42986b2a90ca63717bd79d5525e", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "23ec2166-b97f-41ac-943e-3db2b41f7abd": {"doc_hash": "e9526a86edee30e8535d85902756c3c0d8cfa1ffd6132a391c9bf9a8d20e5722", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "7f3b5414-a4c8-4258-bd02-bc94a292d616": {"doc_hash": "5edb7c74bf37efcfb12c49810b0e484ce9c5cd12f45bde00da0d2843c4bf3317", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "3e4a39cc-25c9-4e31-9ee9-2d8d66f86e9a": {"doc_hash": "3932cfa075bdbcd5d59276e787f85dd9f08a7f120ea90fd04998cda2535ff9e1", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "0b44de64-be2e-47a4-ac8b-16dce5be0959": {"doc_hash": "9929b0d99e3c461ec384f5882152d3008a7fbe29091cba40a8b191ced31c2bbf", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "7d200113-aa10-4a6a-8f7a-c822bdd5863f": {"doc_hash": "a24fd996614d08c3e8913ac0161377693c845a4256cbf16bd98be8ba9bc24a2f", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "cea133d5-66a6-4f90-835e-1ec1234f2bf7": {"doc_hash": "aa4140646b1a8d85437ef88f37afe01ccdc491d5453bc0529f791b5002a090a1", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "799d8f7a-b529-47bb-bf2b-62664bcc6d7f": {"doc_hash": "0a477ef5ca41fca0f4ea1672819952e79741936d55c9f039fa5a33f16a9729a6", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "aad84d13-db91-4c8d-8173-997d518c4a95": {"doc_hash": "b9aa4346b4bf2522236ec06224ad5e322e2e8074b87fe3164e17811bc9ec71a0", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "fe137c23-ba8f-4803-916f-d31c40d2b762": {"doc_hash": "276f72d3eaecee568482a365abb32dba3d8e160349da49c993d92656c40050b5", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "a299f86e-e5b9-4042-8c81-a582272ec134": {"doc_hash": "2e96f7a9519dae3a699d6abec5ecd9331173cbecb782ba02b5d39f091d4393ae", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "4e13316c-ba8d-4432-92cf-c92bbdb07fe5": {"doc_hash": "4c0c3f1dc75138c473d1dc11ae4b69021e6e779abefdd5180520a86a0f7587e9", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "48b319d1-9438-4c0f-ac96-45d169a552e6": {"doc_hash": "c9e58ef5364b20ed1c046529105634ae4970adaf520317e5b7173552cdb9604c", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "4e701e26-36bd-478d-bd3f-593c12f285e0": {"doc_hash": "84137189be8750b08a470cfac049fbab372b1f7a470aafc743f78ac4941ebb39", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "3ab0a1ad-7aeb-40b7-9801-dde4ac52f873": {"doc_hash": "e8718384662943d6451c929fb93d87996b1615108c9e932054071f9e349a92e5", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "a641f0fa-085c-4d0b-9c62-ceafff4f9e81": {"doc_hash": "65ffd9d147a2d2ac8ced66e59819268ed9b70ee48ef217d532604bdd9bb5d4aa", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "b7c16fd4-9a08-497c-acce-4853468f5d63": {"doc_hash": "824178f91f8b7ed53d6431f93c3c3edd68a8fe88a69679d87e40939cd1761e3e", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "a3dba3db-d573-49ee-8a87-b06cc9b17072": {"doc_hash": "40f3fbe7ce5d3f2dedcb52866343183d43674bd749c65473adb344f2c106416d", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "ed91153b-3718-4ad8-bacb-a737aa3646e6": {"doc_hash": "c5f2bb01cc196ef979893fbbb6b629bd241086adba4f528015f3b0cc2dc950ac", "ref_doc_id": "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff"}, "e4fb2b6c-0132-40f8-911f-beff09059274": {"doc_hash": "7c745e9134bfc610fd29c5b2dc196d80427ef1d972e5b07404f113145597bb04", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "e2891e2c-fb4a-4a4a-bbb6-30f8ce2a2180": {"doc_hash": "93386b55a9a27696d76c338a8e52c028d39292fa9614f27884559cdb6480aed4", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "ab0d3d85-832d-4822-8405-a50bc5f83940": {"doc_hash": "e372a222d156a096fdb79457c62e36a09139076747a193241738b206a7b8ccf1", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "40b8b73a-ddb7-417c-b725-c1edbe656da4": {"doc_hash": "01bd41e24945ed4b8c8c52e29ca19179459a25fae80a1fd911e606bf6defc025", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "e143ebd0-c1b7-443a-ac8e-f1d8cabed7e7": {"doc_hash": "4b548d516e5cb424f82a4a3b8f2f3e30a02e97cf057718b9df2eba8f8cf0f7b1", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "f6dd8bfd-16c2-46de-bdec-cf2527b4e436": {"doc_hash": "8bedeeab266760bdb197e1a27efe5406840906d22734cbad510c3f07f63a353e", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "c519122a-729a-4044-bbda-3d4afd83ae36": {"doc_hash": "5a48cb072c5b13a34e848ed1146c2f6fbd24812038c403a473fc70103b7d0641", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "ca5e43c6-92c6-4dfe-82ac-dca517c5c9a1": {"doc_hash": "5e012d86e0c5ac835b752642103e8c04836216107097f6b6ce8fe2b88a9713cc", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "92cb8332-cd4a-4298-8015-6f1a6be372a7": {"doc_hash": "fa2f467655416c3e0e5c9d668781dc7902f03ce95c5e2c590ef526a7308542de", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "8450568a-f48c-41af-8bd8-280915e938a3": {"doc_hash": "9cb6b5ed835a0125df215f1d92dc47f2995ae6608b59d0cdd03621c87135ecad", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "7cca90de-45e0-4897-be82-71ac42034503": {"doc_hash": "57dca6a8d3e4b73a79a3069ce89607c22ea52ee7d2a065c548386be590265e2a", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "66e18f19-6b75-4e11-b3d3-7e9f0fcf60f3": {"doc_hash": "5ba0487038019ba501a1b992b3bd3fbe6f510fc79269b57b4d20a67c6c4f313e", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "0d1ae852-457a-4855-9c62-c0d9effac2f6": {"doc_hash": "c22566741536933e408295c42bc3a969b62e9a5314a2e4f84553668c7b17473a", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "10d02673-1ba1-4958-9639-f289dedb2d50": {"doc_hash": "1bfda692168c5df59e0d3cde97e3ed9ca64c989dcc0967b577a593d2ec20cbe0", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "8af1c89f-adfd-49cb-aeea-6680308f2718": {"doc_hash": "8543c84ae2270bba5d262e713cc066cbfafb1d14772f75e5feee5c4413fee78d", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "5cc1c7f0-65c1-4cfd-8a56-2ef541fa32bf": {"doc_hash": "076963260c56134c8058b705e9d3faed82e4a75390e3a22eec2448a5e46be833", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "5a5d214d-2ab3-4c37-be12-43fe558d6bd5": {"doc_hash": "e0c5f57775d652e40bec53d965cdf3fdd5a91726d669fce547afd7a7c4af87cc", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "9f42739a-163e-4c23-8d54-b76a48daba1e": {"doc_hash": "6c1edff9fe6039164dc429b32c45f80bd234d65a8f29a4be4a0ea642ef8d7e8a", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "def3d3ec-4dd8-4eff-b76e-86bae985454a": {"doc_hash": "3fa22528b74878128161984d3c23a9b06d6940b78cf02497cbaea2c55b201604", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "e6dfdcda-e1ba-44db-ac7c-feb5c14f449e": {"doc_hash": "5b783c77ff9c516031f8b9d3ab0e2324ffce003099dadd65f507def0918d5c8d", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "d71a1a72-fe04-4319-a63f-41db2b7da32f": {"doc_hash": "234e0c736f34e882beaff3dc65fd5636afbec6dd0a7b9ffe24e32f1ae6c3d2ac", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "a4cacede-43ac-418a-a958-2903ff7ddc37": {"doc_hash": "8107cf658656bdd2a50e5d0e84088b520d525df15ff848bebfc686758b4a75bb", "ref_doc_id": "7ffa6e04-827e-4171-b994-23d019284fcd"}, "aabad694-16d4-4d26-a5bc-e3f9766d2ade": {"doc_hash": "5e0eb7634a61960266e1483f54229b874a4a8d47b794519a583deac5bb036269", "ref_doc_id": "38384c4a-c687-41ca-a7e1-32efa5a1015a"}}, "docstore/ref_doc_info": {"ec80978b-137f-4482-889d-7177d5e2d6bd": {"node_ids": ["84d029b5-1235-4b6b-a948-258149099077", "3632ed99-d63e-45f7-a8a8-f7e41a0a253c", "62f2883b-1023-47dc-96bf-d0e6650b9551", "aad4d32f-5033-42d8-b394-5879080777d2", "501befc5-2790-4c7a-b5d7-aa4ac3433459", "c2602981-c2e0-48b1-a358-9cde8aae5c5e", "7b7e580d-2a90-4d2d-986a-3f39122d1204", "42c5ec67-ee86-4b05-9bd1-4378b903197d", "7223bde6-9eed-410c-862b-02b532dcf3df", "a9cac26d-1faf-4848-afd3-32d600d084e1", "7506e5f0-3795-4934-a29e-659717edc616", "8f205d30-9323-43e7-bbce-fa53559188b2"], "metadata": {"window": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR) today reported that in its fiscal year 2024 first quarter ended\nDecember 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the\nprior year first quarter. ", "original_text": "Cencora R epor ts Fiscal 2024 Fir st Quar ter Results\n1/31/2024\nRevenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28\nAdjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "07bd8210-72e7-4ac1-968d-a30965a836af": {"node_ids": ["910713d5-67b7-4518-ac75-e7e5e9345c4f", "e3364d98-7020-46dd-ba48-d049b3a8d6fb", "f9be65c5-87df-46a7-bca1-46c93bc1cd4d", "c6982918-f1dc-4f47-99f8-aff3491867c4", "fed69b32-cd74-47b8-bd7b-1df889def60d", "9ca3cbc0-1c37-4937-827f-73898f30c908", "ed9989f3-68ce-40b1-9ed5-20ff7f9de0af", "2f3ea537-898d-4d65-a75b-0e3dbe9afadb", "ba015488-b4e1-47e3-b8f8-90524046c0ab", "ce1db80d-6020-40e8-bf87-e0f3cb4b52f1", "0b87b31f-979c-49f9-ac74-fe41541fcf35", "6714649b-793b-4bcc-a112-29df51a099fe", "73a49c6e-66b9-4fe6-8fbc-a904261669c7", "e7c2168b-1f56-4331-8f49-a2b79e89810c", "d8095d78-a4d0-4fff-9c8a-517abf14cc81", "55c01c78-0329-4fc9-b292-471c47d53a08", "033f471e-945d-414b-b4a1-f302c6473f13", "a09f03bd-c07d-4389-b092-b38d1c2f130e", "ed336d73-2854-43ea-b6e8-9f42da7dd6dc", "c711e221-a83f-4394-87ad-a033c60a883f", "e4832a68-6a34-4cfc-ae8a-f1a3b06759fe", "c375f1ef-0d30-47a8-b6bb-f411e7771b8d"], "metadata": {"window": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc.  $602M $661M\nDilut ed Earnings P er Shar e$2.98 $3.28\nDilut ed Shar es Outstanding 201.8M 201.8M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In the tables\nthat follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-GAAP financial\nmeasures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information R egarding Non-\nGAAP Financial Measures\u201d following the tables.\n", "original_text": "23.0% 21.0%\nNet Income A ttributable t o Cencora, Inc. ", "page_label": "2", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a051485a-c1e5-4b47-94ab-19a5e3f83b18": {"node_ids": ["576d7163-2b42-4866-9188-4cf36131c16e", "cc729b38-6e98-4c02-ace7-7f968d212a51", "f06d75eb-cc52-46e2-b0ee-5229a91c72d0", "1779473a-735f-4ce4-88a7-f61305fe1ba4", "94c7a456-834a-4c1c-90b0-808b91f2bf1b", "739d0066-4c95-435f-a826-d9fd2995b306", "8132ccf2-f094-472a-935f-01d87cbee875", "1cbcfdfe-d758-41a9-8a86-f849d73f6e88", "1fc906d2-95b0-4d6a-95a4-df4ec293465f", "079cd54f-3349-4df5-b386-fd8006f09d91", "e02e99f0-7a91-43c3-9938-0f530f37b0ea", "e59336fd-00de-4d36-88fa-831de139376f", "217489dc-3299-48e6-b3f2-963a9d15bde4", "0c34ee94-592d-4f5b-98c9-b254af119bfc", "5677678b-0421-4409-8583-7935c47fc472", "bec89659-dcf0-4024-bce1-406efa52f63d", "be544d03-f78b-4e4d-83d0-b5151b0f5426", "c8e1f8c4-e966-48a9-87e6-24ada0e97ba9", "0f7f75e6-fe9b-4e4e-88db-1d11efedc648", "21cf16c9-caec-433d-a92f-036ef5ee7f23", "9d815cc8-ed81-4b7a-8550-73feab3fd37c", "4b29917c-b820-47d2-bc8f-27f8261a360f", "d656d6cc-4edc-400c-b445-9578dda9694b", "f9961832-887a-4091-874d-081e7346b34d"], "metadata": {"window": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.31 percent in the fiscal 2024 first quarter, a decrease of 7 basis points\nfrom the prior year quarter, due to the decline in the U.S.  Healthcare Solutions gross profit margin related to increased sales\nof products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, partially offset\nby increased sales of C OVID-19 vaccines, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2024, adjusted operating expenses were $1.5 billion, an 8.1 percent\nincrease compared to the same period in the previous fiscal year, primarily driven by an increase in distribution, selling, and\nadministrative expenses to support the growth in our businesses.\n", "original_text": "compared to the same period in the previous fiscal year due to increases in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9ebd7c7b-f4d8-44fc-bba4-7356dbc0fdfd": {"node_ids": ["fd38e0f7-5f17-40f8-92f3-6720de87744c", "c123bf81-6dd3-4069-a5f9-eb5a43d9a6aa", "b0b6bf1c-9d59-4459-882e-331b104bd8be", "976bd4e5-7573-456c-a697-e80951802fa7", "81d7be04-c27c-437b-bbdf-9763ee16ce28", "8b8981c3-674a-476d-9201-04add9428ec4", "50934e2a-5449-49d4-b823-b4d8d1e65c62", "f6ff13f6-a333-4fe5-be0c-f5da68de995e", "58abbb71-1e45-4620-b6f6-a71816f03005", "02d0af9e-db43-407a-99d4-0ec6f0cf6300", "fb06f4a9-433f-41c4-a17e-f36dd351e065", "0a1ee768-d38a-4b69-a665-37410a3eb3d1", "a1209509-d1f2-49ef-8083-1771eac74b10", "3821ce94-2fe1-4736-b551-af63d6142c43", "b9cee65f-3e98-4f0d-a0bf-599fbd5eb50a", "c6ebbd7b-5b6c-46b2-bc0b-b8c9c65a17fb", "040ec0ed-e314-414f-a9c2-982f4a6a51b9", "190c6daa-546f-44b2-b891-ad8af2686a71"], "metadata": {"window": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter.  On a constant currency basis, International Healthcare Solutions revenue and\noperating income increased by 8.7 percent and 20.2 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora\u2019s premier global specialty logistics business announced expansion of storage capacity and cold chain capabilities\nwith three new transport stations in the United S tates.\n Cencora earned a top score in Human Rights Campaign Foundation\u2019s 2023-2024 Corporate Equality Index.\n", "original_text": "European distribution business, and the September 2023 divestiture of the Company\u2019s less-than-wholly-owned subsidiary in Egypt,\nwhich was profitable in the prior year quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "00d4b34f-852a-41fa-9a65-39d4e89ad530": {"node_ids": ["936b9e8d-bfcb-48b7-8a19-06076b2fed7b", "122d7c20-7e6b-48b1-a71a-185a233e0e92", "de45eb66-ed9d-4f09-84bf-d436d3f3a082", "42dd1bbf-7a5d-4c42-979b-bcc11b496c6e", "7389a997-000b-4395-8884-2f59578003cd", "c2f0954c-b35f-4cbb-a712-dd4a1702290f", "c545ea75-f9ec-4d0a-9748-4ab4a0fd66d9", "c5051af5-445d-4d26-a8e3-2ab5f2636e48", "d9897959-cdb3-4830-9f04-8ae61de1fa07", "c704000d-de3d-4eef-a706-7af740282ab5", "f212edaf-4249-4837-8cb4-a9c8c84d0644", "2ccc53e3-a503-431e-a1ff-7a3996533257", "71d0612c-6d7c-4d7e-822e-8c311eca54d7", "a2152c4d-5af8-4e8e-b176-c8c1ab07eb1d", "a3342b03-b3be-43d5-93be-ac323380d63f", "6ff000ee-28bb-4b36-925b-41d39d60a847", "21e57375-3914-43c6-abc9-4d9b9c2decae", "b9f4eb73-408d-4ab5-8530-097a203d55a1", "10ae0ec4-46e6-4541-aa29-17cd4d93f2b8", "a755df30-6d53-4bf5-906d-9252fe5c6f27", "ef46d772-00a5-4777-a4ca-345469ec52e2", "bb2ac460-437b-4f24-a659-d8a88fba779f", "4dd3a4df-86d9-47c6-927a-803f3129f125", "ff6d180c-b880-4b02-8bf4-731375eb17b1", "7cf3cd46-3178-4ad7-9ad4-011d62b65fb0", "b8d072e9-f01f-4991-8c16-5ee8e3881290", "2c7f9c5c-bf63-4d8b-924f-bac0f41ce395", "9a56dc27-0721-43a7-af6c-a801a6ab5258", "8a26ad67-cd3c-433f-80f5-f657dfc9b5ef"], "metadata": {"window": "The Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 31, 2024.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.cencora.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "The Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c45ebcc8-9497-4075-9cd5-44ecc708ab11": {"node_ids": ["be7dffdf-6ca7-4933-8c51-192e1ba13100", "da32d30d-ef22-4b7f-a424-a32d3f0fb6ed"], "metadata": {"window": "\u00a0\nCENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months\nEnded \nDecember 31,\n2023 \u00a0% of\nRevenue \u00a0Three Months\nEnded \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$72,252,833 \u00a0\u00a0\u00a0 \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a069,784,021 \u00a0\u00a0\u00a0 \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,468,812 \u00a0\u00a03.42 %\u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a015.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,398,747 \u00a0\u00a01.94 %\u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a08.4 %\nDepreciation and amortization \u00a0\u00a0270,603 \u00a0\u00a00.37 %\u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a057.4 %\nLitigation and opioid-related (credit) expenses 2 \u00a0\u00a0(78,917 )\u00a0\u00a0 \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a021,063 \u00a0\u00a0\u00a0 \u00a0\u00a020,996 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a034,441 \u00a0\u00a0\u00a0 \u00a0\u00a016,240 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,645,937 \u00a0\u00a02.28 %\u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0822,875 \u00a0\u00a01.14 %\u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(1,087 )\u00a0\u00a0 \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a040,564 \u00a0\u00a0\u00a0 \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0(11.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "\u00a0\nCENC ORA, INC.\n", "page_label": "6", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fac5e65a-cab8-45ff-ad9c-ad68aa4a346f": {"node_ids": ["c75d8b03-b331-444b-9b34-0e1ed7aac5cc", "3b1056e6-c638-46f5-9128-91b029e3ecdd", "286ee9f8-d878-4d34-93d7-28dca11c3d39", "674a12e6-dcc8-4706-8fed-cff0cf29e1e6", "d30371a8-9f58-40d9-9dde-5a21022b48fc", "69da5285-393a-4103-9869-ddc5c4d7697f"], "metadata": {"window": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $601,500 \u00a0\u00a00.83 %\u00a0$479,745 \u00a0\u00a00.76 %\u00a025.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.01 \u00a0\u00a0\u00a0 \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a028.1 %\nDiluted \u00a0$2.98 \u00a0\u00a0\u00a0 \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0200,081 \u00a0\u00a0\u00a0 \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0(1.9 )%\nDiluted \u00a0\u00a0201,837 \u00a0\u00a0\u00a0 \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\n________________________________________\n1Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency\nremeasurement expense of $17.2 million in the three months ended December 31, 2023.  Includes a $49.9 million gain from\nantitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6\nmillion in the three months ended December 31, 2022.\n 2The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction\nprimarily as a result of the Company\u2019s commitment, which it made in December 2023, to prepay the net present value of a\nfuture obligation as permitted under its opioid settlement agreements.\n\u00a0\n", "original_text": "Income before income taxes \u00a0\u00a0783,398 \u00a0\u00a01.08 %\u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a032.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0180,390 \u00a0\u00a0\u00a0 \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0603,008 \u00a0\u00a00.83 %\u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a026.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(1,508 )\u00a0\u00a0 \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "7", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cce6d223-032b-4099-8a5f-acb07bd5f1c5": {"node_ids": ["2b8eb401-6fd5-438b-bcd5-7d1ebe96237e"], "metadata": {"window": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income \n Attributable\nto Cencora \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$2,468,812 \u00a0\u00a0$1,645,937 \u00a0\u00a0$822,875 \u00a0\u00a0$783,398 \u00a0\u00a0$180,390 \u00a0\u00a0$(1,508 )\u00a0$601,500 \u00a0\u00a0$2.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(48,248 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,248 )\u00a0\u00a0(48,248 )\u00a0\u00a0(10,456 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,792 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(48,445 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(48,445 )\u00a0\u00a0(48,445 )\u00a0\u00a0(10,498 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,947 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a017,226 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,226 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,919 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(165,724 )\u00a0\u00a0165,724 \u00a0\u00a0\u00a0165,724 \u00a0\u00a0\u00a035,913 \u00a0\u00a0\u00a0(435 )\u00a0\u00a0129,376 \u00a0\u00a0\u00a00.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\ncredit, net 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a078,917 \u00a0\u00a0\u00a0(78,917 )\u00a0\u00a0(78,917 )\u00a0\u00a0(12,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(66,889 )\u00a0\u00a0(0.33 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,063 )\u00a0\u00a021,063 \u00a0\u00a0\u00a021,063 \u00a0\u00a0\u00a04,564 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,499 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\ndh\n8", "page_label": "8", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c8b0a0e3-105f-46b3-bcdc-56e28620bc99": {"node_ids": ["de959daf-1918-49f8-881f-0f555b397209", "56b73020-09a7-4d9f-b269-5c1e6651029b", "edf289cb-61b9-4d88-813f-403785d70887", "3552026b-ae7e-4c7e-8911-f985f70f119d", "5b7fd741-f7a0-4657-b6ab-7e3451d817a9"], "metadata": {"window": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a012.5 %\u00a0\u00a08.1 %\u00a0\u00a020.7 %\u00a0\u00a021.9 %\u00a0\u00a034.0 %\u00a0\u00a0 \u00a0\u00a018.2 %\u00a0\u00a021.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42 %\u00a03.31 %\nOperating expenses \u00a02.28 %\u00a02.08 %\nOperating income \u00a01.14 %\u00a01.23 %\n________________________________________\n1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment,\nwhich it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid\nsettlement agreements.\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n 3The sum of the components does not equal the total due to rounding.\n", "original_text": "and other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,441 )\u00a0\u00a034,441 \u00a0\u00a0\u00a034,441 \u00a0\u00a0\u00a07,463 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,978 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,201 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222 \u00a0\u00a0\u00a0(109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0331 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,685 )\u00a0\u00a0(18,916 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,231 \u00a0\u00a0\u00a00.01 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,389,345 \u00a0\u00a0$1,503,626 \u00a0\u00a0$885,719 \u00a0\u00a0$839,673 \u00a0\u00a0$176,323 \u00a0\u00a0$(1,943 )\u00a0$661,407 \u00a0\u00a0$3.28 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "9", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c6d608a1-af96-4d54-999d-b63c25fc36ca": {"node_ids": ["d9286689-fe56-4f66-a454-2605fa62ea78", "0e96e3fb-7716-471d-967b-dccde8aa7823", "3af2534a-0d9d-48f8-b4b0-035edc402346"], "metadata": {"window": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto Cencora \u00a0Dilut ed\nEarnings\nPer Shar e\u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\n(12706 )12706 12706 2969 9737 005\n10", "original_text": "\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "372c63ac-47ac-4945-bc66-9bfc697c973c": {"node_ids": ["567574be-f297-4af8-bd53-2cf33b66cb85", "0e83fcff-4482-4b57-88e4-9c17c27bae9b", "f218db4d-1e9e-4064-bf37-fec27509c100"], "metadata": {"window": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n 11", "original_text": "expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,996 )\u00a0\u00a020,996 \u00a0\u00a0\u00a020,996 \u00a0\u00a0\u00a04,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,090 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(16,240 )\u00a0\u00a016,240 \u00a0\u00a0\u00a016,240 \u00a0\u00a0\u00a03,794 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,446 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating expenses \u00a02.41 %\u00a02.21 %\nOperating income \u00a01.01 %\u00a01.17 %\n________________________________________\n1Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f45b6f60-bad1-471d-a1bd-3255c08939f0": {"node_ids": ["9c2a2ec3-4c3a-4901-b946-8e27c898ab60", "916a0d52-6be1-4710-b0d0-ed8e7d955e37", "b74c5df6-d1d3-4f28-9434-b030ee45dabb", "4a9557ba-cb7a-4d66-aeb8-63a9c76f49b2"], "metadata": {"window": "\u00a0\nCENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$65,183,802 \u00a0\u00a0$56,236,579 \u00a0\u00a015.9 %\nInternational Healthcare Solutions \u00a0\u00a07,070,227 \u00a0\u00a0\u00a06,611,278 \u00a0\u00a06.9 %\nIntersegment eliminations \u00a0\u00a0(1,196 )\u00a0\u00a0(1,025 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$72,252,833 \u00a0\u00a0$62,846,832 \u00a0\u00a015.0 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$698,124 \u00a0\u00a0$572,416 \u00a0\u00a022.0 %\nInternational Healthcare Solutions \u00a0\u00a0187,595 \u00a0\u00a0\u00a0161,282 \u00a0\u00a016.3 %\nTotal segment operating income \u00a0\u00a0885,719 \u00a0\u00a0\u00a0733,698 \u00a0\u00a020.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a048,248 \u00a0\u00a0\u00a049,899 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0\u00a048,445 \u00a0\u00a0\u00a0(25,050 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(17,226 )\u00a0\u00a0(3,584 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(165,724 )\u00a0\u00a0(71,878 )\u00a0\u00a0\n12", "original_text": "\u00a0\nCENC ORA, INC.\n", "page_label": "12", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "691a8102-2edb-468e-a2ea-ebf6e8c5e94d": {"node_ids": ["760b2366-f13a-46c1-b76e-ef4b8063ca24", "ebedd894-4587-4b80-8d8e-ad0648f5ad15", "1ce8742f-aca9-4cfc-b457-86c82fb5000a", "05552a8d-f47a-465f-a596-75f8c63520ae"], "metadata": {"window": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.41 %\u00a0\u00a02.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.34 %\u00a0\u00a01.45 %\u00a0\u00a0\nOperating income \u00a0\u00a01.07 %\u00a0\u00a01.02 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.56 %\u00a0\u00a011.17 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.91 %\u00a0\u00a08.73 %\u00a0\u00a0\nOperating income \u00a0\u00a02.65 %\u00a0\u00a02.44 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.28 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.14 %\u00a0\u00a01.01 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.31 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.08 %\u00a0\u00a02.21 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.23 %\u00a0\u00a01.17 %\u00a0\u00a0\n13", "original_text": "Litigation and opioid-related credit (expenses) \u00a0\u00a078,917 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(21,063 )\u00a0\u00a0(20,996 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(34,441 )\u00a0\u00a0(16,240 )\u00a0\u00a0\nOperating income \u00a0$822,875 \u00a0\u00a0$633,143 \u00a0\u00a030.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of R evenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "13", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cdc8970d-6d35-4af7-868f-f6f4562a32da": {"node_ids": ["06fec38a-0ae0-43ac-953c-621d3bfb0cd4", "b5330729-80c9-43dd-88c7-d63bdf9c3dcd", "f2f33c94-4334-4d30-a47a-d3e74eb1f016"], "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a02023\u00a02023\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,872,351 \u00a0$2,592,051\nAccounts receivable, net \u00a021,576,594 \u00a0\u00a020,911,081\nInventories \u00a018,652,240 \u00a0\u00a017,454,768\nRight to recover assets \u00a01,242,978 \u00a0\u00a01,314,857\nPrepaid expenses and other\u00a0514,568\u00a0\u00a0526,069\nTotal current assets \u00a044,858,731 \u00a0\u00a042,798,826\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,117,283 \u00a0\u00a02,135,171\nGoodwill and other intangible assets \u00a014,036,973 \u00a0\u00a014,005,900\nDeferred income taxes \u00a0218,325 \u00a0\u00a0200,667\nOther long-term assets\u00a03,458,985\u00a0\u00a03,418,182\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n\u00a0\n", "page_label": "14", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0a36f69b-81ad-4fc2-bb42-f0f8e2999c9d": {"node_ids": ["0c14bc8b-2999-4c9e-bc2f-8f6e4d902659", "04893a0d-db67-47de-95ca-3d6ce9bb9b2c"], "metadata": {"window": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n(unaudited)\n15", "original_text": "Total assets$64,690,297\u00a0$62,558,746\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $47,743,474 \u00a0$45,836,037\nAccrued expenses and other \u00a02,437,219 \u00a0\u00a02,353,817\nShort-term debt\u00a0592,779\u00a0\u00a0641,344\nTotal current liabilities \u00a050,773,472 \u00a0\u00a048,831,198\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,185,944 \u00a0\u00a04,146,113\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0335,293 \u00a0\u00a0310,676\nDeferred income taxes \u00a01,690,785 \u00a0\u00a01,657,944\nAccrued litigation liability \u00a04,731,945 \u00a0\u00a05,061,795\nOther long-term liabilities \u00a01,911,602 \u00a0\u00a01,884,733\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity\u00a01,061,256\u00a0\u00a0666,287\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity$64,690,297\u00a0$62,558,746\n\u00a0\nCENC ORA, INC.\n", "page_label": "15", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7b0f02bf-ba5a-4454-a868-8c9d00be715d": {"node_ids": ["1e1ae334-fdca-4f65-8faf-9368a28adf85"], "metadata": {"window": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "original_text": "\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $603,008 \u00a0\u00a0$476,170 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0336,514 \u00a0\u00a0\u00a0242,947 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(504,086 )\u00a0\u00a0(59,872 )\nInventories \u00a0(1,095,530 )\u00a0\u00a0(1,178,035 )\nAccounts payable \u00a01,765,103 \u00a0\u00a0\u00a01,381,079 \u00a0\nOther, net\u00a0(219,852 )\u00a0\u00a0(152,209 )\nNet cash provided by operating activities\u00a0885,157 \u00a0\u00a0\u00a0710,080 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(74,217 )\u00a0\u00a0(75,727 )\nPrefunded business acquisition \u00a0\u2014 \u00a0\u00a0\u00a0(1,438,124 )\nOther, net\u00a08,417 \u00a0\u00a0\u00a02,693 \u00a0\nNet cash used in investing activities\u00a0(65,800 )\u00a0\u00a0(1,511,158 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,469 )\u00a0\u00a0(10,518 )\nPurchases of common stock 1 \u00a0(385,533 )\u00a0\u00a0(807,214 )\nExercises of stock options \u00a010,926 \u00a0\u00a0\u00a021,863 \u00a0\nCash dividends on common stock \u00a0(105,690 )\u00a0\u00a0(99,713 )\nEmployee tax withholdings related to restricted share vesting \u00a0(56,248 )\u00a0\u00a0(65,217 )\nOther, net\u00a0(4,655 )\u00a0\u00a0(3,145 )\nNet cash used in financing activities\u00a0(551,669 )\u00a0\u00a0(963,944 )\n16", "page_label": "16", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bea30be9-32da-4ef1-8f76-de870e77be9a": {"node_ids": ["e3bc79ff-2f29-41c3-9502-d5dbb0b4f48a", "a3729e6a-4222-4d55-b8ec-a53ac05d2115", "b884219d-f0b8-4e4e-9472-15eb1f0b4098", "f9edd26c-3575-4e32-91a6-b9b5f4688ec1", "f9967efd-b014-40f5-b823-89ca28672c9c", "69299d4a-a253-43c9-89ca-94bd72e7eeaa"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0\n\u00a0 \u00a0December 31, \n2023 \u00a0September 30, \n2023 \u00a0December 31, \n2022 \u00a0September 30, \n2022\nCash and cash equivalents \u00a0$ 2,872,351 \u00a0$ 2,592,051 \u00a0$ 1,692,205 \u00a0$ 3,388,189\nRestricted cash (included in Prepaid Expenses and\nOther) \u00a0\u00a0 99,796 \u00a0\u00a0 97,722 \u00a0\u00a0 159,599 \u00a0\u00a0 144,980\nRestricted cash (included in Other Long-T erm\nAssets) \u00a0\u00a0 63,974\u00a0\u00a0 63,116\u00a0\u00a0 60,853\u00a0\u00a0 60,370\nCash, cash equivalents, and restricted cash \u00a0$ 3,036,121\u00a0$ 2,752,889\u00a0$ 1,912,657\u00a0$ 3,593,539\n\u00a0\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash\u00a015,544 \u00a0\u00a0\u00a084,140 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0283,232 \u00a0\u00a0\u00a0(1,680,882 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2\u00a02,752,889 \u00a0\u00a0\u00a03,593,539 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2$3,036,121 \u00a0\u00a0$1,912,657 \u00a0\n________________________________________\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n", "page_label": "17", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4be5f271-2ad0-4c91-8d95-2a1b67dd14ff": {"node_ids": ["1a1de299-5ed2-48d5-b7df-fb707600c8bd", "4244df3b-bfaa-4020-bd81-56e7fb5abe6f", "2bf15959-015b-40d0-b260-8353baeaffa1", "fd1947a2-be8b-4771-9854-c90eaf41deba", "22fb38ef-6e0f-4736-9001-bc90d29f1eb3", "4bfd451c-cf9d-42e7-b468-91082465bfa0", "e0d42781-2e50-47a4-9c09-5a0150e0bec8", "9e6b2f0f-5fa1-4903-9299-0dd4f1cbd9d2", "0a7e280f-c47e-4ce9-8e15-c7cc39c6c8bc", "23ec2166-b97f-41ac-943e-3db2b41f7abd", "7f3b5414-a4c8-4258-bd02-bc94a292d616", "3e4a39cc-25c9-4e31-9ee9-2d8d66f86e9a", "0b44de64-be2e-47a4-ac8b-16dce5be0959", "7d200113-aa10-4a6a-8f7a-c822bdd5863f", "cea133d5-66a6-4f90-835e-1ec1234f2bf7", "799d8f7a-b529-47bb-bf2b-62664bcc6d7f", "aad84d13-db91-4c8d-8173-997d518c4a95", "fe137c23-ba8f-4803-916f-d31c40d2b762", "a299f86e-e5b9-4042-8c81-a582272ec134", "4e13316c-ba8d-4432-92cf-c92bbdb07fe5", "48b319d1-9438-4c0f-ac96-45d169a552e6", "4e701e26-36bd-478d-bd3f-593c12f285e0", "3ab0a1ad-7aeb-40b7-9801-dde4ac52f873", "a641f0fa-085c-4d0b-9c62-ceafff4f9e81", "b7c16fd4-9a08-497c-acce-4853468f5d63", "a3dba3db-d573-49ee-8a87-b06cc9b17072", "ed91153b-3718-4ad8-bacb-a737aa3646e6"], "metadata": {"window": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and Turkey highly inflationary impact. ", "original_text": "Company\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "18", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7ffa6e04-827e-4171-b994-23d019284fcd": {"node_ids": ["e4fb2b6c-0132-40f8-911f-beff09059274", "e2891e2c-fb4a-4a4a-bbb6-30f8ce2a2180", "ab0d3d85-832d-4822-8405-a50bc5f83940", "40b8b73a-ddb7-417c-b725-c1edbe656da4", "e143ebd0-c1b7-443a-ac8e-f1d8cabed7e7", "f6dd8bfd-16c2-46de-bdec-cf2527b4e436", "c519122a-729a-4044-bbda-3d4afd83ae36", "ca5e43c6-92c6-4dfe-82ac-dca517c5c9a1", "92cb8332-cd4a-4298-8015-6f1a6be372a7", "8450568a-f48c-41af-8bd8-280915e938a3", "7cca90de-45e0-4897-be82-71ac42034503", "66e18f19-6b75-4e11-b3d3-7e9f0fcf60f3", "0d1ae852-457a-4855-9c62-c0d9effac2f6", "10d02673-1ba1-4958-9639-f289dedb2d50", "8af1c89f-adfd-49cb-aeea-6680308f2718", "5cc1c7f0-65c1-4cfd-8a56-2ef541fa32bf", "5a5d214d-2ab3-4c37-be12-43fe558d6bd5", "9f42739a-163e-4c23-8d54-b76a48daba1e", "def3d3ec-4dd8-4eff-b76e-86bae985454a", "e6dfdcda-e1ba-44db-ac7c-feb5c14f449e", "d71a1a72-fe04-4319-a63f-41db2b7da32f", "a4cacede-43ac-418a-a958-2903ff7ddc37"], "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable\nCencora.\n Adjusted net income attributable to Cencora:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "19", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "38384c4a-c687-41ca-a7e1-32efa5a1015a": {"node_ids": ["aabad694-16d4-4d26-a5bc-e3f9766d2ade"], "metadata": {"window": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n20", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n20", "page_label": "20", "file_name": "CEN-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 217915, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}